FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.16  |  FHIR Version n/a  User: [n/a]

FHIR IG Statistics (3797 ms)

Resources - All Kinds, Realm US, Authority Hl7

16260 resources

Type:
Text: Use quotation marks (") for an exact phrase. You can use AND, OR, and NOT. Wildcard = *

By Version

Start Prev Rows 9000 - 9200 Next http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.11
PackageVersionIdentityName/TitleStatusDate
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1033 SGLT2i Allergy NDFRTactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1034 MRA Allergy NDFRTactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1036 Meglitinide Allergy NDFRTactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1037 Alpha glucosidase inhibitor Allergy NDFRTactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1038 TZD Allergy NDFRTactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1041 Hemoglobinactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1042 Hematocritactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1043 Anemia for Erythropoesis Simulating Agents I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1044 Anemia for Erythropoesis Simulating Agents SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1045 Anemia for Erythropoesis Simulating Agentsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1046 AZT Medsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1047 Ferritinactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1048 Knee pain I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1049 Knee pain SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.105 conditions_heartfailureactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1050 Knee painactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1051 Knee decreased ROM SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1052 Knee effusion I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1054 Knee effusionactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1055 Knee crepitus SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1056 OIA_Antiemeticsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1057 OIA_PDE5isactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1058 OIA_Vitaminsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1059 OIA_Plavixactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1061 OIA_Oral_Contraceptivesactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1063 OIA_Topical_Steroidsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1064 OIA_Cough_Cold_Medsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1065 Antiperspirant aluminum saltsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1066 Antiperspirant anticholinergicsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1067 Antieplieptic medicationsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1068 Antidepressant medicationsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1069 Urinary incontinence SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1070 Urinary incontinence I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1071 Urinary incontinenceactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1073 Hemifacial spasm SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1074 Hemifacial spasm I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1075 Hemifacial spasmactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1076 Spasmodic dysphonia SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1077 Physical therapy procedure SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1078 Occupational therapy SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1079 Hyperhidrosis SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1080 Hyperhidrosis I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1081 Hyperhidrosisactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1082 Tic disorder I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1083 Tic disorder SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1084 Tic disorderactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1085 Esophageal achalasia SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1086 Esophageal achalasia I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1087 Esophageal achalasiaactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1088 ET propanolol or primidoneactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1089 ET topiramate alprazolam or gabapentinactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.109 CKD stage4above I10active2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1090 Blephraospasm SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1091 Blepharospasm I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1092 Blepharospasmactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1093 Strabismus SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1094 Strabismus I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1095 Strabismusactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1096 Overactive bladder SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1097 Overactive bladder I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1098 Overactive bladderactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1099 Movement disorders SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.110 CKD stage4above SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1100 Movement disorders I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1101 Movement disordersactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1102 Lateral epicondylitis SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1103 Lateral epicondyltisis I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1104 Lateral epicondylitisactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1105 Plantar fasciitis SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1106 Plantar fasciitis I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1107 Plantar fasciititsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1108 Cardiac CT SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1109 Cardiac CT CPTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.111 CKD stage4aboveactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1111 Cardiac CTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1112 Cardiac MRI SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1113 Cardiac MRI CPTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1114 Cardiac MRIactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1115 CT Angiography of Coronary Artery SCTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1116 CT Angiography of Coronary Artery CPTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1117 CT Angiography of Coronary Arteryactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.112 Chronic kidney disease I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.113 Chronic kidney disease SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.116 DigTx Cognitive Impairment I10active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.117 DigTx Cognitive Impairment SCTactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.120 Diabetic ketoacidosis SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.121 Diabetic ketoacidosisactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.124 DKDactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.146 Long Acting Muscarinic Antagonists (LAMA)active2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.147 HFrEF SCTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.148 HFrEF I10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.15 Kidney tansplantactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.150 History of Hypoglycemia I10active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.151 History of Hypoglycemia SCDactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.153 Hyperlipidemiaactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.159 conditions_COPD I10active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.168 medications_COPDactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.17 Atrial fibrillationactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.173 Asthma I10active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.175 Asthmaactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.184 DigTx Virtual Reality Contraindications Visual Impairmentactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.186 Beta blockers GDMT for heart failureactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.188 medications_heart failureactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.189 SGLT2iactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.193 relatedconditions_COPD I10active2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.197 Blood (Serum and Plasma) Potassiumactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.202 Serum Creatinineactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.21 Thoracic aorta diseaseactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.214 Type 1 Diabetes Mellitus SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.224 Systolic Heart Failure I10active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.226 Systolic Heart Failureactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.238 MRA mineralocorticoid receptor antagonistsactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.244 MRA Mineralocorticoid Receptor Antagonist Allergyactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.252 relatedconditions_Heart failure I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.260 UACR SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.263 Pregnancy I10active2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.281 Statins Allergy SCTactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.282 Statin Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.292 Metabolic syndrome I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.3 Delivery I10active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.314 relatedconditions_hyperlipidemia I10active2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.322 Angina I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.325 Tachyarrhythmia I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.337 Migraine I10active2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.34 Blood pressure panelactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.35 Systolic Blood Pressureactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.350 Coronary artery disease I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.367 Trandolaprilactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.369 Candesartanactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.37 relatedconditions_hypertension SCTactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.377 Valsartanactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.38 relatedconditions_hypertension I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.397 eGFRactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.409 Hypertension I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.412 Statin Moderate Intensityactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.415 LDL Cholesterolactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.43 Urinalysisactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.434 Insulinactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.437 TZD Thiazolidinedionesactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.438 medications_T2DMactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.439 relatedconditions_T2DM I10active2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.440 relatedconditions_T2DM SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.442 Blood Glucoseactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.45 ACE inhibitor allergy RXNORMactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.455 Metabolic acidosis I10active2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.459 Liver canceractive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.47 ACE inhibitor allergy SCTactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.473 Tetanus toxoid, diphtheria (Td) Vaccineactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.474 Allergy to Tdap Vaccineactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.475 Allergy to Td Vaccineactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.476 Allergy To Vaccine Componentactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.478 Allergy to HPV Vaccineactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.481 medications_hypertensionactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.492 Inhaled Corticosteroids Allergyactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.498 Metformin AllergyIntolerance SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.5 Delivery - Procedureactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.508 Abdominal aortic imaging CPTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.516 Allergy to Herpes Zoster Vaccine SCTactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.517 Hemoglobin A1cactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.518 Drug hypersensitivity I10active2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.519 Drug hypersensitivity SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.520 Drug hypersensitivityactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.521 Diabetic Kidney Disease I10active2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.523 Diabetic kidney diseaseactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.524 Chronic Hepatitis SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.525 Chronic Hepatitisactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.527 OCS_Prednisoneactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.528 High Dose Non Combo ICS Adultactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.529 Medium Dose Non Combo Asthma ICS Adultactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.530 Low Dose Non Combo ICSactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.531 Anti IgE Medicationsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.532 IL5 Antagonistsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.533 Mast cell stabilizers for asthmaactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.534 Vasospastic disease I10active2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.535 Vasospastic disease SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.536 Vasospastic diseaseactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.537 Hemiplegic and basilar migraine I10active2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.538 Hemiplegic and basilar migraine SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.539 Hemiplegic and basilar migraineactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.540 Peptic ulcer disease I10active2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.541 Peptic ulcer disease SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.542 Peptic ulcer diseaseactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.544 Bleeding disorder I10active2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.545 Bleeding disorder SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.548 Electronic cigarettes or Vapingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.549 Bleeding disorderactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.551 Heart Rateactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.552 Triptansactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.553 CGRP receptor antagonistsactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.554 Ditansactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.555 Ergotsactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.556 Migraine specific NSAIDsactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.557 OTC migraine analgesicsactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.558 Butalbital analgesicsactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.559 medications_migraine_acuteactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.560 relatedconditions_migraine I10active2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.561 conditions_migraineactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.562 relatedconditions_migraine SCTactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.563 relatedconditions_migraineactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.564 Triptan Allergy Intolerance SCTactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.565 Triptan Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.566 Ischemic bowel disease SCTactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.567 Ischemic bowel disease I10active2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.568 Ischemic bowel diseaseactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.569 Allergen Immunotherapyactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.570 Allergy to house dust mites SCTactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.571 Allergy to house dust mites I10active2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.572 Allergy to house dust mitesactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.573 conditions_hyperlipidemia I10active2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.574 conditions_hyperlipidemia SCTactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.575 conditions_hyperlipidemiaactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.578 PIM_Schedule Vactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.580 PIM_Acarboseactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.581 PIM_Avandametactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.582 PIM_Dulaglutideactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.583 PIM_Glimepirideactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.585 PIM_Glucophageactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.587 PIM_Glucovanceactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.588 Glyburide PIMactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.590 Alpha glucosidase inhibitorsactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.592 Azotemiaactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.594 Intolerance to ARB SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.595 ICS Lowactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.596 ICS Mediumactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.597 ICS Highactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.598 Low Dose ICS Formoterolactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.599 PIM_Vitamin B12 Level_LOINC_CPTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.600 PIM_Vitamin B12 Level_LOINCactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.601 PIM_Vitamin B12 Level_CPTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.604 PIM_Glyburideactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.605 PIM_Pioglitazoneactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.606 PIM_Semaglutideactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.607 PIM_Linagliptinactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.609 Macrolide_Azithromycinactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.61 Secondary antihypertensivesactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.610 Long Acting Beta Agonists (LABA) Non_Formoterolactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.611 relatedconditions_Asthma I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.612 Wolff Parkinson White SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.613 Wolff Parkinson White I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.614 Wolff Parkinson Whiteactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.615 medications_Asthmaactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.617 HighICS_LABA_NonFormoterolactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.618 relatedconditions_Asthma SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.619 ICS_LABA_LAMAactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.620 Low Dose ICS_LABA_Non Formoterolactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.621 Medium ICS_LABA Non Formoterolactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.622 relatedconditions_Asthmaactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.623 LAMA Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.624 LABA Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.625 BetaBlock NonCS Secondary Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.626 Eplerenone Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.627 Spironolactone Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.628 SGLT2 Inhibitors Allergy SCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.629 PIM_Refill_Request_Antilipemics_LFTsactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.630 Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.631 Pneumococcal Vaccine Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.632 Meglitinides Allergy SCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.633 DPP4i Allergy SCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.635 Alpha_glucosidase inhibitors allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.636 Glucagon_Like Peptide 1 Receptor Agonist (GLP1RA) Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.637 Insulins Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.638 TZD Allergy SCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.639 T2DM_Medications Allergy SCTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.642 T2DM_Medications Allergy RXNORMactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.643 T2DM_Medications Allergy SNOMEDactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.646 T2DM_Medication Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.647 Statins Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.649 ACE Inhibitors Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.650 ARB Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.652 Long Acting Muscarinic Antagonists (LAMA) Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.653 Long Acting Beta Agonists (LABA) Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.654 BetaBlocker NonCS Secondary Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.656 MRA Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.657 Eplerenone Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.658 Spironolactone Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.659 SGLT2i Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.660 Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.661 Tetanus, Diphtheria, Pertusis (Tdap) Vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.665 Tetanus toxoid, diphtheria (Td) Vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.666 Human Papillomavirus (HPV) vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.667 Herpes Zoster Vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.670 Pneumococcal Vaccine Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.671 Inhaled Corticosteroids(ICS) Allergy Intoleranceactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.672 LABA(Formoterol only)active2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.674 PIM_Tirzepatideactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.675 GLP1RA Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.676 PIM_Diabetes_Testing_Suppliesactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.677 PIM_H2_Antagonistsactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.678 SGLT2i DM CKDactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.679 SGLT2i DM ASCVDactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.680 GLP1RA DM ASCVDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.683 OIA_Gout_Medicationsactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.684 GlumetzaSubstitutionactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.685 MetforminER500mgactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.686 PIM_Metforminactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.687 PIM_Glipizideactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.689 PIM_Glipizide_Glyburide_Glimepirideactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.690 PIM_Insulin_Meglitinidesactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.691 PIM_Glyxambiactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.692 PIM_Farxigaactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.693 PIM_Invokanaactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.694 PIM_Jardianceactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.695 PIM_Invokana_Jardianceactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.696 Reclastactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.697 LAMA_LABA Combination 1 Inhaleractive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.698 PIM_Contraceptivesactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.699 Selected Oral Antiemetics for Migraineactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.700 PIM_DEXA_Scanactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.701 PIM_DEXA_Scan_CPT_LOINCactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.702 PIM_SSRIsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.703 PIM_SNRIsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.704 PIM_NRIsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.705 PIM_TCAsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.706 PIM_Citalopramactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.707 PIM_Hydroxyzineactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.708 PIM_Buspironeactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.709 PIM_Bupropionactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.710 PIM_Mirtazapineactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.711 PIM_Trazodoneactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.712 PIM_IHD_CHD_CAD_ICD10active2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.713 PIM_IHD_CHD_CAD_SNOMEDactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.714 PIM_Gabapentinactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.715 PIM_Allergy_Nasal_Spraysactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.716 PIM_Allergy_Oral_Medsactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.717 PIM_Allergy_Nasal_Oralactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.719 OCS_Prednisoloneactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.72 Inhaled corticosteroids (IC)active2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.720 COPD_Ofloxacinactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.721 COPD_Ciprofloxacinactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.722 COPD_Doxycyclineactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.723 Macrolide Allergy SCTactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.724 Macrolide Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.725 Prednisone Allergy SCTactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.727 Tetracycline Allergy SCTactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.728 Tetracycline Allergy Intoleranceactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.729 Fluoroquinolones Allergy SCTactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.730 Fluoroquinolone Allergy Intoleranceactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.731 Penicillin Allergy RXNORMactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.732 Penicillin Allergy SCTactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.733 Penicillin Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.734 PIM_Metformin_Single_Ingredient_Onlyactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.735 PIM_Metformin_Combo_Ingredient_Onlyactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.736 Pneumonia I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.737 Pneumonia SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.738 Pneumoniaactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.739 Pulmonary Embolism I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.742 Pulmonary Embolism SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.743 Pulmonary Embolismactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.744 Influenza I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.745 Influenza SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.746 Influenza (Tests for influenza A or B virus Antigen)active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.747 Influenzaactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.748 COVID 19 I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.749 COVID19 SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.750 COVID19active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.752 RSV I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.753 RSV SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.754 RSVactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.755 Respiratory Rate SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.756 Respiratory Rate LOINCactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.757 Respiratory Rateactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.758 Acute Respiratory Failure I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.759 Acute Respiratory Failure SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.760 Acute Respiratory Failureactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.761 Dyspnea SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.762 Dyspnea I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.763 Dyspneaactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.764 Confusion I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.765 Confusion SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.766 Confusionactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.767 Drowsiness SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.768 Drowsiness I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.769 Drowsinessactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.770 Cyanosis I10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.771 Cyanosis SCTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.772 Cyanosisactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.775 Arterial oxygen saturation LOINCactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.776 Arterial oxygen saturation SCTactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.777 Arterial oxygen saturationactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.779 PIM_Potassium_Supplementsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.780 PIM_PPIsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.781 PIM_Migraine_Medications_Abortiveactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.782 PIM_Migraine_Medications_Preventiveactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.783 PIM_Bisphosphonatesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.784 PIM_BPH_Medicationsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.785 PIM_Thyroid_Replacement_Medicationsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.786 PIM_Overactive_Bladder_Medicationsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.787 PIM_Topical_Acne_Medicationsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.788 PIM_Antidepressant_Anxiolytic_Medicationsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.789 Simple Knee Pain I10active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.790 Simple Knee Pain SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.791 Simple Knee Painactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.792 Simple Left Knee Pain SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.793 Simple Right Knee Pain SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.794 Simple Right Knee Pain I10active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.795 Simple Left Knee Pain I10active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.796 Simple Right Knee Painactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.797 Simple Left Knee painactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.798 Knee joint surgery CPTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.799 Knee joint surgery SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.800 Knee joint surgeryactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.801 Knee Osteoarthritis I10active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.802 Knee Osteoarthritis SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.803 Knee Osteoarthritisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.804 Osteoarthritis of right knee SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.805 Osteoarthritis of left knee SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.806 Osteoarthritis of right knee I10active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.807 Osteoarthritis of left knee I10active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.808 Osteoarthritis of right kneeactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.809 Osteoarthritis of left kneeactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.810 Hip Osteoarthritis SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.811 Hip Osteoarthritis I10active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.812 Hip Osteoarthritisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.813 Hip joint surgery CPTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.814 Hip joint surgery SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.815 Hip joint surgeryactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.816 Osteoarthritis of right hip I10active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.817 Osteoarthritis of left hip I10active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.818 Osteoarthritis of right hip SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.819 Osteoarthritis of left hip SCTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.820 Osteoarthritis of right hipactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.821 Osteoarthritis of left hipactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.822 DigTx RelieVR inclusions I10active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.823 Aminoglycosidesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.824 Carbapenemsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.826 Monobactamsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.827 Penicillinsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.828 Antimycobacterialsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.829 Beta_lactamaseactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.830 Cyclic lipopeptidesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.831 Lincosamidesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.832 Macrolidesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.833 Amphenicolactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.834 Oxazolidinonesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.835 Fluoroquinolonesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.836 Sulfonamidesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.837 Tetracyclinesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.838 Phosphonicsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.839 Pleuromutilinactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.840 Streptograminsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.841 Lipoglycopeptidesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.842 Nitroimidazolesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.843 PIM_Hyd_Bus_Mir_Traactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.844 Nitrofuransactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.845 Rifamycinsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.846 Glycylcyclineactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.847 Pyrimidinesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.849 Antibiotics oral and parenteralactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.85 PCSK9iactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.850 Medications_hyperkalemiaactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.852 Hyperkalemia_ICD10active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.853 Hyperkalemia_SCTactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.854 Hyperkalemia Conditionsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.855 Medications_Chronic Hyperkalemiaactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.858 PIM_Alpha_Blockers_2active2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.860 PIM_Ambulatory_Visits_CPTsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.862 PIM_Ambulatory_Visits_SNOMEDactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.863 PIM_Thyroid_Stimulating_Hormone_(TSH)active2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.864 PIM_Triiodothyronine_(T3)active2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.865 PIM_Thyroxine_(T4)active2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.866 PIM_Magnesium_LOINCactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.867 PIM_BMP_CMP_LOINCactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.868 PIM_URIC_ACID_LOINCactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.869 PIM_Migraine_Medicationsactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.870 PIM_Triptansactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.871 ICS_SABA Relieveractive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.873 PIM_Asthma_COPD_Medsactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.874 PIM_Lipid_Panel_CPTsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.875 PIM_Hepatic_Function_Panel_CPTsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.876 Alpha Glucosidase Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.877 Inflammatory bowel disease I10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.878 Inflammatory bowel disease SCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.879 Inflammatory bowel diseaseactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.88 DEPRECATED Diabetesactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.880 Gastrointestinal obstruction SCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.881 Gastrointestinal obstruction I10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.882 Gastrointestinal obstructionactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.883 DPP4i Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.884 Multiple endocrine neoplasia type 2 (MEN II) SCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.885 Multiple endocrine neoplasia type 2 (MEN II) I10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.886 Multiple endocrine neoplasia type 2 (MEN II)active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.887 Gastroparesis SCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.888 Gastroparesis I10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.889 Gastroparesisactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.890 Meglitinide Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.891 Sulfonylurea Allergy Intoleranceactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.892 Peripheral edema I10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.893 Peripheral edema SCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.894 Peripheral edemaactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.895 TZD Allergy Intoleranceactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.896 PIM_Beta_Blockersactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.897 PIM_CCB_DHPsactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.898 PIM_Loop_Diureticsactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.899 PIM_Inhaled_Corticosteroids_(ICS)active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.9 ACE inhibitorsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.90 ASCVD I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.900 PIM_Leukotrienesactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.901 OIA_Asthma_COPD_Meds_Inhalersactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.902 OIA_Asthma_COPD_Meds_Nebulizersactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.903 OIA_Asthma_COPD_Meds_Oralactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.904 OIA_GLP1_Injectablesactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.905 OIA_Insulin_Injectablesactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.906 OIA_Oral_Hypoglycemicsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.907 OIA_DM1_DM2_Medsactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.908 Medium Dose ICS Formoterolactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.909 High Dose ICS Formoterolactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.910 CKD stage5OrESRD I10active2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.911 CKD stage5OrESRD SCTactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.912 CKD stage5OrESRDactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.914 Anxiety_I10active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.915 Anxiety_SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.916 Anxietyactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.918 Stress_SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.919 Stress_I10active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.92 ASCVDactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.920 Stressactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.921 PBH_Anxiety_SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.922 PBH_Depression_SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.923 PBH_Stress_SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.924 PBH_Insomnia_SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.925 PIM_CMP_CPTsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.926 Canagliflozin medsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.927 Empagliflozin medsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.928 Dapagliflozin medsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.929 Ertugliflozin medsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.93 Albuminuria I10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.930 Dulaglutide medsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.931 Liraglutide medsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.932 Semaglutide SC medsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.933 T2DM meds benefitting ASCVDactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.934 T2DM meds benefitting CKD stages 2, 3, and 4 with eGFR >= 20 mL/minactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.935 T2DM meds benefitting CKD stage 5active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.936 T2DM meds benefitting HF with eGFR >= 20 mL/minactiveInterventions Related to Medication Management, Medication Reconciliationactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.110 Interventions Related to Education, Medicationsactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.111 Interventions Related to Education, Medical Equiptment and Devicesactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.112 Interventions Related to Medication Management, Notificationsactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.113 Interventions Related to Medication Management, Refill Synchronizationactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.114 Status of Patient Conditionactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.115 Interventions Related to Education, Diseases and Disordersactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.116 Interventions Related to Educationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.118 Interventions Related to Medication Managementactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.119 Interventions Related to Medication Management, Targeted Medication Reviewactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.120 Interventions Related to Medication Management, Discussionactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.121 Reasons for Interventions Related to Medication Management, Costactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.122 Interventions Related to Education, Immunizationsactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.123 Status of Recommendationsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.124 Interventions Related to Medication Management, Provision of Documentsactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.125 Status of Compliance Abilityactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.126 Status of Interventionsactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.127 Status of Disease Controlactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.128 Status of Complianceactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.129 Occupations of Providersactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.130 Environments of Careactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.131 Findings Related to Medication Management, Body Mass Indexactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.132 Findings Related to Medication Management, Alcohol Useactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.133 Findings Related to Medication Management, Caffeine Useactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.134 Interventions Related to Education, Dietactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.136 Findings Related to Medication Management, Exerciseactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.137 Interventions Related to Education, Behavioractive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.138 Findings Related to Medication Management, Dietactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.139 Status of Care Goalactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.140 Findings Related to Medication Management, Illicit Drug Useactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.141 Interventions Related to Administration, Immunizationsactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.142 Interventions Related to Care Coordination, Communication Needsactive2020-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.144 Findings Related to Medication Management, Life Eventactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.145 Interventions Related to Medication Management, Device or Equipment Fittingactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.146 Findings Related to Medication Management, Immunizationsactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.148 Findings Related to Medication Management, Cultural Beliefsactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.149 Findings Related to Medication Management, Tobacco Useactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.150 Interventions Related to Medication Regimen, Continue Medicationactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.151 Encounter Typeactive2020-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.152 Encounter Classactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.156 Allergy/Intolerance Severityactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.16 Reasons for Interventions Related to Medication Managementactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.160 Allergy/Intolerance Manifestationactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.162 Allergy/Intolerance Substance & Negationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.163 Allergy/Intolerance Negationactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.165 Interventions Related to Care Coordination, Benefit Managementactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.166 Interventions Related to Administrationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.167 Interventions Related to Administration, Medicationsactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.168 Findings Related to Medication Management, Eating Habitsactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.169 Findings Related to Medication Management, Tobacco Exposureactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.170 Interventions Related to Care Coordinationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.176 Interventions Related to Medication Management, Information Gatheringactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.177 Interventions Related to Medication Management, Care Planningactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.178 Interventions Related to Medication Management, Documentationactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.179 Allergy/Intolerance Substance, Foodactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.180 Allergy/Intolerance Substance, Environmentalactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.181 PharmacyEncounterReasonactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.182 Encounter Reasonactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.183 Findings Related to Medication Management, Medication relatedactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.197 PharmacyAllergiesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.198 PharmacyInterventionsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.200 PharmacyReasonsForInterventionsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.201 PharmacyInterventionStatusactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.202 PharmacyCareCoordinationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.203 PharmacyReferralsToactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.204 PharmacyGoalStatusOutcomeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.205 PharmacyTypeOfProfessionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.207 PharmacyEnvironmentsOfCareactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.208 PharmacyEncounterTypeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.209 PharmacytEncounterClassactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.211 PharmacyAllergyIntoleranceTypeactive2018-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.212 PharmacyAllergyIntoleranceManifestationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.213 PharmacyReasonForMedicationChangeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.214 PharmacyEducationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.215 PharmacyEducationStatusactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.216 PharmacyReferralsFromactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.218 Reasons for Interventions Related to Medication Management, Discontinue Medicationactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.224 Social Determinants of Health Problem Observationactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.225 Laboratory results that are used in medication managementactive2020-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.227 Findings Related to Medication Management, Infectious Disease Symptomsactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.229 COVID19 Related Disease, Test, or Exposureactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.230 Maternity Health Interventions Value Setactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.231 Social Determinants of Health Interventionsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.232 Maternity Health Findingsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.233 Reason Medication Discontinued Lack of Indicationactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.234 Reason Medication Discontinued Lack of Effectivenessactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.235 Reason Medication Discontinued Safety Issue Occurredactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.236 Reason Medication Discontinued Compliance Issue other than costactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.237 Recommendation to Resolve Medication Therapy Problemactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.239 Reason Medication Discontinued Patient Unable to Affordactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.240 Medication Listsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.3 Findings Related to Medication Management, Transitions Between Health Care Settingsactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.35 Interventions Related to Medication Management, Comprehensive Medication Reviewactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.5 Reasons for Interventions Related to Medication Management, Unnecessary Therapyactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.53 Reasons for Interventions Related to Medication Management, Adverse Eventsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.55 Reasons for Interventions Related to Medication Management, Adherenceactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.56 Findings Related to Medication Management, Multiple Providersactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.58 Findings Related to Medication Management, Chronic Disease Presentactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.59 Findings Related to Medication Management, Taking Medication for Chronic Diseaseactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.6 Reasons for Interventions Related to Medication Management, New or Additional Therapy Requiredactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.60 Findings Related to Medication Management, Health Literacyactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.61 Findings Related to Medication Managementactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.7 Reasons for Interventions Related to Medication Management, Ineffective Therapyactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.8 Reasons for Interventions Related to Medication Management, Dose Too Lowactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.83 Assessments Related to Medication Management, General Assessmentsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.84 Assessments Related to Medication Managementactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.85 Assessments Related to Medication Management, Assessments Using Assessment Scalesactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.86 Interventions Related to Medication Regimen, Monitoringactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.87 Interventions Related to Care Coordination, Consultationsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.88 Interventions Related to Care Coordination, Referrals to Other Providersactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.89 Interventions Related to Care Coordination, Referrals for Specific Servicesactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.9 Reasons for Interventions Related to Medication Management, Dose Too Highactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.90 Recommendations Related to Medication Regimen, Continue Medicationactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.91 Recommendations Related to Medication Regimen, Initiate Medicationactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.92 Recommendations Related to Medication Regimen, Change Medicationactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.93 Recommendations Related to Medication Regimen, Change Medication Doseactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.94 Recommendations Related to Medication Regimen, Change Medication Dosage Formactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.95 Recommendations Related to Medication Regimen, Change Medication Courseactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.97 Recommendations Related to Medication Regimen, Change Medication Dosing Intervalactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.98 Recommendations Related to Medication Regimen, Discontinue Medicationactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1096.99 Recommendations Related to Medication Regimen, Monitoringactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.10 Care Plan Document Typeactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.11 Medication Statusactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.12 Medication Routeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.24 Extended Pregnancy Statusactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.27 Care Team Member Function (SNOMEDCT)active2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.28 Problem Type (LOINC)active2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.29 Allergy Clinical Statusactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.30 Care Team Member Functionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.33 External Cause of Injury/Morbidityactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.35 Arthritis Feedback Types (SNOMED)active2019-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.36 Arthritis Feedback Types (LOINC)active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.4 DIRSectionTypeCodes LOINCactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.45 Bidirectional Services eReferral Typeactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.46 Bidirectional Services eReferral Reasonactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.49 Disability Status Assessmentactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.50 Transport vehicle typeactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.53 Sexactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.54 Specimen typeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.55 At Home In Vitro Patient Questionsactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.57 Advance Directives Content Typeactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.58 Acute COVID 19 Diagnosisactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1099.59 Medication Adherence SCTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1102.1 Case Management for Behavioral Healthactive2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1102.63 Case Management for Behavioral Healthactive2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1102.64 Case Management for Behavioral Healthactive2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1104.10 Medicare FFS Payeractive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1104.12 Medicare Advantage Payeractive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.101 Myocardial Infarctionactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.124 Follow Up Within 6 Monthsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.125 Follow Up Within 6 Monthsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.126 Bone Scanactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.127 Bone Scanactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.15 Hospice Care Ambulatoryactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.175 Office and Wellness Visits for General Screeningactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.176 Office and Wellness Visits for General Screeningactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.177 Office and Wellness Visits for General Screeningactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.178 Office and Wellness Visits for General Screeningactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.179 Hypertensive disorders in pregnancyactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.180 Outpatient Prenatal Visitactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.182 Eclampsiaactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.183 Gestational Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.184 Preexisting Hypertension in Pregnancyactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.185 Postpartum Encounteractive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.186 Postpartum Encounteractive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.187 Postpartum Encounteractive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.188 Preexisting Hypertension in Pregnancyactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.189 Spontaneous or Elective Abortionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.190 Spontaneous or Elective Abortionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.191 Preeclampsia or Eclampsiaactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.192 Spontaneous or Elective Abortion Procedureactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.193 Spontaneous or Elective Abortionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.28 Non Acute Encounter Codes CPTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.29 Non Acute Encounter Codes HCPCSactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.31 Bleeding Event Diagnosis Codes ICD9active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.78 Statin Associated Muscle Symptomsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.84 Statin Associated Muscle Symptomsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.85 Statin Associated Muscle Symptomsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1108.99 Underweightactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.11 Cornual Ectopic Pregnancyactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.12 Cornual Ectopic Pregnancyactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.13 Perforation of Uterusactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.14 Perforation of Uterusactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.15 Uterine Ruptureactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.16 Uterine Ruptureactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.17 Transabdominal Cerclageactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.18 Transabdominal Cerclageactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.2 Transabdominal Cerclageactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.21 Intravenous or Intraarterial Thrombolytic tPA Therapy Prior to Arrivalactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.23 Intensive Care Unitactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.24 Uterine Hornactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.25 Metroplastyactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.3 Medical Induction of Laboractive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.35 Placenta Previaactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.36 Placenta Accreta Spectrum Previa or Vasa Previaactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.37 Placenta Accreta Spectrum Previa or Vasa Previaactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.38 Outpatient Surgery Serviceactive2019-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.41 Statin Allergenactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.42 Statin Allergenactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.50 Rivaroxaban for VTE Prophylaxisactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.51 Prasugrelactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.52 Pharmacological Contraindications For Antithrombotic Therapyactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.53 Acute Renal Failureactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.54 Total Parenteral Nutritionactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.55 Intravenous Thrombolytic tPA Therapyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.56 Intraarterial Thrombolytic tPA Therapyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.57 Ischemic Stroke Thrombosisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.58 Ischemic Stroke Thrombosisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.59 Ischemic Stroke Otheractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.60 Ischemic Stroke Otheractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.61 Antithrombotic Therapy Antiplateletactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.62 Antithrombotic Therapy for Ischemic Strokeactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.63 Present On Admission is Yes or Exemptactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.64 Application of Venous Foot Pumpsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.65 Application of Intermittent Pneumatic Compression Devicesactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.66 Application of Graduated Compression Stockingsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.67 20 to 42 Plus Weeks Gestationactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.68 37 to 42 Plus Weeks Gestationactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.69 37 to 38 Weeks Gestationactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.70 20 to 42 Plus Weeks Gestationactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.71 20 to 42 Plus Weeks Gestationactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.72 37 to 42 Plus Weeks Gestationactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.73 37 to 42 Plus Weeks Gestationactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.74 37 to 38 Weeks Gestationactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.75 37 to 38 Weeks Gestationactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.76 History of Atrial Ablationactive2022-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.77 Placenta Accreta Spectrum Previa or Vasa Previaactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1110.78 Placenta Previaactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.126 Hospital Settingsactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.143 Observation Servicesactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.146 Buprenorphineactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.159 All Primary and Secondary Canceractive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.161 All Primary and Secondary Canceractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.163 Emergency Department Evaluationactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.164 Admit Inpatientactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.166 Codeine Schedule II and IIIactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.167 Alfentanilactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.168 Remifentanilactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.169 Sufentanilactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.171 Opioid Use Disorderactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.173 Sickle Cell Disease with and without Crisis SNOMEDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.174 Sickle Cell Disease with and without Crisis ICDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.175 Sickle Cell Disease with and without Crisisactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.176 Opioid Medication Assisted Treatment (MAT) HCPCSactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.177 Opioid Medication Assisted Treatment (MAT)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.178 Cancer Related Pain ICD 10active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.179 Cancer Related Pain SNOMEDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1111.180 Cancer Related Painactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1114.14 Medication drug class for allergen intolerance SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.10 Care Experience Preferences at End of Life LOINCactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.11 Care Experience Preferences Groupingactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.12 Healthcare Agent Ordinalityactive2020-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.13 Healthcare Agent Powers or Limitations Indicatoractive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.14 ADIClauseTypeVSactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.15 Upon Death Preferencesactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.17 Preconditions for Treatment Preferencesactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.18 Treatment Intervention Preferences at End of Life Ordinal LOINCactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.19 Obligation or Prohibition Instruction Type Groupingactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.2 InstructionActStatusactive2017-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.20 Advance Healthcare Directive Witness roleCodeactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.21 Witness Categoriesactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.22 Advance Directive Document Typesactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.23 AD Conditions and Prognosis Scenariosactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.26 Healthcare Agent or Advisor Indicatoractive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.27 Initial Treatment portable medical order optionsactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.28 Cardiopulmonary Resuscitation Order Optionsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.30 Cardiopulmonary Resuscitation Order Proceduresactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.31 Cardiopulmonary Resuscitation Procedures Groupingactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.32 Additional Portable Medical Order Proceduresactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.33 Initial Treatment Portable Medical Order Procedures Groupingactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.34 Additional portable medical order Procedures Groupingactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.35 Medically Assisted Nutrition Order Optionsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.36 Medically Assisted Nutrition Portable Medical Order Procedures Groupingactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.37 Healthcare Agent Powersactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.38 Personal Health Goal Options LOINCactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.39 Personal Health Goal Options Groupingactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.40 Portable Medical Order Document Typesactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.41 Advance Healthcare Directive Document Types Grouperactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.5 Advance Directive Content Type SCTactive2022-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.6 Personal Health Goals LOINCactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.7 Health Goals Groupingactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.8 Treatment Intervention Preferences at End of Life LOINCactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1115.9 Treatment Intervention Preferences Groupingactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.1 Rituximab Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.100 Pathological M Stage M1cactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.101 Pathological N Stage N3active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.102 N Stage pN1aactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.103 N Stage pN1bactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.105 Pathological N Stage pN1miactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.106 Pathological N Stage N2bactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.107 Pathological N Stage N2aactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.108 Pathological N Stage N2active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.109 Pathological N Stage N1bactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.110 Pathological N Stage N1aactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.112 Pathological N Stage N0active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.114 Pathological T Stage T4dactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.115 Pathological T Stage T4cactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.116 Pathological T Stage T4bactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.117 Pathological T Stage T4aactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.118 Pathological T Stage T4active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.120 N Stage N2Cactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.121 T Stage T3cactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.122 T Stage T3bactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.123 T Stage T3aactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.124 Pathological T Stage T3active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.125 T Stage T2cactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.126 T Stage T2bactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.127 T Stage T2aactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.128 Pathological T Stage T2active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.129 Pathological T Stage T1cactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.132 Pathological T Stage T1bactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.135 Pathological T Stage T1aactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.136 Pathological T Stage T1active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.137 Pathological T Stage T1micactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.139 Pathological T Stage T0active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.142 Cancer Stage IIIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.143 Cancer Stage IIIAactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.144 Cancer Stage IIIBactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.145 Cancer Stage IIICactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.146 Cancer Stage IVactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.147 Cancer Stage IVAactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.148 Cancer Stage IVBactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.149 Cancer Stage IVCactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.151 Cisplatin Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.153 Vinorelbine Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.154 Gemcitabine Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.155 Docetaxelactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.156 Pemetrexed Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.158 Vinblastine Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.160 ECOG Performance Statusactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.161 ECOG Performance Statusactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.162 ECOG Performance Statusactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.164 Karnofsky Performance Statusactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.165 Carboplatin Injectableactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.166 Paclitaxelactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.168 Doxorubicin Injectableactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.169 Irinotecan Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.179 Bevacizumab Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.181 Methotrexateactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.184 Breast Canceractive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.185 Breast Canceractive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.191 Cancer Stage IIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.192 Cancer Stage IIAactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.193 Cancer Stage IIBactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.194 Pertuzumab Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.196 Ixabepilone Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.197 Goserelinactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.200 Epirubicin Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.202 Ramucirumab Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.204 Letrozoleactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.206 Exemestaneactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.209 Fluorouracilactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.210 Capecitabine Oralactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222 Aprepitant Oralactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.223 Fosaprepitant Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.255 Colorectal Canceractive2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.256 Colorectal Canceractive2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.257 Colorectal Cancer Chemotherapyactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.280 Cancer Stage IAactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.281 Cancer Stage IBactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.286 Cancer Stage IICactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.291 Positive Resultactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.292 Negative Resultactive2015-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.300 Pathological N Stage N1Cactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.332 Daunorubicin Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.336 Palonosetron Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.341 External Beam Radiotherapyactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.349 Metastatic Canceractive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.365 Hospice Care Referral or Admissionactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.439 T Categoryactive2018-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.440 N Categoryactive2018-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.441 M Categoryactive2018-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.442 TNM Stage Groupactive2018-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.449 Opioidsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.492 Pharmacological interventions for depressionactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.535 Ovarian Canceractive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.536 Ovarian Canceractive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.537 Fallopian Tube Canceractive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.539 Fallopian Tube Canceractive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.541 Peritoneal Canceractive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.542 Peritoneal Canceractive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.547 Cancer Stage 1Cactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.555 Gender Femaleactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.556 Gender Maleactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.557 Pathological N Stage N3aactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.558 Pathological N Stage N3bactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.560 Rolapitant Oralactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.599 Obinutuzumab Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.600 Ofatumumab Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.602 Neurokinin 1 Receptor Antagonistactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.604 Serotonin Receptor Antagonistactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.61 Cetuximab Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.63 Panitumumab Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.81 Palonosetron Oralactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.88 Lung Canceractive2015-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.89 Lung Canceractive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.95 M Stage M0active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.97 Pathological M Stage M1active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.98 Pathological M Stage M1aactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.99 Pathological M Stage M1bactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1121.5 Most/Moderately Effective Contraceptive Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1121.6 Most/Moderately Effective Contraceptive SNOMED Findingsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1125.1 Schedule IV Benzodiazepinesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1125.7 PROMIS Depression Assessmentactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.11 Sleep Apneaactive2018-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.12 Toxic Megacolon in adultsactive2019-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.13 Septic Shock due to C. Diffactive2019-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.15 Body Temperatureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.16 Diarrhea Potentially due to CDIactive2019-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.17 Abdominal Distensionactive2019-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.18 Vomiting potentially due to CDIactive2019-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.19 Ileus due to infectionactive2019-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.20 Clostridium difficile infectionactive2019-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.3 Radiation Therapy Indicators from CPTactive2017-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.4 Diagnostic Radiology Surrounding Face and Sinusactive2017-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.5 Ear Surgery Affecting the Tympanic Membraneactive2017-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.6 Allergic Rhinitis Immunotherapyactive2017-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.8 Radiology to Head and Sinusactive2017-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.9 Immunotherapy For Allergic Rhinitisactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1136.63 Aortic Dissection or Ruptured Aortic Aneurysmactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.564 CABG or PCI Procedureactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.565 CABG or PCI Procedureactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.566 CABG or PCI Procedureactive2018-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.1 C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.11 C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.12 C2S Cannabis Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.13 C2S Cannabis Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.14 C2S Cannabis Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.15 C2S Cannabis Use DIsordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.16 C2S Cocaine Use Disorderactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.17 C2S Cocaine Use Disorderactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.18 C2S Cocaine Use Disorderactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.19 C2S Hallucinogensactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.2 C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.20 C2S Hallucinogensactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.21 C2S Hallucinogensactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.22 C2S Hallucinogensactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.23 C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.24 C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.25 C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.26 C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.27 C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.28 C2S Inhalantsactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.29 C2S Inhalantsactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.3 C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.30 C2S Inhalantsactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.32 C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.33 C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.34 C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.35 C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.36 C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.38 C2S Opioidsactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.39 C2S Opioidsactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.4 C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.40 C2S Opioidsactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.42 C2S Opioidsactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.43 C2S Other Psychoactive Substance Use Disorderactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.44 C2S Other Psychoactive Substance Use Disorderactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.45 C2S Other Psychoactive Substance Use Disorderactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.46 C2S Sedative Hypnotic, or anxiolytic related disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.47 C2S Sedative Hypnotic, or anxiolytic related disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.48 C2S Sedative Hypnotic, or anxiolytic related disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.49 C2S Sexuality and reproductive health information sensitivityactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.5 C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.51 C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.52 C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.53 C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.54 C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.55 C2S Substance Use Information Sensitivityactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.56 C2S Substance Use Information Sensitivityactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.58 C2S Sensitive Categoriesactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.59 C2S Opioidsactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.6 C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.60 C2S HIV/AIDS information Sensitivityactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.65 Test C2S Alcohol Use Disordersactive2019-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.67 Test C2S HIV/AIDS Information Sensitivityactive2019-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.7 C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.8 C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.9 C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.10 Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1002 Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1012 S. Typhi Infection (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1016 S. Paratyphi Infection (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1017 S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1021 Dark Urine (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1022 Acute Onset [Qualifier Value] (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1024 Acute Viral Hepatitis (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1027 Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1029 Listeriosis [Listeria species] (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1030 Meningitis [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1032 Encephalitis [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1033 Encephalitis [Unspecified Cause] (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1035 Indeterminate or Equivocal Lab Result Valueactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1037 Smoking Status [Current Nonsmoker] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1040 Organisms (Tests by Unspecified Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1041 Organisms (Tests by Culture and Identification)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1044 Candida auris Infection (Tests for Candida auris by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1045 Candida auris Infection (Tests for Candida auris Nucleic Acid)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1047 Parkinson’s disease (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1048 Parkinson’s disease (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1049 Parkinsonism [Secondary] (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1050 Parkinsonism [Secondary] (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1053 Carbidopa Levodopa Combination (RXNORM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1065 Consciousness [Decreased Level] (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1071 Drug Use [IV Evidence] (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1072 Miosis (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1076 Opioid Overdose and Poisoning (Tests for Opioids [Quantitative])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1077 Poisoning or Overdose by Other Opioids (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1078 Opioid Overdose and Poisoning (Naloxone) (RxNorm)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1083 Rash [Pustular Vesicular] (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1084 Salivary Gland Swelling [Unspecified Cause] (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1090 Syphilis [Congenital] (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1091 Cataracts [Nonspecific]/Congenital glaucoma [Unspecified Cause] (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1092 Congenital heart disease (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1093 Hearing impairment (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1095 Microcephaly (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1096 Developmental delay (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1099 Congenital heart disease (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1100 Hearing impairment (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1104 Developmental delay (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1106 Listeriosis (Tests for Listeria monocytogenes Nucleic Acid in Specimen from Normally Sterile Site)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.112 Tetanus (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1123 COVID_19 (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1124 COVID_19 (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1130 Tickborne Relapsing Fever (Tests for Borrelia hermsii/miyamotoi/parkerii/turicatae Nucleic Acid)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1131 Lyme Disease (Tests for Borrelia afzelii/garinii IgG Antibody by Immunoassayactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1138 Staphylococcus Aureus (Tests by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1139 VISA/VRSA (Tests for Vancomycin Resistance Gene)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1142 COVID_19 (Tests for SARS_CoV_2 Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1143 COVID_19 (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1145 Resistant Lab Result Valueactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1148 Tests for Vancomycin Susceptibility [Ord]active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1149 Proteinuria (Tests for Total Protein in 24H Urine)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.115 Mumps (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1150 Thrombocytopenia (Tests for Platelets [#/volume] in Blood)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1156 Staphylococcus aureus (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1158 COVID_19 (Tests for SARS_CoV_2 Antigen)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1169 Chikungunya Virus Disease (Tests for Chikungunya virus Nucleic Acid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.117 Mumps (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1180 Chikungunya Virus Disease (Tests for Chikungunya Virus Antibody [Quantitative])active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1186 Eastern Equine Encephalitis Virus Disease (Tests for Eastern Equine Encephalitis Virus Antibody [Qualitative])active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1188 Western Equine Encephalitis Virus Disease (Tests for Western Equine Encephalitis Virus Antibody [Qualitative])active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1189 California Serogroup Virus Diseases (Tests for California Serogroup Virus Antibody [Qualitative])active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1196 Anthrax (Tests for Bacillus cereus by Culture and Identification Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1197 us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2038 Bartonella bacilliformis (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2039 Bartonella quintana infection (Tests for Bartonella quintana Nucleic Acid)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.204 Giardiasis (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2040 Bartonella quintana infection (Tests for Bartonella quintana IgM Antibody in a clinical specimen by any method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2041 Bartonella quintana infection (Tests for Bartonella quintana IgG or Total Antibody in a clinical specimen by any method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2042 Bartonella henselae infection (Tests for Bartonella henselae Nucleic Acid)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2043 Bartonella henselae infection (Tests for Bartonella henselae IgM Antibody in a clinical specimen by any method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2044 Bartonella henselae infection (Tests for Bartonella henselae IgG or Total Antibody in a clinical specimen by any method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2045 Bartonella bacilliformis infection (Tests for Bartonella bacilliformis IgM Antibody in a clinical specimen by any method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2046 Bartonella bacilliformis infection (Tests for Bartonella bacilliformis IgG or Total Antibody in a clinical specimen by any method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2047 Bartonellosis (Tests for Bartonella spp. Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2048 Bartonellosis (Tests for Bartonella spp. IgM Antibody in a clinical specimen by any method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2049 Bartonella spp. (Tests by Microscopic Observation)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2050 Bartonellosis (Tests for Bartonella spp. by Culture and Identification Method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2051 Bartonellosis (Tests for Bartonella spp. IgG or Total Antibody in a clinical specimen by any method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2052 Echinococcosis (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2053 Echinococcosis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2054 Cystic Echinococcosis (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2055 Cystic Echinococcosis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2056 Alveolar Echinococcosis (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2057 Alveolar Echinococcosis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2058 Echinococcosis (Tests for Echinococcus species Antibody)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2059 Echinococcus species (Tests by Microscopic Observation)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2060 Echinococcosis (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2061 Genital Warts (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2062 Pseudomembrane [Nose, pharynx, tonsils, or larynx] (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2063 Genital Warts (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2064 Diphyllobothriasis (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2065 Diphyllobothriasis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2066 Diphyllobothriasis (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2067 Nontuberculous Mycobacteria Infection, Pulmonary (Tests for Mycobacterium species Nucleic Acid in a Pulmonary Specimen)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2068 Angiostrongyliasis (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2069 Pelvic Inflammatory Disease (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2070 Pelvic Inflammatory Disease [nonGC and nonCT] (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2071 Pelvic Inflammatory Disease [Unspecified] (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2072 Pelvic Inflammatory Disease (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2073 Pelvic Inflammatory Disease [nonGC and nonCT] (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2074 Pelvic Inflammatory Disease [Unspecified] (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2075 Lower Abdominal Tenderness (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2076 Lower Abdominal Tenderness (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2077 Tenderness with motion of the cervix (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2078 Adnexal Tenderness (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2079 Uterine Tenderness (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2080 Leukocytosis (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2081 Leukocytosis (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2082 Purulent material in the peritoneal cavity (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2083 Pelvic Abscess (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2084 Pelvic Abscess (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2085 Leukocytes [Concentration] (Tests in Blood by Any Method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2087 Nongonococcal Urethritis (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2088 Nongonococcal Urethritis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2089 Urethritis (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2090 Urethritis (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2091 Urethral discharge (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2092 Urethral discharge (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2093 Dysuria (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2094 Dysuria (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2095 Gonorrhea (Tests for Neisseria gonorrhoeae Antigen)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2096 Cyanobacteria and Cyanotoxin Poisoning (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2098 Rhinitis (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2100 Rhinitis (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2101 Pleuritis (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2102 Pleuritis (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2103 Gamma Glutamyl Transferase in Serum (Tests for Gamma Glutamyl Transferase in Serum)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2105 Methemoglobinemia (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2106 Methemoglobinemia [Non Congenital] (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2107 Methemoglobinemia (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2108 Methemoglobinemia [Non Congenital] (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2109 Methemoglobinemia (Tests for Methemoglobin in Blood [Quantitative])active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2110 Anencephaly (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2111 Anencephaly (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2112 Fetal Anencephaly (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2113 Fetal Anencephaly (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2114 Cleft Lip Alone (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2115 Cleft Lip Alone (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2116 Fetal Cleft Lip (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2117 Cleft Palate Alone (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2118 Cleft Palate Alone (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2119 Cleft Lip with Cleft Palate (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2120 Cleft Lip with Cleft Palate (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2121 Fetal Spina Bifida (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2122 Spina Bifida (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2123 Spina Bifida (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2124 Down Syndrome (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2125 Down Syndrome (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2126 Fetal Down Syndrome (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2127 Fetal Down Syndrome (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2128 Down Syndrome (Tests for Trisomy 21 Chromosomal Anomaly)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2129 Bacteremia (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2130 Bacteremia (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2131 Gastroschisis (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2132 Gastroschisis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2133 Fatal Familial Insomnia (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2134 Fatal Familial Insomnia (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2135 Gerstmann Straussler Scheinker Syndrome (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2136 Gerstmann Straussler Scheinker Syndrome (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2137 Prion Disease (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2138 Prion Disease (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2139 Prion Disease (Tests for Abnormal PRNP Gene Variant)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2140 Phenylketonuria (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2141 Phenylketonuria (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2142 Linezolid (RXNORM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2143 Tuberculosis (Pretomanid) (RXNORM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2144 Tuberculosis (Bedaquiline) (RXNORM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2145 Tuberculosis [Suspected] (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2146 Congenital Rubella Syndrome [Suspected] (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2147 Limb Reduction (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2148 Limb Reduction (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2149 NU_Influenza (Test Panels for Novel influenza A virus Nucleic Acid)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2150 Congenital Hearing Loss (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2151 Congenital Hearing Loss (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2152 Naegleria fowleri PAM (Test Panels for Naegleria fowleri Nucleic Acid)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2153 Primary Congenital Hypothyroidism (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2154 Congenital Hypothyroidism [Unspecified] (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2155 Congenital Hypothyroidism [Unspecified] (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2156 Thyroid_stimulating hormone (TSH) [Quantitative] (Tests in serum or plasma by any method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2157 Mpox (Combination Tests that include mpox virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2158 Orthopox (Combination Tests that include Orthopoxvirus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2159 Mpox (Test Panels for mpox virus Nucleic Acid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.216 Pertussis (Tests for Bordetella pertussis Antibody [Excluding Pertussis Toxin Antibody])active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2160 Orthopox (Test Panels for orthopoxvirus Nucleic Acid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2161 COVID_19 (Combination Tests that include SARS_CoV_2 Nucleic Acid)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2163 Dengue Virus Infection [Suspected] (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2164 Mumps [Suspected] (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2165 Pertussis [Suspected] (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2166 Hantavirus Infection (Test Panels for Hantavirus IgM IgG Total Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2167 Organisms (Tests in Cerebrospinal Fluid by Culture and Identification Method)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2168 Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis in Unspecified Specimen by Culture and Identification)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2169 Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis in Cerebrospinal Fluid by Culture and Identification)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2170 Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis in Unspecified Specimen by Culture and Identification)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2171 Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis in Unspecified Specimen by Culture and Identification)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2172 Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Nucleic Acid in Unspecified Specimen)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2173 Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Nucleic Acid in Unspecified Specimen)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2174 Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Nucleic Acid in Unspecified Specimen)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2175 Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Nucleic Acid in Unspecified Specimen)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2176 Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Antigen in Unspecified Specimen)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2177 Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Antigen in Unspecified Specimen)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2178 Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Antigen in Unspecified Specimen)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2179 Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Antigen in Unspecified Specimen)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.218 Listeriosis (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2180 Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis in Unspecified Specimen by Microscopic Observation)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2181 Organisms (Tests by Microscopic Observation in Cerebrospinal Fluid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2183 Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2187 Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2188 Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Antigen in Cerebrospinal Fluid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2189 Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis in Cerebrospinal Fluid by Microscopic Observation)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2190 Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2192 Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2193 Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Antigen in Cerebrospinal Fluid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2194 Organisms (Combination Tests by Culture and Identification)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2195 Organisms (Combination Tests for Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2196 Lung Tissue (Specimen Type) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2197 Granuloma [Unspecified] (Finding by Microscopic Observation in Lab Results)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2198 Anaplasmosis (Disorders) (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2199 NU_Organisms (Tests in Specimen from Wound by Culture and Identification Methodactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2200 Organisms (Tests by Animal Inoculation Method)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2201 Agricultural Chemical Poisoning [Unspecified Chemical] (Disorders) (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2202 Abnormal Lung Sounds (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2203 Abnormal Lung Sounds (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2204 Anemia [Unspecified Cause] (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2205 Anemia [Unspecified Cause] (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2206 Creatinine (Tests in Serum by Any Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2207 Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Tests by Microscopic Observation in Unspecified Specimen)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2208 Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Tests by Microscopic Observation in Blood)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2209 Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Organism or Substance in Lab Results)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2210 Histopathology or Cytopathology Tests by Microscopic Observationactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2211 Ehrlichiosis (Tests for Ehrlichia species IgG Antibody)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2212 Invasive Cronobacter Infection (Organism or Substance in Lab Results)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2213 Invasive Cronobacter Infection (Tests for Cronobacter species by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2214 Necrotizing Enterocolitis (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2215 Necrotizing Enterocolitis (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2216 Abscess [Brain] (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2217 Abscess [Brain] (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2218 Urinary Tract Infection (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2219 Urinary Tract Infection (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2220 Amniotic Fluid (Specimen Type) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2221 Congenital Cytomegalovirus (Organism or Substance in Lab Results)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2222 Organisms (Tests in Amniotic Fluid by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2223 Congenital Cytomegalovirus (Tests for CMV Antigen by Immunohistochemical Stain)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2224 Congenital Cytomegalovirus (Tests for CMV Antigen in Tissue by Immunohistochemical Stain)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2225 Congenital Cytomegalovirus (Tests for CMV in Amniotic Fluid by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2226 Congenital Cytomegalovirus (Tests for CMV Nucleic Acid in Amniotic Fluid by NAAT)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2227 Congenital Cytomegalovirus (Tests for CMV Antigen in Whole Blood)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2228 Congenital Cytomegalovirus (Tests for CMV Antigen)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2229 Congenital Cytomegalovirus (Tests for CMV by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2230 Congenital Cytomegalovirus (Tests for CMV Nucleic Acid by NAAT)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2231 Congenital Cytomegalovirus Infection (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2232 Congenital Cytomegalovirus Infection (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2233 Cytomegalovirus Disease (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2234 Cytomegalovirus Disease (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2235 Toxoplasmosis (Tests for Toxoplasma gondii Antigen by Immunohistochemical Stain)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2236 Toxoplasmosis (Tests for Toxoplasma gondii Antigen in Tissue by Immunohistochemical Stain)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2237 Toxoplasmosis (Tests for Toxoplasma gondii IgG IgM IgA or IgE Antibody)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2238 Toxoplasmosis (Tests for Toxoplasma gondii IgG IgM IgA or IgE Antibody in Blood)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2239 Toxoplasmosis (Tests for Toxoplasma gondii IgG or IgM Antibody)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2240 Toxoplasmosis (Tests for Toxoplasma gondii IgG or IgM Antibody in Cerebrospinal Fluid)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2241 Stillbirth (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2242 Stillbirth (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2243 Zika Virus Disease (Tests for Zika virus IgM Antibody in Blood or CSF)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2244 Candida species (Tests by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2245 Organisms (Tests in Extrapulmonary Specimen by Culture and Identification)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2246 Organisms (Tests for Nucleic Acid in Extrapulmonary Specimen)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2247 Extrapulmonary [NTM] (Specimen Type) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2248 Plasmodium species (Tests by Microscopic Observation)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2249 Baylisascariasis (Tests for Baylisascaris species Antibody in Serum or CSF)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2250 Lower Respiratory [Excluding Sputum] (Specimen Type) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2251 Organisms (Tests in Sputum Specimen by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2252 Organisms (Tests in Lower Respiratory Specimen [Excluding Sputum] by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2253 Organisms (Tests for Nucleic Acid in Lower Respiratory Specimen [Including Sputum] )active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2254 Nontuberculous Mycobacteria Infection, Pulmonary (Tests for Mycobacterium species in Lower Respiratory Specimen [Excluding Sputum] by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2255 Carbapenem Resistant Bacterial Infection [Carbapenemase Producing] (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2256 CP_CRE (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2257 Organisms (Tests in Stool by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2258 Loss of Consciousness (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2259 Neonatal Abstinence Syndrome (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.226 Lyme Disease (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2260 Neonatal Abstinence Syndrome (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2261 High Pitched Cry (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2262 Inability to Console (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2263 Inability to Console (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2264 Hypertonia (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2265 Hypertonia (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2266 Tremors (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2267 Tremors (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2268 Myoclonus (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2269 Myoclonus (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.227 Lyme Disease (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2270 Poor Sleep (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2271 Poor Sleep (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2272 Alterations in Feeding (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2273 Alterations in Feeding (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2274 Excoriation (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2275 Excoriation (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2276 Sneezing (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2277 Sneezing (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2278 Nasal Congestion (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2279 Nasal Congestion (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2280 Yawning (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2281 Cutaneous Mottling (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2282 Sweating (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2283 Sweating (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2284 Feeding Intolerance (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2285 Feeding Intolerance (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2286 Respiratory Distress or Nasal Flaring (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2287 Respiratory Distress or Nasal Flaring (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2288 In Utero Exposure to Opioids, Benzodiazepines, or Barbiturates (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2289 In Utero Substance Exposure (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2290 In Utero Substance Exposure (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2291 Childbirth (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2292 Childbirth (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2293 Opioids, Benzodiazepines, or Barbiturates (Tests by Any Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2294 NonOpioid, NonBenzodiazepine, and NonBarbiturate Substances (Tests by Any Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2295 Opioids, Benzodiazepines, or Barbiturates (Organism or Substance in Lab Results)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2296 NonOpioid, NonBenzodiazepine, or NonBarbiturate Substances (Organism or Substance in Lab Results)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2297 Exposure or suspected exposure to harmful algae or algae toxins (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2298 Exposure or suspected exposure to harmful algae or algae toxins (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2299 Group A Streptococcus (Tests for Group A Strep in Specimen from Normally Sterile Site by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2300 Babesia species (Tests by Microscopic Observation)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2301 Babesia species (Tests by Microscopic Observation in Blood by Giemsa, Wright, or Wright_Giemsa Stain)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2302 Babesia species (Tests by Microscopic Observation by Giemsa, Wright, or Wright_Giemsa Stain)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2303 Organisms (Tests by Microscopic Observation in Blood by Giemsa, Wright, or Wright_Giemsa Stain)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2304 Organisms (Tests by Microscopic Observation by Giemsa, Wright, or Wright_Giemsa Stain)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2305 Gram_negative Diplococcus (Organism or Substance in Lab Results)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2306 Pertussis (Test Panels for Bordetella pertussis and Bordetella parapertussis Culture and Identification Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2307 D_Transposition of the Great Arteries (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2308 L_Transposition of the Great Arteries (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2309 Transposition of the Great Arteries [Unspecified] (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2310 Transposition of the Great Arteries [Unspecified] (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2311 Interrupted Aortic Arch (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2312 Interrupted Aortic Arch (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2313 Coarctation of the Aorta (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2314 Coarctation of the Aorta (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2315 Ebstein Anomaly (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2316 Ebstein Anomaly (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2317 Pulmonary valve atresia (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2318 Pulmonary valve atresia (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2319 Pulmonary valve stenosis (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2320 Pulmonary valve stenosis (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2321 Fetal Pulmonary valve stenosis (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2322 Double Outlet Right Ventricle (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2323 Double Outlet Right Ventricle (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2324 Hypoplastic left heart syndrome (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2325 Hypoplastic left heart syndrome (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2326 Single Ventricle (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2327 Single Ventricle (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2328 Tetralogy of Fallot (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2329 Tetralogy of Fallot (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2330 Truncus Arteriosus (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2331 Truncus Arteriosus (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2332 Atrioventricular septal defect (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2333 Atrioventricular septal defect (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2334 Total Anomalous Pulmonary Venous Connection (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2335 Total Anomalous Pulmonary Venous Connection (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2336 Tricuspid valve atresia (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2337 Tricuspid valve atresia (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2338 Tricuspid valve stenosis (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2339 Tricuspid valve stenosis (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2340 Fetal Tricuspid valve stenosis (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2341 Exposure to Measles (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2342 Increased Risk for Exposure to Measles (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2343 Giardiasis (Tests by Microscopic Observation)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2344 Diphtheria (Tests for Diphtheria Toxin Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2345 Lead in Blood (Tests for Lead in Venous Blood)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2346 Lead in Blood (Tests for Lead in Capillary Blood)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2347 Opioid Overdose and Poisoning (Test Panels for Opioids)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2348 Rubella (Test Panels for rubella virus IgM Antibody)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2349 Consistent with Tuberculosis (Finding in Chest Xray Imaging Results)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2350 Acute Viral Hepatitis (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2351 Shigellosis (Combination Tests that include Shigella species by Culture and Identification)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2352 Acid Fast Bacilli (Tests by Microscopic Observation by Fite Stain)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2353 Acid Fast Bacilli (Tests by Microscopic Observation in Skin or Unspecified Tissue by Fite Stain)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2354 Organisms (Tests by Microscopic Observation by Unspecified Acid Fast Stain)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2355 Organisms (Tests by Microscopic Observation by Unspecified Acid Fast Stain in Skin)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2356 Skin (Specimen Type) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2357 Organisms (Tests by Microscopic Observation in Skin)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2358 Unspecified Tissue (Specimen Type) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2359 Organisms (Tests by Microscopic Observation in Unspecified Tissue)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2360 S. Paratyphi Infection (Tests for S. Paratyphi by Culture and Identification Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2361 S. Paratyphi Infection (Tests for S. Paratyphi Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2362 Tuberculosis (Ethambutol) (RXNORM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2363 Tuberculosis (Isoniazid [INH]) (RXNORM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2364 Tuberculosis (Pyrazinamide [PZA]) (RXNORM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2365 Tuberculosis (Rifabutin) (RXNORM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2366 Tuberculosis (Rifampin) (RXNORM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2367 Tuberculosis (Rifapentine) (RXNORM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2368 Perinatal Hepatitis B (Maternal Hepatitis B Virus Infection) (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2369 Necrotizing Fasciitis (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2370 Necrotizing Fasciitis (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2371 Renal Impairment [Acute or Unspecified] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2372 Renal Impairment [Acute or Unspecified] (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2373 Coagulopathy [Unspecified Cause] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2374 Coagulopathy [Unspecified Cause] (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2375 Rash [Erythematous, Macular, or Desquamating of Unspecified Cause] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2376 Rash [Erythematous, Macular, or Desquamating of Unspecified Cause] (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2377 Soft Tissue Necrosis (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2378 Soft Tissue Necrosis (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2379 Group A Streptococcus (Tests for Group A Strep in Specimen from Nonsterile Site by Culture and Identification Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2380 Organisms (Tests in Specimen from Nonsterile Site by Culture and Identification)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2381 Specimen from a Nonsterile Site (Specimen Type) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2382 Chagas Disease (Tests for Trypanosoma cruzi in specimen from donor)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2383 Absence of Skin Lesions (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2384 Neuralgia (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2385 Neuralgia (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2386 Peripheral Nerve Thickening (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2387 Nerve (Specimen Type) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2388 Hansen’s Disease (Tests for M. leprae or M. lepromatosis Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.239 Chlamydia trachomatis Infection (Tests for Chlamydia trachomatis Nucleic Acid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.240 Chlamydia trachomatis Infection (Tests for Chlamydia trachomatis Antigen)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2403 NU_Hepatitis D Virus Infection (Tests for hepatitis D virus Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2404 Hepatitis D Virus Infection (Tests for hepatitis D virus IgG Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2405 Hepatitis D Virus Infection (Test for hepatitis D virus Antigen)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2406 Hepatitis B Virus Infection (Combination Tests that include hepatitis B virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2407 Firearm Injury (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2408 Firearm Injury (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2409 Babesiosis (Tests for B. microti IgG or Total Antibody [Titer])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2410 Babesiosis (Tests for B. divergens IgG or Total Antibody [Titer])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2411 Babesiosis (Tests for B. duncani IgG or Total Antibody [Titer])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2412 Babesiosis (Tests for Babesia species IgG or Total Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2413 Brucellosis (Tests for Brucella species IgG Antibody by ELISA)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2414 Cranial Nerve Involvement (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2415 Cranial Nerve Involvement (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2416 Unusual Change in Behavior (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2417 Radiculitis (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2418 Subarachnoid Hemorrhage (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2419 Subarachnoid Hemorrhage (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2420 Discitis (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2421 Discitis (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2423 Respiratory Insufficiency [Unspecified Cause] (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2424 Respiratory Insufficiency [Unspecified Cause] (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2425 Conjunctival Suffusion (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2426 Leptospira species (Tests by Microscopic Observation)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2427 Leptospirosis (Tests for Leptospira Antibody by Agglutination)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2428 Leptospirosis (Tests for Leptospira Antibody by Indirect Immunofluorescence)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2429 Conjunctival Suffusion (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2430 Pleural effusion (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2431 Pleural effusion (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2432 Abdominal swelling (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2433 Abdominal swelling (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2434 Neck swelling (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2435 Neck swelling (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2436 Diaphoresis (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2437 Diaphoresis (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2438 Edema (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2439 Edema (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.244 Gonorrhea (Tests for Neisseria gonorrhoeae Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2440 Anthrax (Tests for Bacillus anthracis Protective Antigen Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2441 Anthrax (Tests for Bacillus species by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2442 Anthrax [Anthrax toxin lethal factor] (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2443 Influenza A (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2444 Influenza B (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2445 Influenza [Unspecified] (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2446 Influenza A (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2447 Influenza [Unspecified] (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2448 Influenza (Tests for unspecified influenza virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2449 Influenza (Tests for influenza B virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2450 Influenza (Tests for unspecified influenza virus Antigen)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2451 Influenza (Tests for influenza B virus Antigen)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2452 Influenza (unspecified influenza virus in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2453 Influenza (influenza B virus in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2454 Influenza (Tests for unspecified influenza virus by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2455 Influenza (Tests for influenza B virus by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2456 Hepatitis B Virus Infection (Tests for Hepatitis B Virus Total Core Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2457 Hepatitis C Virus Infection (Combination Tests that include hepatitis C virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2458 Louseborne relapsing fever (Tests for Borrelia recurrentis Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2459 Louseborne relapsing fever (Tests for Borrelia recurrentis Nucleic Acid in Blood)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2460 Borrelia species (Tests by Microscopic Observation)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2461 Borrelia species (Tests by Microscopic Observation in Blood)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2462 Spirochetes (Tests by Microscopic Observation)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2463 Carbapenem Resistant Enterobacterales (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2464 CP_ Carbapenem Resistant Enterobacterales (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2465 CRE (Tests for Enterobacterales species [excluding Proteus spp., Providencia spp., and Morganella spp.] by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2466 CRE (Tests for Proteus spp., Providencia spp., and Morganella spp. by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2467 CRE (Tests for Enterobacterales species Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2468 CRE (Combination Tests that include Enterobacterales by Culture and Identification)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2469 Tests for Carbapenem Susceptibility [Meropenem and Doripenem]active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2470 Enterobacterales species [excluding Proteus spp., Providencia spp., and Morganella spp.] (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2471 Proteus spp., Providencia spp., and Morganella spp. (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2473 Enterobacterales species [Carbapenem Resistant] (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2474 Enterobacterales species [Carbapenemase Producing] (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2475 Aortic valve stenosis (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2476 Aortic valve stenosis (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2477 Anotia (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2478 Microtia (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2479 Microtia (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2480 Anotia (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2482 Anophthalmia (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2483 Anophthalmia (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2484 Microphthalmia (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2485 Microphthalmia (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2486 Atrial septal defect (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2487 Atrial septal defect (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2488 Fetal Aortic valve stenosis (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2489 Congenital Posterior Urethral Valves (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2490 Congenital Posterior Urethral Valves (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2491 Bladder Exstrophy (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2492 Bladder Exstrophy (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2493 Encephalocele (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2494 Fetal Encephalocele (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2495 Encephalocele (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2496 Choanal Atresia (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2497 Choanal Atresia (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2498 Cloacal Exstrophy (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2499 Cloacal Exstrophy (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2500 Renal Agenesis or Hypoplasia (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2501 Renal Agenesis or Hypoplasia (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2502 Trisomy 13 (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2503 Trisomy 13 (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2504 Fetal Trisomy 13 (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2505 Trisomy 13 (Tests for Trisomy 13 Chromosomal Anomaly)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2506 Galactosemia (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2507 Galactosemia (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2508 Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative] in Blood)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2509 Galactosemia (Tests for Galactokinase (GALK) [Quantitative] in Blood)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2510 Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative] in Blood)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2511 Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2512 Galactosemia (Tests for Galactokinase (GALK) [Quantitative])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2513 Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2514 Galactosemia (Tests for GALT gene allele 1)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2515 Galactosemia (Tests for GALT gene allele 2)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2516 Hypospadias (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2517 Hypospadias (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2518 Trisomy 18 (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2519 Fetal Trisomy 18 (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2520 Fetal Trisomy 18 (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2521 Trisomy 18 (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2522 Trisomy 18 (Tests for Trisomy 18 Chromosomal Anomaly)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2523 Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2524 Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2525 Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Antigen)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2526 Chlamydia trachomatis Infection (Combination Tests that include Chlamydia trachomatis Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2527 Chlamydia species [Unspecified] (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2528 Ventricular septal defect (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2529 Ventricular septal defect (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2530 Gonorrhea (Combination Tests that include Neisseria Gonorrhea Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2531 Intracellular Gram Negative Diplococcus (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2532 Congenital Cytomegalovirus (Tests for CMV Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2533 Congenital Cytomegalovirus (Tests for CMV Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.264 Viral Hemorrhagic Fever (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.265 Viral Hemorrhagic Fever (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.268 Mumps (Tests for mumps virus IgM Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.272 Present or Positive Lab Result Valueactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.282 Varicella (Tests for Varicella zoster virus by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.283 Varicella (Tests for Varicella zoster virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.285 Encephalitis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.287 Varicella (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.289 Carbon Monoxide Poisoning (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.293 Toxic Effects of Lead (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.297 Measles (Tests for measles virus Nucleic Acid)active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.299 Measles (Tests for measles virus IgM Antibody)active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.300 Meningococcal Disease (Organism or Substance in Lab Results)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.301 Shigellosis (Tests for Shigella species by Culture and Identification Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.304 Pesticide Related Illness (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.305 Organisms (Tests by Microscopic Observation in Specimen from Normally Sterile Site by Gram Stain)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.307 Leptospirosis (Tests for Leptospira IgM Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.308 Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.310 Bacteria (Tests by Culture and Identification Method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.311 Viruses (Tests by Culture and Identification Method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.316 Rubella (Tests for rubella virus IgM Antibody)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.317 Shigellosis (Tests for Shigella species Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.319 Fungi (Tests by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.322 Pesticide Related Illness (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.326 Arboviral Disease [Other] (Disorders) (ICD10CM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.329 Apnea (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.330 Apnea (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.333 Shigellosis (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.335 Influenza (Tests for influenza A virus by Culture and Identification Method)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.336 Influenza (Tests for influenza A or B virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.340 Influenza (influenza A or B virus in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.341 Campylobacteriosis (Organism or Substance in Lab Results)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.342 Campylobacteriosis (Tests for Campylobacter species by Culture and Identification Method)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.343 Campylobacteriosis (Tests for Campylobacter species Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.344 Campylobacteriosis (Tests for Campylobacter species Antigen)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.349 Hepatitis A (Tests for hepatitis A virus IgM Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.353 Diarrhea (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.356 HIV Infection (Organism or Substance in Lab Results)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.359 Botulism (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.362 Hansen’s Disease (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.365 Silicosis (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.366 Silicosis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.371 Cryptosporidiosis (Organism or Substance in Lab Results)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.372 Cryptosporidiosis (Tests for Cryptosporidium species Nucleic Acid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.375 Cyclosporiasis (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.376 Cyclosporiasis (Tests for Cyclospora cayetanensis Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.379 Giardiasis (Tests for Giardia species Nucleic Acid)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.384 Listeriosis (Tests for Listeria monocytogenes Nucleic Acid)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.386 Vibriosis (Organism or Substance in Lab Results)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.388 Vibriosis (Tests for Vibrionaceae species [except Toxigenic Vibrio cholera O1 and O139] Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.390 Trichinellosis (Tests for Trichinella species Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.395 Syphilis (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.396 Syphilis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.398 Hepatitis C Virus Infection (Tests for hepatitis C virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.399 Hepatitis C Virus Infection (Tests for hepatitis C virus Antigen)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.40 STEC Infection (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.400 Hepatitis B Virus Infection (Tests for hepatitis B virus IgM Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.401 Hepatitis B Virus Infection (Tests for hepatitis B virus surface Antigen)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.403 Hepatitis B Virus Infection (Tests for hepatitis B virus Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.405 Hantavirus Infection and Diseases (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.407 Hepatitis C Virus Infection (Tests for hepatitis C virus Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.408 Hepatitis B Virus Infection (Organism or Substance in Lab Results)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.422 Tuberculosis (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.427 STEC Infection (Tests for Shiga toxin genes, or STEC, EHEC, or E. coli O157 Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.43 Gonorrhea [Cervicitis Urethritis] (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.436 Coccidioidomycosis (Tests for Coccidioides species IgM Antibody)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.437 Coccidioidomycosis (Tests for Coccidioides species Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.438 Coccidioidomycosis (Tests for Coccidioides species Antigen)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.44 Gonorrhea [Cervicitis Urethritis] (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.445 Legionellosis (Tests for Legionella species Antigen)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.446 Legionellosis (Tests for Legionella species Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.451 Tuberculosis (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.460 HIV Infection or AIDS (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.464 Malaria (Tests for Plasmodium species Nucleic Acid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.468 Leptospirosis (Tests for Leptospira Nucleic Acid)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.471 Leptospirosis (Tests for Leptospira Antibody [Quantitative] by Agglutination)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.472 Leptospirosis (Tests for Leptospira Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.476 Babesia species (Tests by Microscopic Observation in Blood)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.478 Anthrax (Tests for Bacillus anthracis by Culture and Identification Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.479 Anthrax (Tests for Bacillus anthracis Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.48 Salmonellosis (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.480 Anthrax (Tests for Bacillus anthracis Antigen)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.481 Anthrax (Tests for Bacillus anthracis Antibody)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.494 Ehrlichiosis (Organism or Substance in Lab Results)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.496 Q Fever (Tests for Coxiella burnetii IgM IgG Antibody [Excluding Quantitative IFA Tests for IgG Antibody against Phase I or II Antigen])active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.500 Q Fever (Tests for Coxiella burnetii Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.505 Toxic Shock Syndrome (TSS) (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.507 Toxic Shock Syndrome (TSS) (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.512 Brucellosis (Tests for Brucella species Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.515 Brucellosis (Tests for Brucella species Antibody [Quantitative])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.516 Brucellosis (Organism or Substance in Lab Results)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.519 Dengue Virus Infection (Tests for dengue virus Nucleic Acid)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.523 Dengue Virus Infection (Tests for dengue virus Antigen)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.524 Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Quantitative])active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.525 Dengue Virus Infection (Tests for dengue virus IgM Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.527 Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Qualitative])active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.530 Borrelia species (Tests for Nucleic Acid)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.531 Lyme Disease (Tests for Borrelia burgdorferi IgM IgG Antibody by Immunoblot)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.532 Lyme Disease (Tests for Borrelia burgdorferi Antibody by Immunoassay)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.534 Smallpox (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.542 Spotted Fever Rickettsiosis (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.548 St. Louis Encephalitis Virus Infection (Tests for Saint Louis encephalitis virus Antibody [Qualitative])active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.550 Syphilis (Tests for Treponema pallidum Nucleic Acid)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.553 Anaplasma species (Tests by Microscopic Observation)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.555 Yellow Fever (Tests for yellow fever virus Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.557 Yellow Fever (Tests for yellow fever virus Antibody [Quantitative])active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.56 Diarrhea (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.560 West Nile Virus Infection (Tests for West Nile virus Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.569 Plague (Tests for Yersinia pestis Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.575 Arboviral Disease [Other] (Tests for Arbovirus [Other] Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.576 Arboviral Disease [Other] (Tests for Arbovirus [Other] Antigen)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.577 Arboviral Disease [Other] (Tests for Arbovirus [Other] IgM Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.578 Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Quantitative])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.579 Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Qualitative])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.58 Pertussis (Tests for Bordetella pertussis Nucleic Acid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.580 Arboviral Disease [Other] (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.581 Viral Hemorrhagic Fever (Tests for Viral Hemorrhagic Fever Virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.584 Viral Hemorrhagic Fever (Tests for Viral Hemorrhagic Fever Virus IgG Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.586 Viral Hemorrhagic Fever (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.595 Tularemia (Tests for Francisella tularensis Nucleic Acid)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.598 Tularemia (Tests for Francisella tularensis Antibody)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.6 Diphtheria (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.605 Organisms (Tests by Microscopic Observation by Acid Fast Stain)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.606 Tuberculosis (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.614 Pertussis (Tests for Bordetella pertussis Toxin Antibody)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.621 Inspiratory Whoop (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.632 Chlamydia trachomatis Infection [Secondary Sites Complications] (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.645 Pertussis (Test Panels for Bordetella pertussis and Bordetella parapertussis Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.648 Vomiting (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.650 Jaundice (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.652 Bacteria (Tests in Specimen from Normally Sterile Site by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.660 Hypertonia [Excluding Congenital Hypertonia] (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.662 Chest Pain (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.663 Erythema Nodosum (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.664 Congenital Zika Syndromes (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.665 Congenital Zika Syndromes (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.666 Guillain Barré syndrome (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.668 Rash (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.671 Fever (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.672 Arthralgia (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.673 Arthralgia (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.674 Conjunctivitis (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.675 Conjunctivitis (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.676 Pregnant (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.677 Postpartum (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.678 Postpartum (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.679 Hearing Loss (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.680 Abdominal Pain (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.681 Abdominal Pain (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.686 Erythema Multiforme (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.687 Myalgia (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.689 Periorbital Edema (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.691 Eosinophilia (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.692 Eosinophilia (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.70 Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi by Culture and Identification Method)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.702 Weight Loss (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.705 Syphilis (Tests for Treponemal or Non Treponemal Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.709 Cough [Non Productive] (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.71 Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi Nucleic Acid)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.711 Wound Infection (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.712 Pneumonia (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.713 Sepsis [Septicemia] [Unspecified Organism] (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.714 Sepsis [Septicemia] [Unspecified Organism] (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.715 Meningitis (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.717 Cellulitis (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.718 Cellulitis (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.719 Myositis [Unspecified Cause] (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.720 Myositis [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.721 Otitis Media (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.722 Otitis Media (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.723 Otitis Externa (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.724 Otitis Externa (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.727 Acute Upper Respiratory Illness (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.728 HIV Infection (Tests for HIV Nucleic Acid [Qualitative])active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.730 HIV Infection (Tests for HIV Antibody)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.733 Perinatal Hepatitis B Virus Infection (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.741 Hepatitis B Immune Globulin (RXNORM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.744 Coccidioidomycosis (Tests for Coccidioides species IgG Antibody)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.746 Treponema pallidum (Tests by Microscopic Observation)active2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.747 Penicillin G [Benzathine] [Injectable] [Bicillin] (RXNORM)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.750 Chest Pain (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.755 Acute Upper Respiratory Illness (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.756 Purpura (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.757 Muscle Spasms (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.758 Muscle Spasms (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.762 Mumps (Test Panels for mumps virus IgM IgG Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.763 Parotitis [Unspecified Cause] (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.764 Mumps (Tests for mumps virus IgG Antibody)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.765 Aseptic Meningitis (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.766 Encephalitis (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.767 Hearing Loss (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.770 Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid in Specimen from Normally Sterile Site)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.773 Invasive Haemophilus influenzae Disease (Tests for Haemophilus influenzae Nucleic Acid in Specimen from Normally Sterile Site)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.777 Mastitis (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.779 Pancreatitis (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.780 Pancreatitis (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.782 Rubella (Test Panels for rubella virus IgM IgG Antibody)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.785 Opioid Overdose and Poisoning (Tests for Opioids [Qualitative])active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.789 Purpura (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.79 Campylobacteriosis (Disorders) (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.792 Novel Influenza A Virus Infection (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.793 Novel Influenza A Virus Infection (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.794 Sore Throat (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.795 Influenza (influenza A virus in Lab Results)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.796 Influenza (Novel influenza A virus in Lab Results)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.797 Influenza (Tests for influenza A or B virus by Culture and Identification Method)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.798 Influenza (Tests for influenza A virus Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.799 Influenza (Tests for influenza A virus Antigen)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.802 Influenza (Tests for Novel influenza A virus Nucleic Acid)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.803 Tests by Microscopic Observation in Tissue by H&E or PAS Stainactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.808 Headache (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.809 Headache (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.810 Backache (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.811 Backache (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.815 NU_Anaplasmosis (Tests for Anaplasma species Antibody [Qualitative])active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.816 Rubella (Tests for rubella virus IgG Antibody [Ratio] in Serum)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.818 Measles (Tests for measles virus IgG Antibody [Ratio] in Serum)active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.820 Rubella (Tests for rubella virus IgG Antibody [Quantitative] in Serum)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.822 Pneumoconiosis (Unspecified) (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.823 Pneumoconiosis (Unspecified) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.824 Computerized Tomography of Chest (Imaging)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.830 Poliovirus Infection (Tests for Poliovirus Antibody Titer in Serum Specimen)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.835 Lead in Blood (Disorders) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.836 Lead in Blood (Disorders) (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.839 Acid Fast Bacilli (Organism or Substance in Lab Results)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.841 Tuberculosis (Interferon Gamma Release Assays)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.842 Tests by Microscopic Observation in Tissueactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.844 Tuberculosis (Second Line Drugs for Treatment) (RXNORM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.846 SARS (Tests for SARS_CoV by Culture and Identification Method)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.847 SARS (Tests for SARS_CoV Nucleic Acid)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.86 Hemolytic Uremic Syndrome (HUS) (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.864 Nausea (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.865 Confusion (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.867 Dyspnea (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.869 Loss of Consciousness (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.87 Thrombotic Thrombocytopenic Purpura (TTP) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.875 SARS (Organism or Substance in Lab Results)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.878 MERS (Tests for MERS_CoV Nucleic Acid)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.88 Hemolytic Uremic Syndrome (HUS) (Disorders) (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.881 Difficulty Breathing (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.884 Tests by Microscopic Observation in Bloodactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.889 Hantavirus Infection (Tests for Hantavirus IgM IgG Total Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.892 Organisms (Tests by Microscopic Observation in Tissue by Acid Fast Stain)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.895 Rhinorrhea (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.896 Tests by Microscopic Observation in Blood Smearactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.897 Dengue Virus Infection (Test Panels for dengue virus IgM IgG Antibody)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.9 Xray of Chest (Imaging)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.90 Cough (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.900 Organisms (Tests by Microscopic Observation)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.902 Acute Renal Failure [Unspecified Cause] (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.907 Arthritis [Unspecified Cause] (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.91 Cough (SNOMED)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.910 Epididymitis [Unspecified Cause] (SNOMED)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.911 Epididymitis [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.914 Osteomyelitis [Unspecified Cause] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.915 Osteomyelitis [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.918 Spondylitis [Unspecified Cause] (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.919 Arthritis [Unspecified Cause] (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.92 Thrombotic Thrombocytopenic Purpura (TTP) (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.927 Thrombocytopenia [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.928 Bleeding [Unspecified Cause] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.930 ECG Abnormalities [Unspecified Cause] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.931 Hematemesis [Unspecified Cause] (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.932 Hematemesis [Unspecified Cause] (ICD10CM)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.934 Hematuria [Unspecified Cause] (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.935 Hemoptysis (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.937 Gastrointestinal Hemorrhage [Unspecified Cause] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.942 Petechiae [Non Traumatic] (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.952 Thrombocytopenia [Unspecified Cause] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.956 Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.957 Regional Lymphadenitis [Including Bubo] (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.958 Regional Lymphadenitis (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.96 Salmonellosis [Salmonella Species and Subspecies] (Organism or Substance in Lab Results)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.963 Arboviral Disease [Other] (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.965 Proteinuria [Unspecified Cause] (ICD10CM)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.969 Proteinuria [Unspecified Cause] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.970 Bulbar Weakness (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.971 Bulbar Weakness (ICD10CM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.976 Dysphagia (SNOMED)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.978 Impaired Respiration [Unspecified Cause] (SNOMED)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.979 Botulism (Organism or Substance in Lab Results)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.98 Shigellosis (Disorders) (SNOMED)active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.989 Tests for Mycobacterium species by Culture and Identification Methodactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.991 Rifampin (RXNORM)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.994 Organisms (Tests for Nucleic Acid)active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.998 Shigellosis (Tests for Enteroinvasive E. coli Nucleic Acid)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.999 Chlamydia species (Organism or Substance in Lab Results)active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.109 Pressure Injury Stage 2, 3, 4 or Unstageableactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.110 Pressure Injury Stage 2, 3, 4 or Unstageableactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.112 Pressure Injury Deep Tissueactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.113 Pressure Injury Stage 2, 3, 4 or Unstageableactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.119 Inpatient Fallsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.120 Major Injuriesactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.122 Inpatient Fallsactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.125 Bleeding at Non Critical Siteactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.130 Anticoagulants for VTE Prophylaxisactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.131 Anticoagulants for Indications Other than VTE Prophylaxisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.135 Bleeding at Critical Siteactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.143 Bleeding at Critical Siteactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.144 Bleeding at Critical Siteactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.145 Bleeding at Non Critical Siteactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.146 Bleeding at Non Critical Siteactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.160 Abdominal or Pelvic CT Scan with Contrastactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.163 Ultrasound of Lower Extremitiesactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.164 Ultrasound of Lower Extremitiesactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.165 Ultrasound of Lower Extremitiesactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.171 Inpatient Fallsactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.183 Anti Factor Xa Assayactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.187 Extracorporeal Membrane Oxygenation (ECMO)active2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.188 Extracorporeal Membrane Oxygenation (ECMO)active2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.190 Intra Aortic Balloon Pumpactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.191 Intra Aortic Balloon Pumpactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.193 Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)active2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.194 Pressure Injury Deep Tissue Diagnosesactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.196 Pressure Injury Stage 2, 3, 4, or Unstageable Diagnosesactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.197 Present on Admission or Clinically Undeterminedactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.198 Not Present On Admission or Documentation Insufficient to Determineactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.1 DEXA Dual Energy Xray Absorptiometry, Bone Densityactive2016-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.11 Bladder Cancer Staging Ta for Urology Careactive2016-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.12 Bladder Cancer staging T1 for Urology Careactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.13 Bladder Cancer staging Tis for Urology Careactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.15 Carcinoma of urinary bladder, superficialactive2016-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.16 Injection Leuprolide Acetateactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.17 High grade bladder cancer Ta for Urology Careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.18 Immunocompromised state for Urology Careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.19 Systemic chemotherapy for urology careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.2 Bladder Cancer in Situactive2016-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.20 Corticosteroids for patients receiving Urology Careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.21 Calcineurin inhibitors for patients receiving Urology Careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.23 Immunomodulators for patients undergoing Urology Careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.24 Monoclonal antibody for patient undergoing Urology Careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.28 Radiotherapy for patients undergoing Urology Careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.29 Plasmacytoid cell, morphologic abnormality for urology careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.3 Bladder Cancer in Situactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.30 Sarcomatoid, morphologic abnormality for Urology Careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.31 Micropapillary, morphologic abnormality, for Urology Careactive2017-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.32 Immunosuppressive Drugs for Urology Careactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.38 DEXA Dual Energy Xray Absorptiometry, Bone Density for Urology Careactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.39 Mixed histology urothelial cell carcinoma for Urology Careactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.4 BCG Bacillus Calmette Guerin, Ticeactive2016-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.40 Cystectomy for Urology Careactive2017-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.44 Unavailability of Bacillus Calmette Guerin for urology careactive2017-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.45 Bladder Cancer for Urology Careactive2017-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.48 Androgen deprivation therapy for Urology Careactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.5 BCG Bacillus Calmette Guerin, Connaughtactive2016-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.52 BCG Bacillus Calmette Guerin for Urology Careactive2020-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.53 Cystectomy for Urology Careactive2018-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.54 Acute Tuberculosis for Urology Careactive2018-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.55 Cystectomy for Urology Careactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.56 Active Tuberculosis for Urology Careactive2018-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.57 Bladder Cancer Staging Tis for Urology Careactive2019-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.58 Bladder Cancer Staging Tis for Urology Careactive2019-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.59 Hospital Services for Urologyactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.6 Peripheral DXA Scanactive2016-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.60 Chemotherapy Agents for Advanced Canceractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.8 Tuberculosis Diagnosis Prior to Urology Careactive2016-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.9 Leukemia Diagnosis Prior to Urology Careactive2016-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.13 Preventative Clinical Encountersactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.14 Intensive Lifestyle Interventionsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.15 Intensive Lifestyle Interventionsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.16 Intensive Lifestyle Interventionsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.17 Intensive lifestyle interventionsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.21 Outpatient Clinical Encountersactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.22 Outpatient Clinical Encountersactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.23 Outpatient Clinical Encountersactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.24 Outpatient Clinical Encountersactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.25 Reason for No Intensive Lifestyle Interventionactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.27 Type 2 Diabetes Diagnosesactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.28 Type 2 Diabetes Diagnosesactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.29 Type 2 Diabetes Diagnosesactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.30 Prediabetes HbA1c Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.31 Prediabetes HbA1c Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.32 Prediabetes HbA1c Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.33 Prediabetes Oral Glucose Tolerance Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.34 Prediabetes Oral Glucose Tolerance Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.35 Prediabetes Oral Glucose Tolerance Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.36 Prediabetes Fasting plasma glucose or Plasma Glucose Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.37 Prediabetes Fasting plasma glucose or Plasma Glucose Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.38 Prediabetes Fasting plasma glucose or Plasma Glucose Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.4 Glycemic Screening Testsactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.40 Sickle Cell Disease with Vaso Occlusive Episodeactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.41 Sickle Cell Disease with Vaso Occlusive Episodeactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.42 Sickle Cell Disease with Vaso Occlusive Episodeactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.43 Analgesics for Acute Painactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.49 Medication Therapy Management Services for Essential Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.5 Glycemic Screening Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.52 Remote Physiologic Blood Pressure Monitoringactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.57 Aldosterone Receptor Blocker for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.58 Alpha Blocker for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.59 Angiotensin Converting Enzyme Inhibitor for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.6 Glycemic Screening Testsactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.60 Angiotensin II Receptor Blocker for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.61 Beta Blocker for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.62 Calcium Channel Blocker Dihydropyridine for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.63 Calcium Channel Blocker Non Dihydropyridine for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.64 Central Acting for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.65 Direct Renin Inhibitor for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.66 Loop Diuretic for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.67 Neuronal Blocking Agent for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.68 Potassium Sparing Diuretic for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.69 Thiazide Diuretic for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.7 Preventative Clinical Encountersactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.70 Vasodilator for Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.73 Analgesics for Acute Pain (Non Parenteral Route)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.74 Analgesics for Acute Pain (Parenteral Route)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.75 Analgesics for Acute Pain Non Oral Enteral/Mucosal Routesactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.77 Antihypertensive Medication Classesactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.78 Medication Therapy Management Services for Essential Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.79 Medication Therapy Management Services for Essential Hypertensionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.8 Preventative Clinical Encountersactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.84 Renal Colicactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.85 Renal Colicactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.86 Renal Colicactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.88 Direct LDL Cholesterolactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.89 Calculated LDL Cholesterolactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.9 Preventative Clinical Encountersactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.50 Urinary retentionactive2017-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.51 Urinary retentionactive2017-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.52 Urinary retentionactive2017-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.65 Morbid Obesityactive2018-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.66 Morbid Obesityactive2018-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.67 Morbid Obesityactive2018-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.68 BMI greater than 40active2019-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.69 Morbid Obesityactive2019-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.1 Pregnancy Statusactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.10 Pap Smear Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.103 Female Sterilization HCPCS Devicesactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.105 Female Sterilization ICD10CM Provision Encountersactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.109 Sterilization SNOMED Findingsactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.11 HIV Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.110 Pregnancy Bundle Visitsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.111 Prenatal Care Specific Visits CPTactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.112 Prenatal Care Specific Visits HCPCSactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.113 Prenatal Care Specific Visits SNOMEDactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.114 Prenatal Care Specific Visitsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.115 Self Identified Need for Contraception (SINC)active2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.117 Syphilis Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.118 Infecund Not for Contraceptive Reasons CPT Proceduresactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.119 Infecund Not for Contraceptive Reasons HCPCS Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.12 Human Papilloma Virus Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.120 Prenatal Care Visits CPTactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.121 Prenatal Care Visits HCPCSactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.122 Prenatal Care Visits SNOMEDactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.123 Pregnancy Related Diagnoses ICD10CMactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.124 Pregnancy Related Diagnoses SNOMEDactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.125 Non Live Birth Diagnoses ICD10CMactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.126 Non Live Birth Diagnoses SNOMEDactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.127 Non Live Birth CPT Proceduresactive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.128 Non Live Birth ICD10PCS Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.129 Contraceptive Ring RXNORM Medicationsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.13 Chlamydia Trachomatis Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.130 Contraceptive Implants RXNORM Medicationsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.131 Injectable Contraceptive RXNORM Medicationsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.132 Oral Contraceptive Pills RXNORM Medicationsactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.133 Pregnancy Related Diagnosesactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.134 Female Sterilization SNOMED Provision Proceduresactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.135 General Prenatal Care Visitsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.136 Non Live Birth Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.137 Non Live Birth Diagnosesactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.138 IUD Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.139 IUD Provision Proceduresactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.14 Neisseria Gonorrhoeae Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.140 IUD Devicesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.141 Contraceptive Patch SNOMED Devicesactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.142 Female Sterilization Provision Proceduresactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.143 Live Birth Delivery CPT Proceduresactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.144 Contraceptive Patch SNOMED Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.145 Contraceptive Patch SNOMED Findingsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.146 Contraceptive Patch ICD10CM Provision Encountersactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.147 Contraceptive Patch ICD10CM Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.148 Live Birth Delivery ICD10PCS Proceduresactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.149 Contraceptive Patch HCPCS Devicesactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.15 Chlamydia trachomatis and Neisseria Gonorrhoeae combined Testsactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.150 Contraceptive Patch LOINCactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.151 Infecund Not for Contraceptive Reasons Proceduresactive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.152 Live Birth Delivery Procedures SNOMED CTactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.153 Contraceptive Ring SNOMED Surveillance Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.154 Contraceptive Ring SNOMED Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.155 Contraceptive Ring SNOMED Findingsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.156 Contraceptive Ring ICD10CM Provision Encountersactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.157 Contraceptive Ring ICD10CM Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.159 Contraceptive Ring HCPCS Devicesactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.160 Contraceptive Ring LOINCactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.161 Contraceptive Implant SNOMED Devicesactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.162 Contraceptive Implant ICD10PCS Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.163 Contraceptive Implant SNOMED Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.164 Contraceptive Implant SNOMED Findingsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.165 Infecund Not for Contraceptive Reasons SNOMED Proceduresactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.167 Contraceptive Implant LOINCactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.168 Pregnancy Bundle CPTactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.169 Pregnancy Bundle HCPCSactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.17 Contraceptive Typeactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.170 Contraceptive Implant ICD10CM Provision Encountersactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.171 Contraceptive Implant ICD10CM Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.173 Contraceptive Implant HCPCS Devicesactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.174 Contraceptive Patch Devicesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.177 Live Birth Delivery Proceduresactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.178 Contraceptive Ring Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.18 Contraception Not Used Reasonactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.180 Contraceptive Implant CPT Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.181 Injectable Contraceptive SNOMED Surveillance Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.182 Injectable Contraceptive SNOMED Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.183 Injectable Contraceptive SNOMED Findingsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.185 Injectable Contraceptive ICD10CM Provision Encountersactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.186 Injectable Contraceptive ICD10CM Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.187 Injectable Contraceptive HCPCS Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.188 Injectable Contraceptive LOINCactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.189 Oral Contraceptive Pill SNOMED Surveillance Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.190 Oral Contraceptive Pill SNOMED Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.191 Oral Contraceptive Pill SNOMED Findingsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.192 Contraceptive Implant SNOMED Surveillance Proceduresactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.193 Oral Contraceptive Pill ICD10CM Provision Encountersactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.194 Oral Contraceptive Pill ICD10CM Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.195 Oral Contraceptive Pill HCPCS Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.196 Oral Contraceptive Pill LOINCactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.197 Injectable Contraceptive Provision Proceduresactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.198 Injectable Contraceptive Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.199 Oral Contraceptive Pill Provision Proceduresactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.200 Oral Contraceptive Pill Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.201 Contraceptive Implant Devicesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.202 Contraceptive Implant Provision Proceduresactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.203 Contraceptive Implant Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.204 Prenatal Care Bundle CPTactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.205 Prenatal Care Bundle Visitsactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.206 Infecund Not for Contraceptive Reasons ICD10PCS Proceduresactive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.209 Yes and No Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.21 Contraceptive Provision Methodactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.210 Pap Smear Resultsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.211 Contraceptive discussionactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.22 Pregnancy Intentionactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.24 Clinical Provider Roleactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.29 Insurance Coverage Typeactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.3 Organism Detectionactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.31 English Proficiencyactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.76 Contraceptive Patch RXNORM Medicationsactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.78 Intrauterine Devices CPT Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.79 Intrauterine Devices HCPCS Devicesactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.80 Intrauterine Devices LOINCactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.81 Intrauterine Devices HCPCS Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.83 Intrauterine Devices ICD10CM Provision Encountersactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.84 Intrauterine Devices ICD10CM Surveillanceactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.85 Intrauterine Devices RXNORM Medicationsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.86 Intrauterine Devices SNOMED Devicesactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.87 Intrauterine Devices SNOMED Findingsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.88 Intrauterine Device SNOMED Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.89 Intrauterine Devices SNOMED Surveillance Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.91 Intrauterine Devices ICD10PCS Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.93 Female Sterilization CPT Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.96 Infecund Not for Contraceptive Reasons SNOMED Findingsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.97 Infecund Not for Contraceptive Reasons ICD10CMactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.98 Female Sterilization LOINCactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.99 Female Sterilization ICD10PCS Provision Proceduresactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.10 ASN Screening Declinedactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.11 Transportation Insecurity Diagnosisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.12 Food Insecurity Diagnosisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.13 Homelessness Diagnosisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.14 Housing Instability Diagnosisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.15 Intervention for Positive Transportation Insecurity Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.16 Intervention for Positive Food Insecurity Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.17 Intervention for Positive Food Insecurity Screenactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.18 Intervention for Positive Food Insecurity Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.19 Intervention for Positive Food Insecurity Screenactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.2 Intracranial or Intraspinal surgeryactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.20 Intervention for Positive Homelessness Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.21 Intervention for Positive Housing Instability Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.22 Emergency Department Observationactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.27 Mental Health Diagnosis without Substance Use Disordersactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.28 Mental Health Diagnosis without Substance Use Disordersactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.29 Bed Assignedactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.3 Malignant Intracranial Neoplasm Groupactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.31 Healthcare Agent & Power of Attorney Documentationactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.32 Healthcare Agent and Power of Attorney Documentationactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.33 Advance Directive Documentationactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.34 Advance Directive Documentationactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.35 Advance Directive Documentationactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.36 Portable Medical Order(s) Documentationactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.37 Portable Medical Order(s) Documentationactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.38 Advance Care Planning Discussion Documentationactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.4 Thrombolytic medicationsactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.40 Advance Care Planning Documentationactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.41 Advance Care Planning Documentationactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.42 Healthcare Agent & Power of Attorney Documentationactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.43 Advance Directive Documentationactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.45 Advance Care Planning Documentationactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.46 Advance Care Planning Documentationactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.47 Portable Medical Order(s) Documentationactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.48 Portable Medical Order(s) Documentationactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.49 Intervention for Positive Utility Insecurity Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.5 Allergy to thrombolyticsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.50 Intervention for Positive Utility Insecurity Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.51 Intervention for Positive Transportation Insecurity Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.52 Intervention for Positive Transportation Insecurity Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.53 Intervention for Positive Housing Instability Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.54 Intervention for Positive Housing Instability Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.55 Intervention for Positive Homelessness Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.56 Intervention for Positive Homelessness Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.57 Non Invasive Oxygen Therapy Device Codesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.58 Goals, preferences, and priorities for medical treatmentactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.6 Thrombolytics Adverse Eventactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.7 Intraspinal surgeryactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.8 Intervention for Positive Utility Insecurity Screenactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.9 Utility Insecurity Diagnosisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1176.58 Food Insecurity Screening Positiveactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.1 Ezetimibe Therapyactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.10 Antihypertensive Medicationsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.100 Allergy or Intolerance to ACE Medicationactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.101 Allergy or Intolerance to ARB Medicationactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.102 Chronic Kidney Disease Stage 1active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.103 Chronic Kidney Disease Stage 2active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.104 Chronic Kidney Disease Stage 3active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.105 Chronic Kidney Disease Stage 4active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.106 Chronic Kidney Disease Stage 5active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.107 ICD10 CM Chronic Kidney Disease Stage 1active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.108 ICD10 CM Chronic Kidney Disease Stage 2active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.111 AHA GWTG Chronic Kidney Disease Stage 2active2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.112 ICD10 CM Chronic Kidney Disease Stage 3active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.113 ICD10 CM Chronic Kidney Disease Stage 4active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.114 ICD10 CM Chronic Kidney Disease Stage 5active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.115 AHA GWTG Chronic Kidney Disease Stage 1active2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.116 AHA GWTG Chronic Kidney Disease Stage 3active2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.117 AHA GWTG Chronic Kidney Disease Stage 4active2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.118 SNOMED CT Atrial Fibrillationactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.119 ICD10 CM Atrial Fibrillationactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.121 AHA GWTG Atrial Fibrillationactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.123 SNOMED CT Hyperlipidemiaactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.124 ICD10 CM Hyperlipidemiaactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.125 AHA GWTG Hyperlipidemiaactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.126 SNOMED CT Hypertriglyceridemiaactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.127 ICD10 CM Hypertriglyceridemiaactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.129 AHA GWTG Hypertriglyceridemiaactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.130 SNOMED CT Gestational Diabetesactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.131 ICD10 CM Gestational Diabetesactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.132 AHA GWTG Gestational Diabetesactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.133 SNOMED CT Hyperglycemiaactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.134 ICD10 CM Hyperglycemiaactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.135 AHA GWTG Hyperglycemiaactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.136 SNOMED CT Nonobstructive CADactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.137 ICD10 CM Nonobstructive Coronary Artery Diseaseactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.138 AHA GWTG Nonobstructive coronary artery diseaseactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.139 AHA GWTG Anti Obesity Pharmacotherapyactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.15 Non Tobacco Smoking Product Useractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.16 Antihypertensive Fixed Dose Combination Medicationsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.2 PCSK9 Inhibitorsactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.20 CCB and Thiazide and Thiazide Like Diureticsactive2021-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.21 Referral to cardiac rehabactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.22 Cardiac Rehabilitationactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.25 2 Hour Blood Glucose Testactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.26 NYHA Functional Classificationactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.27 ARNI Therapyactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.29 MRA Therapyactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.3 Cholesterol non HDL Laboratory Testactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.30 SGLT2 Inhibitorsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.31 Heart Transplantactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.32 Heart Transplantactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.33 Heart Transplantactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.34 Allergy to MRA Therapyactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.35 Aspirin or Clopidogrelactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.39 Cardiac Rehabilitationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.4 Hypothyroidismactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.40 Cardiac Rehabilitationactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.43 SGLT2 Ingredientsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.44 MRA Ingredientsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.49 Minnesota Living with Heart Failure Questionnaireactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.5 Hypothyroidismactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.50 Kansas City Cardiomyopathy Questionnaireactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.51 Cardiac Paceractive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.52 Cardiac Paceractive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.53 Cardiac Paceractive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.54 Heart Transplant Complicationsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.55 Heart Transplant Complicationsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.56 Heart Transplant Complicationsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.57 Left Ventricular Assist Device Complicationsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.58 Left Ventricular Assist Device Complicationsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.59 Left Ventricular Assist Device Placementactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.6 Hypothyroidismactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.60 Left Ventricular Assist Device Placementactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.61 Left Ventricular Assist Device Placementactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.62 Left Ventricular Assist Device Placementactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.63 Heart Transplantactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.65 Cardiac Paceractive2022-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.66 Diastolic Heart Failureactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.67 Diastolic Heart Failureactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.68 Diastolic Heart Failureactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.69 Allergy to SGLT2 Inhibitorsactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.7 Anorexia Nervosaactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.70 Intolerance to SGLT2 Inhibitorsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.71 Intolerance to MRA Therapyactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.72 ARNI Ingredientactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.73 Mitral Stenosisactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.74 Mitral Stenosisactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.75 Mitral Stenosisactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.76 Mechanical Prosthetic Heart Valveactive2022-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.77 Mechanical Prosthetic Heart Valveactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.78 Mechanical Prosthetic Heart Valveactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.79 Mechanical Prosthetic Heart Valve in Situactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.8 Anorexia Nervosaactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.82 Systolic Heart Failureactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.83 Systolic Heart Failureactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.84 Systolic Heart Failureactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.85 Carotid Interventionactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.86 Serum Creatinineactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.87 Urine Creatinineactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.88 Urine Albuminactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.9 Anorexia Nervosaactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.90 Non Steroidal Mineralcorticoid Receptor Antagonistactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.91 Glucagon like peptide 1 medicationsactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.96 AHA GWTG Long COVID19active2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.97 AHA GWTG Long COVID19 SNOMEDCTactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.98 AHA GWTG Long COVID19 ICD10CMactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.1 Wound internal item and/or body structure visible value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.11 Wound exudate appearance value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.12 Wound exudate color value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.13 Exudate odor value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.14 Wound anatomic location value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.16 Skin temperature value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.17 Skin color enumerated value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.18 Skin turgor value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.19 Skin and mucous membrane integrity value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.2 Periwound condition value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.20 Skin moisture value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.3 Wound Type Etiology value setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.4 Wound episode value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.6 Wound bed appearance value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.60 Wound type reference setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.7 Wound bed color value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.74 Nonverbal pain indicators reference setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.76 Pain associated signs and symptoms reference setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.77 Pain body location reference setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.8 Wound edge description value set (foundation metadata concept)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.80 Pain quality reference setactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.81 Pain speed of onset reference setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.9 Presence absence value set (foundation metadata concept)active2018-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.1 Common drug substances for allergy and intolerance documentationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.2 Common drug classes for allergy and intolerance documentationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.3 Common dietary substances for allergy and intolerance documentationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.4 Common environmental substances for allergy and intolerance documentationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.5 Common refutations for substance causes for allergy and intolerance documentationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.7 Common substances for allergy and intolerance documentationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.8 Common substances for allergy and intolerance documentation including refutationsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.10 NHSNCriterionOfDiagnosisCode(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.11 NHSNCriterionOfDiagnosisCode(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.12 NHSNInfectionConditionCode(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.13 NHSNInfectionConditionCode(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.14 NHSNInfectionTypeCode(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.15 NHSNInfectionTypeCode(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.16 NHSNInfectionFirstReportedSource(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.17 NHSNInfectionFirstReportedSource(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.18 NHSNLOS/MENDischargeDisposition(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.19 NHSNLOS/MENDischargeDisposition(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.20 NHSNPopulationSummaryReportTypeCode(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.21 NHSNPopulationSummaryReportTypeCode(LOINC)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.22 NHSNSameDayOutcomeMeasure(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.23 NHSNSameDayOutcomeMeasure(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.24 NHSNSignificantPathogenCode(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.25 NHSNSignificantPathogenCode(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.26 NHSNSpinalFusionApproachCode(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.27 NHSNSpinalFusionApproachCode(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.28 NHSNVascularAccessTypeCode(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.29 NHSNVascularAccessTypeCode(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.30 NHSNVascularSpecimenCollectionSite(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.31 NHSNVascularSpecimenCollectionSite(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.38 Blood Glucose Laboratory and Point of Care Testsactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.58 Diabetes Medicationsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.6 NHSNPathogenCodeAROactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.62 Lab Tests for Clostridioides difficileactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.63 Bacterial and Fungal Blood Culture Testsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.7 NHSNRoleOfPerformerCode(CDCNHSN)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.74 Enteral Medication Routeactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.75 Intravenous Medication Routeactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.76 Fidaxomicinactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.77 Vancomycinactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.78 Metronidazoleactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.79 Fidaxomicin, Vancomycin, and Metronidazoleactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.8 NHSNRoleOfPerformerCode(SNOMEDCT)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.85 Baloxaviractive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.86 Peramiviractive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.87 Zanamiviractive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.88 Digestive, Intramuscular, Intravenous Route of Administrationactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.89 Maternal Diagnosesactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.9 NHSNRoleOfPerformerCode(HealthCareProviderTaxonomy)active2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.90 NHSN LTC AU Antimicrobial Agentsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.91 Long Term Care Discharge Dispositionactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.94 NHSNNeurogenicBladderactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.95 NHSNSpinalCordInjuryactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1139 S4G Hyperlipidemiaactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1291 S4G Cardiomyopathyactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1292 S4G Tricuspid valve disorderactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1293 S4G Pompe diseaseactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1294 S4G Malignant hyperthermiaactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1295 S4G Malignancyactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1297 S4G Intestinal polypactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1298 S4G Hamartomaactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1299 S4G Diabetes mellitusactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1300 S4G Muscular dystrophy and weaknessactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1325 S4G Hamartoma and S4G Intestinal Polypactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1326 S4G Malignancy and S4G Intestinal Polypactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1344 Tests for Neisseria gonorrhoeae of unspecified site reported by presenceactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1352 Body weightactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1354 Cefixime preparations for oral administrationactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1358 Beta lactam medicinal product SNOMEDactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1370 Beta lactam ingredients for allergy determination RXNORMactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.147 SCIP Major Surgical Procedureactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.158 Multiple Myeloma Regimen Drugsactive2019-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.226 Opioids, Allactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3483 Financial Insecurity Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3484 Food Insecurity Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3485 Health Literacy Screening Assessments Questionsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3486 Homelessness Screening Assessments Questionsactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3487 Housing Instability Screening Assessments Questionsactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3488 Less Than High School Education Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3519 Health Insurance Coverage Status Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3520 Inadequate Housing Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.393 Hypoglycemics Severe Hypoglycemiaactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.394 Hypoglycemics Treatment Medicationsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4436 Gentamicin medicationsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4437 Azithromycin medicationsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4448 Lidocaineactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4466 Pharyngeal specimensactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4467 Urogenital & Anorectal Specimensactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4469 Cabotegravir Injectable Productsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4470 Emtricitabine oral for HIV PrEPactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4474 HIV Laboratory Based Testsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4502 Ceftriaxone all code typesactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.491 Medium Dose ICS Formoterol Preparationsactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495 ICS LABA LAMA Preparationsactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.788 Social Determinants of Health Conditionsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.789 Social Determinants of Health Proceduresactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.790 Social Determinants of Health Service Requestsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.93 CPIC RxNORM abacavir SCDGactive2019-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.94 CPIC RxNORM allopurinol SCDGactive2019-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.95 CPIC RxNORM amitriptyline SCDGactive2019-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.96 CPIC RxNORM atazanavir SCDGactive2019-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.97 CPIC RxNORM atomoxetine SCDGactive2019-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.99 CPIC RxNORM capecitabine SCDGactive2019-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.1 Mechanical Complications Related To Hip and Knee Proceduresactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.10 Surgical Site Bleeding and Other Surgical Site Complicationsactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.11 Procedures Resulted From Surgical Site Bleeding and Other Surgical Site Complicationsactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.12 Opioid (Oral Tablets and Patches only)active2019-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.13 Comorbidity Risk Factorsactive2020-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.14 Treatment of Hemorrhage or Hematomaactive2020-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.15 General Surgeryactive2020-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.17 Coagulation Disorder Conditionsactive2020-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.18 Acute Respiratory Failureactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.19 Anticoagulant Medicationsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.2 Fracture Exclusions For Hip And Knee Proceduresactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.20 Anticoagulant Medications, Oralactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.21 Anticoagulant Medications, Injectionactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.28 Active Bleedingactive2020-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.29 Fall Risk Increasing Drugs (FRIDs)active2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.3 Pulmonary Embolism Complications Related To Hip and Knee Proceduresactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.30 Fall Risk Factorsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.32 Total Hip Arthroplasty Surgeryactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.33 Total Knee Arthroplasty Surgeryactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.34 AbnormalityOfGaitAndMobilityactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.35 Assymetry Symptomsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.36 Hemiplegia Symptomsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.37 Leg Weakness Symptomsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.38 Osteopenia Symptomsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.39 Stroke Symptomsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.4 Sepsis Complications Related To Hip and Knee Proceduresactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.40 Vestibular Symptomsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.41 TricyclicAntidepressantsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.42 Benzodiazepinesactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.43 LoopDiureticsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.44 Antiepilepticsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.45 Antipsychoticsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.46 Opioid Medicationsactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.47 Imaging Related to VTEactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.48 Anticoagulant Medicationactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.49 VTE Diagnosesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.5 Nonprimary Total Hip, Total Knee Replacementactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.50 Bisphosphonate Therapyactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.51 VTE Symptomsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.52 Oncology Critical Care Unitsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.53 Provider Typesactive2022-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.56 FOBT_Labactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.57 Colorectal Screeningactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.58 Screening Mammogram (CPT)active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.59 Screening Mammogram (LOINC)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.6 Pneumonia Complications Related To Hip and Knee Proceduresactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.60 Screening Mammogram (SNOMEDCT)active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.61 Screening Mammogram (Grouping)active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.62 Diagnostic Mammography (CPT)active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.63 Diagnostic Mammography (LOINC)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.64 Diagnostic Mammography (SNOMEDCT)active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.65 Diagnostic Mammographyactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.66 Breast Cancer Biopsy and Surgical Excisionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.67 BI_RADS Categories 0, 4, and 5active2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.68 BI_RADS Categories 1, 2, and 3active2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.7 Malignant Neoplasm Complications Related To Hip and Knee Proceduresactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.8 Periprosthetic Joint Infection/Wound Infection and Other Wound Complicationsactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.9 Procedures Resulted From Periprosthetic Joint Infection/Wound Infectionsactive2019-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.101 Local Anestheticsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.102 Ophthalmic Epinephrinesactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.103 Inhaled Epinephrinesactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.104 Clopidogrelsactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.105 Cytochrome P450 2C19 inhibitorsactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.106 Cytochrome P450 2C9 inhibitorsactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.107 Aspirin Ingredient and Risk of GI Bleedingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.109 Oral Anticoagulant Ingredients and Risk of GI Bleedingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.110 Corticosteroid Ingredients and Risk of GI Bleedingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.111 Antidepressant Ingredients and Risk of GI Bleedingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.112 PPI and Risk of GI Bleedingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.113 Antiplatelet Ingredients and Risk of GI Bleedingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.114 NSAIDs Ingredients and Risk of GI Bleedingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.115 Kratom containing compoundsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.117 Clopidogrel Ingredients and Risk of GI Bleedingactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.121 Gastrointestinal bleeding episode and Risk of GI Bleeding 1active2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.122 Gastrointestinal bleeding episode and Risk of GI Bleeding 2active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.123 Gastrointestinal bleeding episode and Risk of GI Bleedingactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.24 Oxycodonesactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1217.2 TESTSemanticBitsValueSetactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.1 Bronchiectasis Disorder SNOMEDactive2020-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.10 Interstitial Lung Disease ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.100 Occupational Therapy Procedure HCPCSactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.101 Occupational Therapy Procedureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.102 Speech Language Therapy Procedure HCPCSactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.103 Speech Language Therapy Procedureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.104 Home Health Procedureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.105 Intermittent Skilled Nursing Home Health Procedureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.106 pH, Hematocrit, Partial Pressure Carbon Dioxide, Partial Pressure Oxygen or Bicarbonate Laboratory Test for Breathing Assistance Device Evaluation Excluding Oxygen Saturationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.107 Breathing Test Procedure During Sleepactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.108 Ambulance Transport Procedureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.109 Prefabricated Spinal Orthotic Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.11 Interstitial Lung Disease SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.110 Custom Fitted Spinal Orthotic Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.111 Custom Fabricated Spinal Orthotic Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.112 Orthotic Device Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.113 Spinal Orthotic Device or Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.115 Spine or Neck Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.116 Spine or Neck Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.117 Spine or Neck Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.118 Total Electric Hospital Bed Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.119 Hypoventilation Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.12 Interstitial Lung Diseaseactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.120 Hypoventilation Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.121 Hypoventilation Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.122 Respiratory Assist Device Qualifying Conditionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.123 Apnea Hypopnea Index Rate Measurementactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.124 Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC) Measurementactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.125 Maximal Inspiratory Pressure Measurementactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.126 Forced Vital Capacity (FVC) Measurement by Spirometryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.127 Oxygen Saturation Measurement At Restactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.128 Respiratory Assist Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.129 Respiratory Assist Device Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.13 Cystic Fibrosis Lung Disease ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.130 Home Oxygen Therapy Accessoryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.131 Forced Vital Capacity (FVC) Measurement Predictionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.132 Oxygen Saturation Laboratory Test and Setting for Breathing Assistance Device Evaluationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.133 Respiratory Disturbance Indexactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.134 Sleep Related Symptom for Positive Airway Pressure Device Use Evaluationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.135 Past Medical History Condition Related to Need for Positive Airway Pressure Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.136 Home or Facility Care Locationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.137 Fracture of Bone Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.138 Fracture of Bone Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.139 Fracture of Bone Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.14 Cystic Fibrosis Lung Disease SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.140 Severe Obesity Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.141 Severe Obesity Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.142 Severe Obesity Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.143 Transfer from Bed Impairment SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.144 Bed Confinement Impairmentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.145 Transfer from Bed Impairmentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.146 Ability to Safely Sit in Chair or Wheelchair Impairment SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.147 Mobility Impairment or Fall From Chair ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.148 Ability to Safely Sit in Chair or Wheelchair Impairmentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.149 Fall or Fall Risk from Wheelchair or Stretcher SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.15 Cystic Fibrosis Lung Diseaseactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.150 Fall or Fall Risk from Wheelchair or Scooter ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.152 Muscle, Tendon or Joint Contracture Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.153 Muscle, Tendon or Joint Contracture Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.154 Muscle, Tendon or Joint Contracture Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.155 Muscle Weakness or Myasthenia Gravis Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.156 Muscle Weakness or Myasthenia Gravis Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.158 Myocardial Infarction Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.159 Myocardial Infarction Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.16 Neoplasm of Lung or Trachea Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.160 Myocardial Infarction Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.161 Amputation Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.162 Amputation Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.164 Lower Extremity Deep Vein Thrombosis Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.165 Lower Extremity Deep Vein Thrombosis Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.167 Spinal Cord Injury or Paralysis Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.168 Spinal Cord Injury or Paralysis Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.169 Spinal Cord Injury or Paralysis Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.17 Neoplasm of Lung or Trachea Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.170 Demyelinating Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.171 Demyelinating Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.172 Demyelinating Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.173 Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.174 Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.176 Wound Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.177 Wound Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.178 Wound Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.179 Danger to Self or Others Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.18 Neoplasm of Lung or Trachea Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.180 Danger to Self or Others Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.181 Danger to Self or Others Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.182 Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.183 Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.184 Behavioral Disorder Related to Need for Non Emergency Ambulance Transferactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.185 Pain on Movement or Joint Pain Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.186 Pain in Joint Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.187 Pain on Movement or Joint Pain Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.188 Non Emergency Ambulance Transport Reasonactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.189 Osteoarthritis Disorder SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.19 Secondary Erythrocytosis Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.190 Osteoarthritis Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.191 Osteoarthritis Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.192 Immunosuppressive Medication RxNormactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.193 Medication Supporting Immunosupressive Medication RxNormactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.194 Non Emergency Ambulance Transport Qualifying Procedureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.197 Turalioactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.198 Hepatic Medical Historyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.2 Bronchiectasis Disorder ICD10CMactive2020-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.20 Secondary Erythrocytosis Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.21 Secondary Erythrocytosis Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.22 Acute or Chronic Heart Failure Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.23 Acute or Chronic Heart Failure Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.24 Acute or Chronic Heart Failure Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.25 Home Oxygen Therapy Qualifying Conditionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.26 Device Use Patient Activity Levelactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.27 Portable Liquid Oxygen Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.28 Stationary Liquid Oxygen Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.29 Sleep Apnea or Breathing Related Sleep Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.3 Bronchiectasis Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.30 Sleep Apnea or Breathing Related Sleep Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.31 Sleep Apnea or Breathing Related Sleep Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.32 Positive Airway Pressure Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.33 Diabetes Mellitus Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.34 Diabetes Mellitus Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.35 Diabetes Mellitus Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.36 Restrictive Lung Disease SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.37 Restrictive Lung Disease ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.38 Restrictive Lung Diseaseactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.39 Chest Wall Deformity Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.4 Chronic Obstructive Lung Disease (COPD) ICD10CMactive2020-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.40 Chest Wall Deformity Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.41 Chest Wall Deformity Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.42 Motor Neuron Disease or Spinal Muscular Atrophy Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.43 Motor Neuron Disease or Spinal Muscular Atrophy Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.44 Motor Neuron Disease or Spinal Muscular Atrophy Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.45 Chronic Respiratory Failure Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.46 Chronic Respiratory Failure Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.47 Chronic Respiratory Failure Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.48 Ventilator Therapy Qualifying Conditionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.49 Ventilator Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.5 Chronic Obstructive Lung Disease SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.50 Fixed Height Hospital Bed Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.51 Variable Height Hospital Bed Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.52 Semi electric Hospital Bed Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.53 Heavy Duty Extra Wide Hospital Bed Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.54 Extra Heavy Duty Hospital Bed Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.55 Hospital Bed Trapeze Accessory Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.56 Hospital Bed Cradle Accessory Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.57 Hospital Bed Side Rail or Safety Enclosure Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.58 Hospital Bed Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.59 Intermittent Urinary Catheter or Urological Supply for Intermittent Urinary Catheter Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.6 Chronic Obstructive Lung Disease (COPD)active2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.60 Indwelling Urinary Catheter Supply or Urological Supply for Indwelling Urinary Catheter Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.61 Urinary Collection and Irrigation System Device or Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.62 External Catheter or Urinary Collection Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.63 Miscellaneous Urinary Catheter Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.64 Urinary Incontinence Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.65 Urinary Incontinence ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.66 Urinary Incontinence Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.67 Chronic Urinary Retention Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.68 Urinary Retention Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.69 Chronic Urinary Retention Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.7 Hypoxemia Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.70 Urinary Incontinence or Chronic Urinary Retention Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.72 Portable Compressed Gas Oxygen Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.73 Stationary Oxygen Concentrator Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.74 Compressed Gas Oxygen Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.75 Stationary Compressed Gas Oxygen Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.76 Portable Oxygen Concentrator Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.77 Liquid Oxygen Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.78 Oxygen Concentrator Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.79 Portable Oxygen Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.8 Hypoxemia Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.80 Stationary Oxygen Therapy Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.81 Organ Transplant History Significant to Immunosuppressive Therapyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.82 Immunosuppressive Medication HCPCSactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.83 Medication Supporting Immunosuppressive Medication HCPCSactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.84 Home Blood Glucose Monitor Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.85 Insulin Medicationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.86 Hyperglycemia or Hypoglycemia Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.87 Hyperglycemia or Hypoglycemia Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.88 Hyperglycemia or Hypoglycemia Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.89 Diabetic Test Strip or Lancet Supplyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.9 Hypoxemia Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.90 Organ Transplant Procedure Significant to Immunosuppressive Therapyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.91 Pulmonary Hypertension Disorder SNOMEDCTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.92 Pulmonary Hypertension Disorder ICD10CMactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.93 Pulmonary Hypertension Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.94 Laboratory Test for Home Glucose Monitor Evaluationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.95 Physical Therapy Procedure SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.96 Occupational Therapy Procedure SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.97 Speech Language Therapy Procedure SNOMED CTactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.98 Physical Therapy Procedure HCPCSactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.99 Physical Therapy Procedureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.135 Last Menstrual Period (LMP)active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.146 Abortion, All (ICD 10 CM)active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.149 Abortion, All (SNOMED CT)active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.150 Abortion, Allactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.151 Abortion, All (CPT)active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.152 Abortion, 1st Trimesteractive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.153 Abortion, 2nd Trimesteractive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.154 Abortion, 2nd Trimesteractive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.155 Abortion, 3rd Trimesteractive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.156 Abortion, Electiveactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.157 Abortion, Electiveactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.158 Abortion, Failed Attemptactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.159 Abortion, Inducedactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.160 http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.533 Cellulitisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.535 Diabetic Hand or Diabetic Cheiroarthropathyactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.538 Necrobiosis Lipoidica (Skin Lesions)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.539 Necrobiosis Lipoidica (Skin Lesions)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.540 Necrobiosis Lipoidica (Skin Lesions)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.541 Gangreneactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.542 Gangreneactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.543 Gangreneactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.544 Dupuytren's Contractureactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.545 Dupuytren's Contractureactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.546 Dupuytren's Contractureactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.547 Scleroderma or Thick Skin Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.548 Scleroderma or Thick Skin Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.549 Scleroderma or Thick Skin Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.554 Acanthosis Nigricansactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.555 Acanthosis Nigricansactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.556 Acanthosis Nigricansactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.557 Eruptive Xanthomatosisactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.558 Periodontitisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.559 Periodontitisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.560 Periodontitisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.561 Amputated Limb (Not Traumatic)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.562 Amputated Limb (Not Traumatic)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.563 Amputated Limb (Not Traumatic)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.564 Hypertension, Essential or Primary ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.565 Hypertension, Essential or Primary SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.567 Hypertension, Secondary ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.568 Hypertension, Secondary SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.571 Hypertension Stageactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.579 Cardiomyopathyactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.58 Hypercalcemia Conditions SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.580 NYHA Heart Failure Functional Classificationsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.581 American Heart Association Heart Failure Stageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.582 Framingham Risk Assessmentsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.583 American College of Cardiology or American Heart Association Ascvd Risk Score (acc/aha Ascvd Risk)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.584 Atherosclerotic Cardiovascular Diseaseactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.586 Goutactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.587 Psoriatic Arthritisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.588 Reactive Arthritisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.59 Hypercalcemia Conditions ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.590 Experience of Traumatic Eventsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.591 Cannabis Useactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.592 Hearing Impairmentactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.6 Chronic Kidney Disease Type or Causeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.60 Hypercalcemia Conditionsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.606 Anginaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.607 Anginaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.608 Anginaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.609 Unstable Anginaactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.61 Hypocalcemia Conditionsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.610 Unstable Anginaactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.611 Unstable Anginaactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.613 Ischemic Heart Diseaseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.614 Ischemic Heart Diseaseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.615 Left Ventricular Hypertrophy SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.616 Stroke Historyactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.618 Strokeactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.619 Transient Ischemic Attackactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.62 Hypocalcemia Conditions ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.620 Transient Ischemic Attackactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.621 Transient Ischemic Attackactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.625 Aneurysmactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.626 Aneurysmactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.627 Aneurysmactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.63 Hypocalcemia Conditions SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.634 Aortic Diseaseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.635 Aortic Diseaseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.636 Aortic Diseaseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.637 Carotid Stenosisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.638 Carotid Stenosisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.639 Carotid Stenosisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.64 Hyperphosphatemia Conditions SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.640 Intracranial Stenosisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.641 Intracranial Stenosisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.642 Intracranial Stenosisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.643 Pulmonary Edemaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.644 Pulmonary Edemaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.645 Pulmonary Edemaactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.646 Osteoarthritis (Oa)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.647 Osteoarthritis (Oa)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.648 Osteoarthritis (Oa)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.649 Rheumatoid Arthritis (Ra)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.65 Hyperphosphatemia Conditions ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.650 Rheumatoid Arthritis (Ra)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.651 Rheumatoid Arthritis (Ra)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.652 Infectious Arthritisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.653 Infectious Arthritisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.654 Infectious Arthritisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.656 Temporomandibular Disorder Diagnosisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.658 Irritable Bowel Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.659 Irritable Bowel Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.66 Hyperphosphatemia Conditionsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.660 Irritable Bowel Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.661 Neuropathic Pain (Neuralgia)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.662 Neuropathic Pain (Neuralgia)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.663 Neuropathic Pain (Neuralgia)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.664 Neuromasactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.665 Neuromasactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.666 Neuromasactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.667 Phantom Painactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.668 Phantom Painactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.669 Phantom Painactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.67 Hematuria Conditionsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.670 Entrapment Neuropathyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.671 Entrapment Neuropathyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.672 Entrapment Neuropathyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.673 Myalgic Encephalomyelitis or Chronic Fatigue Syndromeactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.674 Myalgic Encephalomyelitis or Chronic Fatigue Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.675 Myalgic Encephalomyelitis or Chronic Fatigue Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.676 Psychotic Depressionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.677 Psychotic Depressionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.678 Psychotic Depressionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.679 Post Partum Depressionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.68 Hematuria Conditions ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.680 Post Partum Depressionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.681 Post Partum Depressionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.682 Seasonal Affective Disorderactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.683 Seasonal Affective Disorderactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.684 Seasonal Affective Disorderactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.685 Psychological Traumaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.686 Psychological Traumaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.687 Psychological Traumaactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.688 Grief or Lossactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.689 Grief or Lossactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.69 Hematuria Conditions SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.690 Grief or Lossactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.691 Suicide Riskactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.692 Suicide Riskactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.693 Suicide Riskactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.694 Vapingactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.695 Vapingactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.696 Vapingactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.697 Tobacco Use or Exposureactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.699 Tobacco Use or Exposureactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.70 Metabolic Acidosis Conditionsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.701 Binge Drinkingactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.702 Binge Drinkingactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.703 Binge Drinkingactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.704 Drug Misuseactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.705 Drug Misuseactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.706 Drug Misuseactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.707 Drug Misuseactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.708 Sensory Statusactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.709 Sensory Statusactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.71 Metabolic Acidosis Conditions ICD10active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.711 Fall Riskactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.713 Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasiaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.714 Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasiaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.715 Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasiaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.716 Urinary Incontinenceactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.717 Urinary Incontinenceactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.718 Urinary Incontinenceactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.719 Urinary Urgencyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.72 Metabolic Acidosis Conditions SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.720 Urinary Urgencyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.721 Urinary Urgencyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.722 Urinary Frequencyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.723 Urinary Frequencyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.724 Urinary Frequencyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.725 Nocturiaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.726 Nocturiaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.727 Nocturiaactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.728 Pelvic Organ Prolapseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.729 Pelvic Organ Prolapseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.73 Hyperlipidemia Conditionsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.730 Pelvic Organ Prolapseactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.731 Erectile Dysfunctionactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.732 Erectile Dysfunctionactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.733 Erectile Dysfunctionactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.734 Interstitial Cystitis or Bladder Pain Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.735 Interstitial Cystitis or Bladder Pain Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.736 Interstitial Cystitis or Bladder Pain Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.737 Recurrent Urinary Tract Infectionsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.738 Recurrent Urinary Tract Infectionsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.739 Recurrent Urinary Tract Infectionsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.74 Hyperlipidemia Conditions ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.740 Hypertriglyceridemiaactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.741 Hypertriglyceridemiaactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.742 Hypertriglyceridemiaactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.743 Hypothyroidismactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.744 Hypothyroidismactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.745 Hypothyroidismactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.746 Menopauseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.747 Menopauseactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.748 Menopauseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.749 Testicular Hypofunctionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.75 Hyperlipidemia Conditions SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.750 Testicular Hypofunctionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.751 Testicular Hypofunctionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.752 Primary Aldosteronismactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.753 Primary Aldosteronismactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.754 Primary Aldosteronismactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.755 Restless Leg Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.756 Restless Leg Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.757 Restless Leg Syndromeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.759 Claudicationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.76 Chronic Pain Conditionsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.760 Claudicationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.761 Claudicationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.762 Angioedemaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.763 Angioedemaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.764 Angioedemaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.768 Nonalcoholic Fatty Liver Diseaseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.769 Nonalcoholic Fatty Liver Diseaseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.77 Chronic Pain ICD10active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.770 Nonalcoholic Fatty Liver Diseaseactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.771 Thalassemiaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.772 Thalassemiaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.773 Thalassemiaactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.78 Chronic Pain SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.79 Arthritis Disorders SCTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.790 Urine Protein to Creatinine Ratio (UPCR)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.791 24 Hour Urine Volumeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.792 24 Hour Urine Protein Excretionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.793 Total Carbon Dioxide or Bicarbonate in blood, serum or plasmaactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.794 Calcium (Not Corrected for Serum Albumin) in Blood, Plasms, or Serumactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.795 B Type Natriuretic Peptide [Bnp] in Blood, Serum or Plasmaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.797 N Terminal Pro_B_Type Natriuretic Peptide [Nt_Probnp] in blood, serum or plasmaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.799 Temporomandibular Disorder Diagnosisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.80 Arthritis Disorders ICD10active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.800 Temporomandibular Disorder Diagnosisactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.801 High Sensitivity Troponinactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.804 Aspartate Transaminase or Alanine Aminotransferase Ratioactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.805 Alkaline Phosphatase (Alp) in Blood, Serum or Plasmaactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.806 Gamma Glutamyl Transpeptidase (Ggt) in blood, serum or plasmaactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.807 Triiodothyronine in serum or plasmaactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.808 Fasting Blood Glucoseactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.809 Random Blood Glucose Testactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.81 Arthritis Disordersactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.810 Uric Acid (Urate) in blood, serum or plasmaactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.811 Aldosterone/Renin Ratioactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.812 Serum Rheumatoid Factoractive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.813 Blood Ethanol Levelactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.814 Drugs of Abuse Screen in Hairactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.815 Drugs of Abuse Screen in Urineactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.816 Drugs of Abuse Screen in Bloodactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.817 Drugs of Abuse Screen in Tissueactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.818 Drugs of Abuse Screen in Body Fluidactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.819 Urea Reduction Ratioactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.82 Preeclampsia Disorders SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.822 Bowel Soundsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.823 Uroflowmetryactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.826 Gait Qualityactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.828 Balance Assessmentsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.83 Preeclampsia Disorders ICD10active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.836 Sit to Stand Abilityactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.84 Preeclampsia Disordersactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.840 Spinal Cord Compressionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.841 Spinal Cord Compressionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.842 Alcohol Use (Revised 2021)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.843 Alcohol Use (Revised 2021)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.844 Alcohol Use (Revised 2021)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.845 Alcohol Useactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.85 Hyperuricemia Conditionsactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.86 Hyperuricemia Conditions ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.864 Kidney Biopsy Reportactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.867 Skin Biopsy Reportactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.868 Muscle Biopsy Reportactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.869 Gastric Tissue Biopsy Reportactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.87 Hyperuricemia Conditions SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.870 Bone Biopsy Reportactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.873 Echocardiogramactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.88 Vitamin D Deficiency Conditions SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.880 Spinal or Back CTactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.881 Chest CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.882 Abdominal or Pelvic CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.883 Limb CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.884 Heart Calcium Scoreactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.885 Coronary CT Angiogramactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.886 Limb CT Angiogramactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.888 Chest CT Angiogramactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.889 Head and Neck CT Angiogramactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.89 Vitamin D Deficiency Conditions ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.891 Gastrointestinal Tract X Rayactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.892 Gallbladder X Rayactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.893 Kidney X Rayactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.894 Abdomen X Rayactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.895 Pelvis X Rayactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.896 Hand X Rayactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.897 Wrist X Rayactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.898 Forearm X Rayactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.899 Elbow X Rayactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.90 Vitamin D Deficiency Conditionsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.900 Upper Arm X Rayactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.901 Shoulder X Rayactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.902 Upper Extremity X Rayactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.903 Foot X Rayactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.904 Ankle X Rayactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.905 Shin X Rayactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.906 Knee X Rayactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.907 Thigh X Rayactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.908 Hip X Rayactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.909 Lower Extremity X Rayactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.91 Alkaline Phosphatase Deficiency Conditions SCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.910 Abdominal MRIactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.911 Adrenal Gland MRIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.912 Kidney MRIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.913 Pancreas MRIactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.915 Kidney MRAactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.916 Chest Region MRIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.917 Pulmonary MRIactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.918 Cardiac MRIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.92 Alkaline Phosphatase Deficiency Conditions ICD10active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.920 Spine MRIactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.921 Head and Neck MRIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.922 Brain MRIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.923 Pelvic Region MRIactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.924 Knee MRIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.925 Foot MRIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.927 Shoulder MRIactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.928 Lower Extremity MRAactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.93 Alkaline Phosphatase Deficiency Conditionsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.930 Spine X Rayactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.933 Hip MRIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.934 Thigh or Femur MRIactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.935 Ankle MRIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.936 Lower Extremity MRIactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.937 Forearm MRIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.938 Elbow MRIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.939 Wrist MRIactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.94 Uremic Pruritus Conditions ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.940 Hand MRIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.942 Upper Extremity MRIactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.943 Abdominal MRAactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.944 Chest MRAactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.945 Upper Extremity MRAactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.947 Head and Neck MRAactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.948 Pelvic Region MRAactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.949 Functional MRIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.95 Uremic Pruritus Conditions SCTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.951 Optical Coherence Tomographyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.954 Bathing or grooming/hygiene (ADL/IADL)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.955 Dressing (ADL or IADL)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.956 Toileting (ADL or IADL)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.957 Transferring (ADL or IADL)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.958 Walking or ambulation/locomotion (ADL/IADL)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.96 Uremic Pruritus Conditionsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.960 Domestic Duties or Household Tasks (ADL/IADL)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.961 Telephone Use (ADL or IADL)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.962 Bed Mobility (ADL or IADL)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.963 Stair Use (ADL or IADL)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.964 Medication Management (ADL or IADL)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.967 Electromyographyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.968 Electroencephalogramactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.969 Exercise Stress Testactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.97 Insomnia Disordersactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.976 Sleep Duration, Deviceactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.977 Steps Per Time, Deviceactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.978 Physical Activity Level, Deviceactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.979 Cognitive Function Clinician Interpretationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.98 Insomnia Disorders ICD10active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.987 Psychosisactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.99 Insomnia Disorders SCTactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.991 Suicidal Ideation and Behaviorsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.994 Sleep Durationactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.996 Pain Intensity or Severityactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.997 Pain Qualityactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.4 Glaucoma ICD10active2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.5 Glaucoma SNOMEDactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.1 Scleritisactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.2 Scleritisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.3 Scleritisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.1 Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomographyactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.2 Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Non Diagnostic or Non CTactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.3 Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Nuclear Medicine With CTactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.4 Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography CT Without Specified Body Regionactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.6 Outpatient Encounter Locationsactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.7 Outpatient Activity Codesactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.6 Anaphylaxis, ICD10CM codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.60 Guillain Barre Syndrome, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.61 Febrile seizure, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.62 Encephalomyelitis and encephalitis, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.63 Disseminated Intravascular Coagulation, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.64 Deep Vein Thrombosis, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.65 Bells Palsy, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.66 Appendicitis, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.67 Anaphylaxis, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.68 Acute Myocardial Infarction, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.69 Multisystem Inflammatory Syndrome, SNOMED codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.7 Anaphylaxis, SNOMED codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.70 Multisystem Inflammatory Syndrome, diagnosis codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.71 Transfusion CPT codes for exposure identificationactive2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.72 Transfusion ICD9 codes for exposure identificationactive2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.73 Transfusion ICD10PCS codes for exposure identificationactive2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.74 Transfusion CPT, ICD9, ICD10PCS codes for exposure identificationactive2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75 COVID19 vaccine ICD10PCS codes for exposure identificationactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.8 Appendicitis, SNOMED codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.9 Appendicitis, ICD10CM codes for AE reportingactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.1 Test Diabetes codesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.100 Cardiomyopathy Hypertrophic Conditionactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.12 Metabolic Syndrome LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.15 MetabolicSyndromeConditionactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.16 Annual Physical ICD9 CN5active2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.164 Diabetic Retinal Screening HD CPT for Tax Pairactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.165 Optometrist and Ophthalmologist Taxonomy HD Taxonomyactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.167 End Stage Renal Disease (ESRD)_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.168 End Stage Renal Disease (ESRD)_HD_ICD9active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.169 End Stage Renal Disease (ESRD)_HD_ICD10active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.17 Annual Physical ICD10 CN5active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.170 End Stage Renal Disease (ESRD)_HD_HCPCSactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.171 End Stage Renal Disease (ESRD)_HD_LOINCactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.172 End Stage Renal Disease (ESRD)_HD_Clinical Condition Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.173 Systolic Blood Pressure_HD_SNOMEDactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.174 Systolic Blood Pressure_HD_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.175 Systolic Blood Pressure_HD_LOINCactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.176 Systolic Blood Pressure_HDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.177 Diastolic Blood Pressure_HD_SNOMEDactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.178 Diastolic Blood Pressure_HD_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.179 Diastolic Blood Pressure_HD_LOINCactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.18 Annual Physical SNOMED CN5active2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.180 Diastolic Blood Pressure_HDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.181 Remote Blood Pressure_HD_SNOMEDactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.182 Remote Blood Pressure_HDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.183 Remote Blood Pressure_HD_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.184 Acute Inpatient_CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.185 Acute Inpatient_CN_HD_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.186 Acute Inpatient_HD_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.187 ED Visit_CN_HD_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.188 ED Visit_CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.19 Annual Physical Taxonomy CN5active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.190 Pregnancy_HD_Groupingactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.191 Pregnancy_CN_HD_SNOMEDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.192 Pregnancy_CN_HD_ICD10active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.193 ED Visit_HD_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.194 Lipid Panel_Event_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.195 Lipid Panel_Event_HCPCSactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.196 Lipid Panel_Event_LOINCactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.197 Lipid Panel_Event_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.198 Lipid Panel_Event_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.199 Unknown Glucose_Event_ICD9active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.20 Annual Physical CN5active2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.200 Unknown Glucose_Event_ICD10active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.201 Unknown Glucose_Event_LOINCactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.202 Unknown Glucose_Event_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.203 Unknown Glucose_Event_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.204 Unknown Glucose_Lab_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.205 Bone Marrow Transplant CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.206 Bone Marrow Transplant CN_HD_ICD10active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.207 Bone Marrow Transplant_HD_CN_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.208 Immunocompromising Conditions CN_HD_ICD9active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.209 Immunocompromising Conditions CN_HD_ICD10PCSactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.21 Annual Physical CPT CN5active2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.210 Immunocompromising Conditions CN_HD_ICD10CMactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.211 Immunocompromising Conditions_HD_CN_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.212 Immunocompromising Conditions CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.213 Cerebrospinal Fluid Leak CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.214 Cerebrospinal Fluid Leak CN_HD_ICD10active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.215 Cerebrospinal Fluid Leak_HD_CN_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.216 Anatomic or Functional Asplenia CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.217 Anatomic or Functional Asplenia CN_HD_ICD9active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.218 Anatomic or Functional Asplenia CN_HD_ICD10active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.219 Anatomic or Functional Asplenia_HD_CN_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.22 Annual Physical HCPCS CN5active2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.220 Sickle cell Anemia and HB S Disease CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.221 Sickle cell Anemia and HB S Disease CN_HD_ICD10active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.222 Sickle cell Anemia and HB S Disease_HD_CN_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.223 Pneumococcal Vaccine CN_HD_SNOMEDactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.224 Pneumococcal Vaccine CN_HD_HCPCSactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.225 Pneumococcal Vaccine CN_HD_CVXactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.226 Pneumococcal Vaccine CN_HD_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.227 Pneumococcal Vaccine_HD_CN_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.228 Influenza Vaccine CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.229 Influenza Vaccine CN_HD_HCPCSactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.23 Annual Physical CPT for Tax Pair CN5active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.230 Influenza Vaccine CN_HD_CVXactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.231 Influenza Vaccine CN_HD_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.232 Influenza Vaccine_HD_CN_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.233 Cochlear Implant CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.234 Cochlear Implant CN_HD_ICD10active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.235 Cochlear Implant CN_HD_HCPCSactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.236 Cochlear Implant CN_HD_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.237 Cochlear Implant_HD_CN_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.238 Chemotherapy CN_HD_SNOMEDactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.239 Chemotherapy CN_HD_ICD10active2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.24 Annual Physical ICD9 for Tax Pair CN5active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.240 Chemotherapy CN_HD_CPTactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.241 Chemotherapy_HD_CN_Groupingactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.244 Fasting Blood Glucose_Lab_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.245 Chronic Heart Failure (CHF)_ICD9active2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.246 Chronic Heart Failure (CHF)_ICD10active2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.251 Asthma_LOINCactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.253 Asthma_Clinical Condition Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.254 Pregnancy Loss_HD_SNOMEDactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.255 Pregnancy Loss_HD_ICD10active2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.257 Pregnancy Loss_HD_Clinical Condition Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.258 Heart Failure (CHF)_ICD9active2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.259 Heart Failure (CHF)_ICD10active2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.260 Heart Failure (CHF)_SNOMEDactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.261 Heart Failure (CHF)_HCPCSactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.262 Heart Failure (CHF)_LOINCactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.263 Heart Failure (CHF)_CPTactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.264 Heart Failure (CHF)_RxNormactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.265 Heart Failure (CHF)_Clinical Condition Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.270 Triglyceride_Lab_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.274 Total Cholesterol_CPTactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.275 Total Cholesterol_Lab_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.276 LDL_SNOMEDactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.280 LDL_Lab_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.284 HDL_LOINCactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.285 HDL_Lab_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.286 Colectomy_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.288 Colectomy_ICD9active2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.29 Hospice Exclusions Groupingactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.290 Colectomy_Event_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.291 CT Colonography_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.292 CT Colonography_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.294 CT Colonography_Event_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.295 FIT DNA_LOINCactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.296 FIT DNA_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.297 FIT DNA_HCPCSactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.298 FIT DNA_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.299 FIT DNA Test_Lab_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.30 Annual Physical Codes for Tax Pair CN5active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.300 Sigmoidoscopy_CPTactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.302 Sigmoidoscopy_ICD9active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.303 Sigmoidoscopy_SNOMEDactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.304 Sigmoidoscopy_Event_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.305 Colonoscopy_CPTactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.306 Colonoscopy_HCPCSactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.307 Colonoscopy_ICD9active2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.308 Colonoscopy_SNOMEDactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.309 Colonoscopy_Event_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.310 FOBT Lab_CPTactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.311 FOBT Lab_HCPCSactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.312 FOBT Lab_LOINCactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.313 FOBT Lab_SNOMEDactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.314 FOBT Lab Test_Lab_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.315 Colorectal Cancer_HD_ICD10active2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.316 Colorectal Cancer_HD_ICD9active2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.317 Colorectal Cancer_HD_SNOMEDactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.318 Colorectal Cancer_HD_Groupingactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.319 Absence of Cervix Diagnosis_HD_ICD10active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.320 Absence of Cervix Diagnosis_HD_ICD9active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.321 Absence of Cervix Diagnosis_HD_SNOMEDactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.322 Absence of Cervix Diagnosis_HD_Groupingactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.323 Hysterectomy With No Residual Cervix_HD_CPTactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.324 Hysterectomy With No Residual Cervix_HD_ICD10active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.325 Hysterectomy With No Residual Cervix_HD_ICD9active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.326 Hysterectomy With No Residual Cervix_HD_SNOMEDactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.327 Hysterectomy With No Residual Cervix_HD_Groupingactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.328 High Risk HPV Test_HD_CPTactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.329 High Risk HPV Test_HD_HCPCSactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.330 High Risk HPV Test_HD_LOINCactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.331 High Risk HPV Test_HD_SNOMEDactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.332 High Risk HPV Test_HD_Groupingactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.333 Cervical Cytology_HD_CPTactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.334 Cervical Cytology_HD_HCPCSactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.335 Cervical Cytology_HD_LOINCactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.336 Cervical Cytology_HD_SNOMEDactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.337 Cervical Cytology_HD_Groupingactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.338 AFib (Atrial Fibrillation)_ICD9active2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.339 AFib (Atrial Fibrillation)_ICD10active2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.340 AFib (Atrial Fibrillation)_SNOMEDactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.341 AFib (Atrial Fibrillation)_LOINCactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.342 AFib (Atrial Fibrillation)_RxNORMactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.343 AFib (Atrial Fibrillation)_CPTactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.344 AFib (Atrial Fibrillation)_Clinical Condition Groupingactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.345 COVID19 Vaccine_CPTactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.346 COVID19 Vaccine_HCPCSactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.348 COVID19 Vaccine_RxNormactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.349 COVID19 Vaccine_CVXactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350 COVID19 Vaccine_Event Clinical Groupingactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.351 Coronary Artery Disease (CAD)_ICD9active2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.352 Coronary Artery Disease (CAD)_ICD10PCSactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.353 Coronary Artery Disease (CAD)_ICD10CMactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.354 Coronary Artery Disease (CAD)_CPTactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.355 Coronary Artery Disease (CAD)_HCPCSactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.356 Coronary Artery Disease (CAD)_LOINCactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.357 Coronary Artery Disease (CAD)_SNOMEDactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.358 Coronary Artery Disease (CAD)_CUI_UMLSactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.359 Coronary Artery Disease (CAD)_Clinical Condition Groupingactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.360 Allergy List_SNOMEDactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.361 Allergy List_ICD10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.362 Allergy List_Clinical Grouping Eventactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.363 Statin Use_RxNormactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.364 Other Revascularization_SNOMEDactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.365 Other Revascularization_CPTactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.366 Other Revascularization_Groupingactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.367 Ischemic Vascular Disease (IVD)_SNOMEDactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.368 Ischemic Vascular Disease (IVD)_ICD10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.369 Ischemic Vascular Disease (IVD)_Groupingactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.370 Muscular Pain and Disease_SNOMEDactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.371 Muscular Pain and Disease_ICD10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.372 Muscular Pain and Disease_Groupingactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.373 Cirrhosis_SNOMEDactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.374 Cirrhosis_ICD10active2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.375 Cirrhosis_Groupingactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.376 IVF_SNOMEDactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.377 IVF_HCPCSactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.378 IVF_Groupingactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.379 Estrogen Agonists Medications_RXNORMactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.382 Pre_Hypertension (Pre_HTN)_Clinical Condition Groupingactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.384 Family History Hypertension (HTN)_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.385 Family History Hypertension (HTN)_Clinical Condition Groupingactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.386 Obesity_Condition_UMLSactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.387 Podiatry_Taxonomyactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.388 Cardiology _Taxonomyactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.393 BMI >=40_Event_Clinical Condition Groupingactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.400 Smoker Status_Event_Clinical Condition Groupingactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.401 First Trimester_ICD10active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.402 First Trimester_SNOMEDactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.403 First Trimester_LOINCactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.404 First Trimester_CPTactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.405 First Trimester_UMLS CUIactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.406 First Trimester_Clinical Grouping Eventactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.408 Birth Event_ICD10active2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.409 Birth Event_SNOMEDactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.413 Birth Event_Clinical Grouping Eventactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.414 Obesity_Condition_SNOMEDactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.415 Obesity_Condition_ICD10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.416 Obesity_Condition_ICD9active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.417 Obesity_Clinical Grouping Conditionactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.418 Pre_Hypertension (Pre_HTN)_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.419 Pre_Hypertension (Pre_HTN)_ICD9active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.420 Pre_Hypertension (Pre_HTN)_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.424 BMI >=30_Event_Clinical Condition Groupingactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.427 Obesity_Condition_LOINCactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.428 Vitals Body Height LOINCactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.429 Vitals Body Height SnoMedactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.430 Vitals Body Heightactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.431 bwell_Vital_Blood Glucose_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.432 Anxiety_Clinical Grouping Condition_ICD9active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.433 Anxiety_Clinical Grouping Condition_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.434 Anxiety_Clinical Grouping Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.435 Anxiety_Clinical Grouping Condition_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.436 Anxiety_Clinical Grouping Conditionactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.437 bwell_Vital_Blood Oxygen_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.438 bwell_Vital_Systolic Blood Pressure_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.439 bwell_Vital_Diastolic Blood Pressure_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.440 bwell_Vital_Heart Rate_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.441 bwell_Vital_BMI_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.442 bwell_Vital_Body Fat_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.443 bwell_Vital_Body Temperature_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.444 bwell_Vital_Body Height_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.445 bwell_Vital_Body Weight_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.446 bwell_Vital_Respiratory Rate_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.447 bwell_Vital_Waist Circumference_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.448 bwell_Vital_Blood Glucose_Clinical Grouping Labactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.449 bwell_Vital_Blood Oxygen_Clinical Grouping Eventactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.450 bwell_Vital_Systolic Blood Pressure_Clinical Grouping Eventactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.451 bwell_Vital_Diastolic Blood Pressure_Clinical Grouping Eventactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.452 bwell_Vital_Heart Rate_Clinical Grouping Eventactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.453 bwell_Vital_BMI_Clinical Grouping Eventactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.454 bwell_Vital_Body Fat_Clinical Grouping Eventactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.455 bwell_Vital_Body Temperature_Clinical Grouping Eventactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.456 bwell_Vital_Body Height_Clinical Grouping Eventactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.457 bwell_Vital_Body Weight_Clinical Grouping Eventactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.458 bwell_Vital_Respiratory Rate_Clinical Grouping Eventactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.459 bwell_Vital_Waist Circumference_Clinical Grouping Eventactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.460 Pregnancy_CN_HD_LOINCactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.461 Pregnancy_CN_HD_CPTactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.462 Pregnancy_CN_HD_UMLSactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.463 Second Trimester_ICD10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.464 Second Trimester_SNOMEDactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.465 Second Trimester_Clinical Grouping Eventactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.466 Third Trimester_SNOMEDactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.467 Third Trimester_ICD10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.468 Third Trimester_Clinical Grouping Eventactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.469 Pregnancy Due Date_LOINCactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.470 Second Trimester_LOINCactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.472 OGTT_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.473 OGTT_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.475 OGTT_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.476 OGTT_Groupingactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.477 Second Trimester_CPTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.479 Prostate Cancer Screening_HD_ICD9active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.482 Prostate Cancer Screening_HD_Groupingactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.484 Prostate Dysplasia_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.486 Prostate Dysplasia_Groupingactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.487 Prostectomy_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.488 Prostectomy_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.490 Prostectomy_Groupingactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.494 PSA Testing _LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.495 PSA Testing_Groupingactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.496 Active Pregnancy_CPTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.497 Active Pregnancy_ICD10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.498 Active Pregnancy_LOINCactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.499 Active Pregnancy_SNOMEDactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.5 ADD/ADHD Conditionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.500 Active Pregnancy_Clinical Grouping Eventactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.501 Abnormal PSA Testing _SNOMEDactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.502 Prediabetes_Clinical Grouping Condition_ICD10active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.503 Prediabetes_Clinical Grouping Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.504 Prediabetes_Clinical Grouping Conditionactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.505 Third Trimester_CPTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.506 Third Trimester_LOINCactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.508 bwell_Vital_Waist Circumference_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.509 bwell_Vital_Blood Oxygen_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.510 bwell_Vital_Body Temperature_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.511 bwell_Vital_Diastolic Blood Pressure_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.512 bwell_Vital_Systolic Blood Pressure_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.513 bwell_Vital_Systolic_and_Diastolic Blood Pressure_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.514 bwell_Vital_Systolic_and_Diastolic Blood Pressure_Clinical Grouping Eventactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.515 bwell_Vital_Heart Rate_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.516 bwell_Vital_Respiratory Rate_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.517 Lupus_Clinical_Condition_ICD10active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.519 Lupus_Clinical_Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.520 Lupus_Clinical Condition Groupingactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.523 UTI_Clinical_Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.524 UTI_Clinical Condition Groupingactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.525 Postpartum_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.526 Postpartum_HCPCSactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.527 Postpartum_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.528 Postpartum_ICD9CMactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.529 Postpartum_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.530 Postpartum_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.531 Postpartum_Clinical Grouping Eventactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.532 bwell_Vital_Head Circumference_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.533 bwell_Vital_Head Circumference_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.534 bwell_Vital_Head Circumference_Clinical Grouping Eventactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.535 bwell_Vital_Body Surface Area_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.536 bwell_Vital_Body Surface Area_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.537 bwell_Vital_Body Surface Area_Clinical Grouping Eventactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.538 bwell_Vital_Vital Signs Panel_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.539 bwell_Vital_Vital Signs Panel_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.540 bwell_Vital_Vital Signs Panel_Clinical Grouping Eventactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.541 bwell_Vital_Blood Pressure Panel_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.542 bwell_Vital_Blood Pressure Panel_Clinical Grouping Eventactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.543 Depression_Clinical Grouping Condition_CPTactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.544 Depression_Clinical Grouping Condition_HCPCSactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.545 Depression_Clinical Grouping Condition_ICD10active2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.546 Depression_Clinical Grouping Condition_ICD9active2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.547 Depression_Clinical Grouping Condition_LOINCactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.548 Depression_Clinical Grouping Condition_SNOMEDactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.549 Depression_Clinical Grouping Conditionactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.550 MI (Myocardial Infarction)_Clinical Grouping Condition_ICD9active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.551 MI (Myocardial Infarction)_Clinical Grouping Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.552 MI (Myocardial Infarction)_Clinical Grouping Condition_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.553 MI (Myocardial Infarction)_Clinical Grouping Conditionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.554 CABG_Clinical Grouping Condition_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.555 CABG_Clinical Grouping Condition_HCPCSactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.556 CABG_Clinical Grouping Condition_ICD10PCSactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.557 CABG_Clinical Grouping Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.558 CABG_Clinical Grouping Conditionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.559 PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.56 Diabetic Retinal Screening HD CPTactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.560 PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_HCPCSactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.561 PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_ICD10PCSactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.562 PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_ICD9PCSactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.563 PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.564 PCI (Percutaneous Coronary Intervention)_Clinical Grouping Conditionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.565 Essential HTN_HD_Clinical Grouping Condition_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.566 Essential HTN_HD_Clinical Grouping Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.567 Essential HTN_HD_Clinical Grouping Conditionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.568 Total and Partial Neph_HD_Clinical Grouping Condition_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.569 Total and Partial Neph_HD_Clinical Grouping Condition_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.570 Total and Partial Neph_HD_Clinical Grouping Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.571 Total and Partial Neph_HD_Clinical Grouping Conditionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.572 Kid Trans and Hx_HD_Clinical Grouping Condition_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.573 Kid Trans and Hx_HD_Clinical Grouping Condition_HCPCSactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.574 Kid Trans and Hx_HD_Clinical Grouping Condition_ICD10CMactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.575 Kid Trans and Hx_HD_Clinical Grouping Condition_ICD10PCSactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.576 Kid Trans and Hx_HD_Clinical Grouping Condition_ICD9active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.577 Kid Trans and Hx_HD_Clinical Grouping Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.578 Kid Trans and Hx_HD_Clinical Grouping Conditionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.579 HbA1c Level Less Than 8.0_HD_Clinical Grouping Condition_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.580 HbA1c Level Less Than 8.0_HD_Clinical Grouping Conditionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.581 Systolic Less than 140_HD_Clinical Grouping Event_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.582 Diastolic Less than 90_HD_Clinical Grouping Event_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.583 Systolic Less than 140_HD_Clinical Grouping Eventactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.584 Diastolic Less than 90_HD_Clinical Grouping Eventactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.585 COPD_Clinical_Grouping_Condition_ICD9active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.586 COPD_Clinical_Grouping_Condition_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.587 COPD_Clinical_Grouping_Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.588 COPD_Clinical Condition Groupingactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.589 Polypharmacy_Clinical_Grouping_Condition_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.590 Polypharmacy_Clinical_Grouping_Condition_ICD9active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.591 Polypharmacy_Clinical_Grouping_Condition_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.592 Polypharmacy_Clinical_Grouping_Condition_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.593 Polypharmacy_Clinical Condition Groupingactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.595 Thyroid Cancer_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.596 Thyroid Cancer_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.597 Thyroid Cancer_Groupingactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.598 Allergy Iodine_SNOMEDactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.599 Allergy to contrast_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.600 Allergy to contrast_ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.601 Allergy to contrast_Groupingactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.602 Contrast induced nephropathy_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.603 Contrast induced nephropathy_ICD10active2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.604 Contrast induced nephropathy_Groupingactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.605 Systolic Blood Pressure_Compliantactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.606 Diastolic Blood Pressure_Compliantactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.607 Diastolic Blood Pressure_Compliant_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.608 Systolic Blood Pressure_Compliant_CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.609 bwell Systolic Blood Pressure Vitals_UI_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.610 bwell Systolic Blood Pressure Vitals_UI_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.611 bwell Diastolic Blood Pressure Vitals_UI_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.612 bwell Diastolic Blood Pressure Vitals_UI_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.613 bwell Combo Blood Pressure Vitals_UI_LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.614 bwell Combo Blood Pressure Vitals_UI_SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.615 bwell Systolic Blood Pressure_UIactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.616 bwell Diastolic Blood Pressure_UIactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.617 bwell Combo Blood Pressure_UIactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.618 b.well Herpes Zoster Vaccine CN_HDactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.619 b.well Herpes Zoster Vaccine CN_HD_SNOMEDactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.620 b.well Herpes Zoster Vaccine CN_HD_CVXactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.621 b.well Herpes Zoster Vaccine CN_HD_CPTactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.622 b.well Herpes Zoster Vaccine CN_HD_2doseactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.623 b.well Herpes Zoster Vaccine CN_HD_2dose_CPTactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.624 b.well Herpes Zoster Vaccine CN_HD_2dose_CVXactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.625 b.well Herpes Zoster Vaccine CN_HD_2dose_SNOMEDactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.626 b.well Herpes Zoster Vaccine CN_HD_Exclusionsactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.627 b.well Herpes Zoster Vaccine CN_HD_Exclusions_SNOMEDactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.628 b.well Adult RSV Vaccine CN_CVXactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.629 b.well Adult RSV Vaccine CN_CPTactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.630 b.well Adult RSV Vaccine CN_HCPCSactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.631 b.well Adult RSV Vaccine CN_SNOMEDactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.633 Lp(a) Test_SNOMEDactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.634 Lp(a) Test_LOINCactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.635 LP(a) Test_ICDactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.636 Lp(a) Test_CPTactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.637 LP(a) Testactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.638 b.well Adult Tetanus Vaccine CNactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.639 BWellAdultTetanusVaccineCN_SNOMEDactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.640 b.well Adult Tetanus Vaccine CN_CPTactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.641 b.well Adult Tetanus Vaccine CN_CVXactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.642 b.well Adult Tetanus Vaccine CN_Exclusions_SNOMEDactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.643 b.well Adult Tetanus Vaccine CN_Exclusionsactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.644 BWellAdultTetanusVaccineCN_RxNormactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.645 Pneumococcal Vaccine HD_CN_ Allergyactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.646 bwell COVID Vaccine CN_Allergyactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.647 bwell Covid Vaccine CN_Allergy_SNOMEDactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.648 bwell COVID Vaccine CN_Metactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.9 Metabolic Syndrome ICD10active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.91 Cardiomyopathy Dilated ICD9active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.92 Cardiomyopathy Dilated ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.93 Cardiomyopathy Dilated SNOMEDactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.94 Cardiomyopathy Dilated Conditionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.95 Cardiomyopathy Dilated LOINCactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.96 Cardiomyopathy Hypertrophic ICD9active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.97 Cardiomyopathy Hypertrophic ICD10active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.98 Cardiomyopathy Hypertrophic SNOMEDactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.99 Cardiomyopathy Hypertrophic LOINCactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.12 SNOMEDFindingValuesQualifierValueactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.13 SNOMED Organism from LOINC Answer Listactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.18 Medication Prescribable Brand Nameactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.2 SNOMED Organismsactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.22 Medicinal Ingredients RXNORMactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.1 Mental Status Observationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.10 Other Unknown Nullsactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.11 Sexual Orientation Including nulls and Data Absent Reasonactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.12 Pregnancy Status Observationactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.2 No Healthcare Agent Included Reasonactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.3 Sexactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.4 Asked Declined Data Absent Reasonactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.5 Act Encounter Codesactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.6 Completed or Nullified Act Statusactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.7 Data Absent Reason Types of Unknownactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.8 Medication Adherenceactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.2 Sickle Cell Diseaseactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.4 Depressionactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.1 Food Insecurity Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.100 Intimate Partner Violence Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.101 Less Than High School Education Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.102 Less Than High School Education Diagnoses ICD10CMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.103 Less Than High School Education Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.106 Transportation Insecurity Interventions SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.107 Financial Insecurity Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.108 Financial Insecurity Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.109 Financial Insecurity Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.11 Food Insecurity Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.110 Medical Cost Burden Goals SNOMED CTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.111 Health Insurance Coverage Status Goals SNOMED CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.112 Health Literacy Diagnoses SNOMED CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.113 Health Literacy Diagnoses ICD10CMactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.114 Health Literacy Goals SNOMED CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.115 Health Literacy Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.116 Health Literacy Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.117 Health Literacy Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.118 Health Literacy Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.119 Health Literacy Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.120 Medical Cost Burden Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.121 Health Insurance Coverage Status Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.122 Medical Cost Burden Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.123 Medical Cost Burden Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.124 Health Insurance Coverage Status Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.125 Health Insurance Coverage Status Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.126 Social Determinants of Health Screening Assessmentsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.127 Food Insecurity Screening Assessmentsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.128 Transportation Insecurity Screening Assessmentsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.129 Homelessness Screening Assessmentsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.13 Homelessness Diagnoses ICD10CMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.130 Housing Instability Screening Assessmentsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.131 Inadequate Housing Screening Assessmentsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.132 Less Than High School Education Screening Assessmentsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.133 Unemployment Screening Assessmentsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.134 Veteran Status Screening Assessmentsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.135 Social Connection Screening Assessmentsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.136 Stress Screening Assessmentsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.137 Cognitive disorder Diagnosisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.138 Financial Insecurity Screening Assessmentsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.139 Material Hardship Screening Assessmentsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.14 Homelessness Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.140 Intimate Partner Violence Screening Assessmentsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.141 Health Literacy Screening Assessmentsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.142 Medical Cost Burden Screening Assessmentsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.143 Health Insurance Coverage Status Screening Assessmentsactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.144 Elder Abuse Screening Assessmentsactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.145 Less Than High School Education Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.146 Financial Insecurity Diagnoses ICD10CMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.147 Health Insurance Coverage Status Diagnoses ICD10CMactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.148 Health Insurance Coverage Status Diagnosesactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.149 Health Insurance Coverage Status Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.15 Food Insecurity Interventions CPTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.150 Material Hardship Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.151 Medical Cost Burden Diagnoses ICD10CMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.152 Medical Cost Burden Diagnoses SNOMED CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.153 Medical Cost Burden Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.154 Medical Cost Burden Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.157 Transportation Insecurity Diagnoses ICD10CMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.158 Homelessness Goals SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.159 Homelessness Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.16 Food Insecurity Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.160 Housing Instability Goals SNOMED CTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.161 Housing Instability Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.162 Transportation Insecurity Goals SNOMED CTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.163 Transportation Insecurity Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.164 Veteran Status Interventions SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.167 Inadequate Housing Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.168 Material Hardship Screening Assessments Questionsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.169 Stress Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.17 Food Insecurity Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.170 Transportation Insecurity Screening Assessments Questionsactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.171 Unemployment Screening Assessments Questionsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.172 Veteran Status Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.173 Financial Insecurity Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.174 Food Insecurity Screening Assessments Answersactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.175 Health Literacy Screening Assessments Answersactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.176 Homelessness Screening Assessments Answersactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.177 Housing Instability Screening Assessments Answersactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.178 Inadequate Housing Screening Assessments Answersactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.179 Less Than High School Education Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.18 Homelessness Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.180 Material Hardship Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.181 Stress Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.182 Transportation Insecurity Screening Assessments Answersactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.183 Unemployment Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.184 Veteran Status Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.185 Health Insurance Coverage Status Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.186 Health Insurance Coverage Status Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.187 Medical Cost Burden Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.188 Medical Cost Burden Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.189 Elder Abuse Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.19 Homelessness Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.190 Elder Abuse Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.191 Elder Abuse Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.192 Veteran Status Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.193 Financial Insecurity Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.194 Food Insecurity Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.195 Health Literacy Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.196 Homelessness Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.197 Housing Instability Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.198 Intimate Partner Violence Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.199 Less Than High School Education Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.20 Homelessness Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.200 Material Hardship Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.201 Medical Cost Burden Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.202 Social Connection Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.203 Stress Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.204 Transportation Insecurity Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.205 Unemployment Screening Assessments And Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.206 Social Determinants of Health Screening Assessments And Questionsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.207 Social Determinants of Health Screening Assessments Questionsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.208 Social Determinants of Health Screening Assessments Answersactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.209 Intimate Partner Violence Screening Assessments Answersactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.21 Homelessness Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.210 Social Connection Screening Assessments Answersactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.211 Intimate Partner Violence Screening Assessments Questionsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.212 Social Connection Screening Assessments Questionsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.213 Health Insurance Coverage Status Diagnoses SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.214 Veteran Status Goalsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.215 Veteran Status Goals SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.217 Digital Literacy Diagnoses SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.218 Digital Literacy Diagnoses ICD10CMactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.219 Digital Literacy Goals SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.22 Housing Instability Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.220 Digital Literacy Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.224 Digital Literacy Diagnosesactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.225 Digital Literacy Goalsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.226 Digital Literacy Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.227 Digital Literacy Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.229 Digital Access Diagnoses SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.23 Housing Instability Diagnoses ICD10CMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.230 Digital Access Diagnoses ICD10CMactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.231 Digital Access Diagnosesactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.232 Digital Access Goals SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.233 Digital Access Goalsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.234 Digital Access Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.235 Digital Access Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.236 Digital Access Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.237 Digital Access Screening Assessmentsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.238 Digital Access Screening Assessments Questionsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.239 Digital Access Screening Assessments Answersactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.24 Housing Instability Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.240 Digital Access Screening Assessments And Questionsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.241 Utility Insecurity Diagnoses SNOMED CTactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.242 Utility Insecurity Diagnoses ICD10CMactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.243 Utility Insecurity Diagnosesactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.244 Utility Insecurity Goals SNOMED CTactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.245 Utility Insecurity Goalsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.246 Utility Insecurity Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.247 Utility Insecurity Proceduresactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.248 Utility Insecurity Screening Assessmentsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.249 Utility Insecurity Screening Assessments Questionsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.25 Transportation Insecurity Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.250 Utility Insecurity Screening Assessments Answersactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.251 Utility Insecurity Screening Assessments And Questionsactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.252 Utility Insecurity Service Requestsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.253 Social Determinants of Health General Interventions HCPCSactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.254 Incarceration Status Diagnoses ICD10CMactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.255 Incarceration Status Diagnoses SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.256 Incarceration Status Goals SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.257 Incarceration Status Goalsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.258 Incarceration Status Diagnosesactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.259 Incarceration Status Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.26 Transportation Insecurity Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.260 Incarceration Status Proceduresactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.261 Incarceration Status Service Requestsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.262 Language Access Diagnosesactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.263 Language Access Diagnoses ICD10CMactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.264 Language Access Diagnoses SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.265 Language Access Goals SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.266 Language Access Goalsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.267 Language Access Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.268 Language Access Proceduresactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.269 Language Access Service Requestsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.27 Transportation Insecurity Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.270 Language Access Screening Assessmentsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.271 Language Access Screening Assessments Answersactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.272 Language Access Screening Assessments Questionsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.273 Language Access Screening Assessments And Questionsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.28 Transportation Insecurity Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.29 Financial Insecurity Goals SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.3 Food Insecurity Diagnoses ICD10CMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.30 Financial Insecurity Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.31 Financial Insecurity Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.32 Financial Insecurity Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.33 Material Hardship Diagnoses ICD10CMactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.34 Material Hardship Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.35 Material Hardship Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.36 Material Hardship Goals SNOMED CTactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.37 Material Hardship Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.38 Material Hardship Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.39 Material Hardship Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.4 Food Insecurity Goals SNOMED CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.40 Unemployment Diagnoses ICD10CMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.41 Unemployment Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.42 Unemployment Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.43 Housing Instability Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.44 Housing Instability Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.45 Housing Instability Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.46 Inadequate Housing Diagnoses SNOMED CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.47 Inadequate Housing Diagnoses ICD10CMactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.48 Inadequate Housing Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.49 Inadequate Housing Goals SNOMED CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.5 Social Determinants of Health General Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.50 Inadequate Housing Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.51 Inadequate Housing Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.52 Inadequate Housing Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.53 Inadequate Housing Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.54 Less Than High School Education Goals SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.55 Less Than High School Education Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.56 Less Than High School Education Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.57 Less Than High School Education Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.58 Unemployment Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.59 Unemployment Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.6 Food Insecurity Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.60 Unemployment Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.61 Elder Abuse Diagnoses ICD10CMactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.62 Elder Abuse Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.63 Elder Abuse Diagnosesactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.64 Elder Abuse Goals SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.65 Elder Abuse Goalsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.66 Elder Abuse Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.67 Elder Abuse Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.68 Elder Abuse Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.69 Unemployment Goals SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.7 Food Insecurity Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.70 Unemployment Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.71 Social Determinants of Health Goalsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.72 Stress Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.73 Stress Interventions SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.74 Stress Diagnoses ICD10CMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.75 Stress Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.76 Veteran Status Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.77 Veteran Status Diagnoses ICD10CMactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.78 Veteran Status Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.79 Social Connection Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.8 Social Determinants of Health General Interventions CPTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.80 Social Connection Diagnoses ICD10CMactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.81 Social Connection Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.82 Intimate Partner Violence Diagnoses SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.83 Intimate Partner Violence Diagnoses ICD10CMactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.84 Intimate Partner Violence Diagnosesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.85 Stress Goals SNOMED CTactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.86 Stress Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.87 Stress Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.88 Social Connection Goals SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.89 Social Connection Goalsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.9 Food Insecurity Interventions HCPCSactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.90 Veteran Status Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.91 Veteran Status Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.92 Stress Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.93 Social Connection Interventions SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.94 Social Connection Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.95 Social Connection Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.96 Intimate Partner Violence Interventions SNOMED CTactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.97 Intimate Partner Violence Proceduresactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.98 Intimate Partner Violence Service Requestsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.99 Intimate Partner Violence Goals SNOMED CTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.105 Mechanical Ventilation Proceduresactive2022-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.106 Mechanical Ventilationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.107 Mechanical Ventilationactive2022-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.109 aPTT Testsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119 Opioid Antagonistactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.12 High Risk Diagnosis for AKIactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.120 Opioidsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.124 Immune Modulatorsactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.130 Suicide Attemptactive2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.134 Central Nervous System Depressantsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.136 Leukemia or Lymphomaactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.137 Liver Disease Moderate to Severeactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.138 COVID19active2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.139 COVID 19active2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.14 Hemolytic Uremic Syndrome (HUS)active2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.140 COVID 19active2022-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.162 Obesityactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.163 Antidepressantsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.164 Antihypertensivesactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.165 Deliriumactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.166 Dementiaactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.167 Psychosisactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.168 Delirium or Dementia and Other Psychosesactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.169 Depressionactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.170 Diureticsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.171 Epilepsyactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.172 Neurologic Movement Disordersactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.173 Neurologic Disorders, Otheractive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.174 Neurologic Movement and Related Disordersactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.175 Peripheral Neuropathyactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.176 Strokeactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.177 Abnormal Weight Loss and Malnutritionactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.178 Intubationactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.179 Intubationactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.180 Tracheostomy Proceduresactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.181 Tracheostomy Proceduresactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.182 Head and Neck Surgeries with High Risk Airway Compromiseactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.185 Spinal Surgeryactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.187 Routes of Administration for Opioid Antagonistsactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.19 High Risk Procedures for AKIactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.197 Hospital Based Dialysis Servicesactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.198 Hospital Based Dialysis Servicesactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.199 Hospital Based Dialysis Servicesactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.200 Nephrectomyactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.201 Thrombotic Thrombocytopenic Purpuraactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.204 VTE Prophylaxisactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.205 Moderate Injuriesactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.206 General and Neuraxial Anesthesiaactive2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.207 General and Neuraxial Anesthesiaactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.208 General and Neuraxial Anesthesiaactive2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.209 Non Invasive Oxygen Therapy by Nasal Cannula or Maskactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.21 Creatinine Mass Per Volumeactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.210 Continuous and Bilevel Positive Airway Pressureactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.211 Continuous and Bilevel Positive Airway Pressureactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.213 Non Invasive Oxygen Therapyactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.214 Non Invasive Oxygen Therapy Devicesactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.216 Procedural Hospital Locationsactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.217 ASA physical status classactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.218 Blood urea nitrogen lab testactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.219 Hemoglobin lab testactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.22 Anticoagulants for All Indicationsactive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.220 Smoking statusactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.221 Albumin lab testactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.222 Leukocyte count lab testactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.223 Bilirubin lab testactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.224 Aspartate transaminase lab testactive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.226 Cardiac Arrestactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.23 Coagulation Disordersactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.230 PO Antibacterialsactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.231 Injectable Antifungalsactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.238 Neuromuscular Disorderactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.239 Neuromuscular Disorderactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.24 Malignant Bone Diseaseactive2022-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.240 Degenerative Neurological Disorderactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.241 Degenerative Neurological Disorderactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.242 Heart and Lung Transplantsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.243 Heart and Lung Transplantsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.245 Lung Resections and Excisionsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.246 Lung Resections and Excisionsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.247 Chest Wall Proceduresactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.248 Chest Wall Proceduresactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.249 Maxillary Proceduresactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.250 Maxillary Proceduresactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.251 Head, Neck, and Thoracic Surgeries with High Risk Airway Compromiseactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.252 Anesthesia Requiring Monitored Careactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.253 Anesthesia Requiring Monitored Careactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.255 Anesthesia Requiring Monitored Careactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.256 Osteoporosisactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.260 Rivaroxaban Anticoagulantactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.262 Fondaparinux Anticoagulantactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.263 Dalteparin Anticoagulantactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.264 Heparinactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.268 Enoxaparin Anticoagulantactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.271 Undetectable Lab Result Valueactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.272 Undetectable Lab Result Valueactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.274 Dietary Recommendationsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.275 Bariatric Proceduresactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.276 Telemedicine Servicesactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.277 Prostate Cancer Treatmentactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.28 Traumatic Avulsion of Kidneyactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.29 Rapidly Progressive Nephritic Syndromeactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.301 LDL Cholesterolactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.33 Obstetrics and VTE Obstetricsactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34 Glucose Lab Test Mass Per Volumeactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.349 Tuberculosis for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.350 Tuberculosis for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351 Tuberculosis for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.352 Androgen Deprivation Therapy for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353 Bacillus Calmette Guerin for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354 Bladder Cancer for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.355 Chemotherapy Agents for Advanced Canceractive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.356 Cystectomy for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.357 Cystectomy for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.358 Cystectomy for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 DEXA Bone Density for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.360 Hospital Services for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.361 Immunocompromised Conditionsactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.362 Immunocompromised Conditionsactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363 Immunocompromised Conditionsactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.364 Immunosuppressive Drugs for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365 Mixed Histology Urothelial Cell Carcinoma for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.366 Morbid Obesityactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.367 Morbid Obesityactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.368 Morbid Obesityactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.369 Unavailability of Bacillus Calmette Guerin for Urology Careactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.370 Urinary Retentionactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.371 Urinary Retentionactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.372 Urinary Retentionactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.374 Face to Face Interactionactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.375 Face to Face Interactionactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.376 HIV Viral Load Testsactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.377 HIV Viral Load Testsactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.389 Syphilis Testsactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.4 Nephrectomyactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.79 Acute Brain or Spinal Injury or Hemorrhageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.8 Large Body Surface Area (BSA) Burnsactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.80 Pulmonary Arterial Thrombectomyactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.81 Extracorporeal Membrane Oxygenationactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.85 Elective Inpatient Encounteractive2023-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.86 Intubationactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.88 Acute Respiratory Failureactive2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.89 Tracheostomy Diagnosesactive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.90 Tracheostomy Proceduresactive2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.91 Neuromuscular Disorderactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.92 Degenerative Neurological Disorderactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.93 Head and Neck Surgeries with High Risk Airway Compromiseactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.94 Oxygen Partial Pressure in Arterial Bloodactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.95 Carbon Dioxide Partial Pressure in Arterial Bloodactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.96 Arterial Blood pHactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.2 Psychological Neuropsychological or Neurobehavioral Testingactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.3 Psychological or Neuropsychological Testingactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.10 Tricuspid Valve Regurgitationactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.12 Hypertensionactive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.2 Valvular Heart Diseaseactive2022-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.22 Acute Kidney Injuryactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.23 Anemiaactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.24 Cardiac Arrhythmiasactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.25 Attention Deficit and Hyperactivity Disorderactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.26 Cerebrovascular Diseaseactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.27 Seizure Disorderactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.28 Proteinuriaactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.29 Thyroid Hormone Disorderactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.30 Thromboembolic Diseaseactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.31 Parkinson's Disease and Parkinsonismactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.32 Upper GI Diseasesactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.33 Failure to Thriveactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.34 Osteoporosisactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.35 Mood Disordersactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.36 Dyslipidemiaactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.37 Heart Failureactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.38 Coronary Artery Diseaseactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.39 Chronic Kidney Diseaseactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.40 Chronic Obstructive Pulmonary Diseaseactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.41 Diabetes Mellitusactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.1 EventTiming-TimingEventactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.2 EventTiming-EventTimingactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.1 Gonorrhea Screeningactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.2 Abnormal Weight Lossactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.2 Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetesactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.3 Prescribable brand and generic insulins and analoguesactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.4 eGFR Using 2021 Race Free Formulasactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.5 Fructosamine in Serum or Plasmaactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.6 Glucose tests in venous blood, capillary blood, serum/plasma for Diabetesactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.7 Creatinine in serum/plasmaactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9 IgE Agonists, prescribableactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.10 Estrogen Receptor Testing for Orserduactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.100 MMR Proficientactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.101 Systemic Cancer Directed Therapyactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.102 Face To Face Interactionactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.104 Erdafitinibactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.107 Chemotherapy Encounteractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.108 Urothelial Cancers ICD9active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.109 Urothelial Cancer ICD10active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.11 Estrogen Receptor Test for Orserduactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.110 Urothelial Cancersactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.111 Prior Therapies for Erdafitinibactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.112 Urothelial Cancer Histologiesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.113 Malignant Tumor Behavioractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.114 Localized Bladder Cancer Stage SNOMEDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.116 Localized Bladder Cancer Stagingactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.117 Advanced Bladder Cancer Stageactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.118 Localized Bladder Cancer T Stageactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.119 Localized Bladder Cancer T Stageactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.12 Negativeactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.120 Localized Bladder Cancer N Stageactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.121 Localized Bladder Cancer M Stageactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.122 Advanced Bladder Cancer M Stageactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.124 Locoregional Urothelial Cancer ICD9active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.125 Locoregional Urothelial Cancer ICD10active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.126 Locoregional Urothelial Cancer SNOMEDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.127 Locoregional Urothelial Canceractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.128 FGFR3 Geneactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.129 FGFR3 Gene Interpretation Positive SNOMEDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.13 HER2 Negativeactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.130 FGFR3 Gene Interpretation Positive LOINCactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.131 FGFR3 Gene Interpretation Positive NCIactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.133 FGFR3 Gene Interpretation Positiveactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.134 FGFR3 Gene Interpretation Negative SNOMEDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.135 FGFR3 Gene Interpretation Negative NCIactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.137 FGFR3 Gene Interpretation Negativeactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.138 FGFR3 Molecular Variantsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.139 Tumor Behavioractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.14 Endocrine Therapyactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.140 Physcological Support for Canceractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.141 Referral For Pain From Canceractive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.142 Cancer Pain Educationactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.143 Telehealth Encountersactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.144 Pain Assessment Scoreactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.146 Telehealth Encounters SNOMEDCTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.147 Telehealth Encounters CPTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.148 Telehealth Encounters HCPCSactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.149 Telehealth Encounters Allactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.15 All Metastatic Sitesactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.150 Chemo Admin SNOMEDCTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.151 Chemo Admin CPTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.152 Chemo Admin HCPCSactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.153 Chemotherapy Administration Allactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.154 Radiation Treatment CPTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.155 Radiation Treatment HCPCSactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.156 Radiation Treatment SNOMEDCTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.157 Radiation Treatment Allactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.158 Bipolar Diagnosis Codesactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.159 Telephone Visits SNOMEDactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.16 All Metastatic Sitesactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.160 Telephone Visit CPTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.161 Telephone Visits Allactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.162 Adolescent depression screening assessmentactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.163 Adult depression screening assessment LOINCactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.165 Referral for Depression Adultactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.166 Referrals for Adolescent Depressionactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.167 Follow Ups for Adolescent Depressionactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.168 FollowUps for Adult Depressionactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.169 Depression Screen Declined for Medical Reasonactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.17 Metastatic Breast Canceractive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.170 Physical Therapy Evaluations SNOMEDCTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.171 Physical Therapy Evaluation CPTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.172 Physical Therapies Evaluationsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.173 Non Opioid Analgesicsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.174 Adjuvant Analgesicsactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.176 Lung Cancer ICD9active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.177 Lung Cancer ICD10active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.178 Lung Canceractive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.179 Prior Therapies for Osimertinibactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.18 Stage IAactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.181 Plan of Care for Painactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.182 All Antineoplastic Agentsactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.183 Locally Advanced NSCLC Stage Groupactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.185 Localized NSCLC Stage Group SNOMEDactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.186 Radiation Treatment Managementactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.187 Plan of Careactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.188 Documentation of Plan of Careactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.189 Pain Presentactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.19 Stage IBactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.190 Localized NSCLC Stage Group NCIMactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.192 Localized NSCLC Stage Groupactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.193 Advanced NSCLC Stage Groupactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.194 NSCLC M Stage (metastatic)active2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.195 NSCLC T Stageactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.196 NSCLC N Stageactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.197 SCLC and rarer lung cancer histologyactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.198 EGFR Geneactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.199 EGFR Gene Interpretation Positive SNOMEDactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.20 Stage IIAactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.200 EGFR Gene Interpretation Positive LOINCactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.201 EGFR Gene Interpretation Positiveactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.202 EGFR Osimertinib Molecular Variantsactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.203 EGFR Generic Molecular Variant NCIMactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.204 EGFR Generic Molecular Variant SNOMEDactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.205 EGFR Generic Molecular Variant LOINCactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.206 EGFR Molecular Variants Osimertinib PMactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.207 Osimertinibactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.208 Pemetrexedactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.209 Radiation Treatment Management SNOMEDCTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.21 Stage IIBactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.210 Radiation Treatment Management Codesactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.211 Radiation Treatment Delivery CPTactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.212 77427 Management Codeactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.213 Radiation Treatment Delivery HCPCSactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.214 Radiation Treatment Delivery NCIMactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.215 Radiation Treatment Delivery SNOMEDactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.216 Radiation Treatment Deliveryactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.217 MET Gene Testactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.219 Tepotinibactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.22 Stage IIIAactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.220 MET Positive gene interpretationactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.227 MET Exon 14 skipping molecular variantactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.23 Stage IIIBactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.230 All Cancer Directed therapiesactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.231 EGFR Amivantamab Molecular Variantsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.232 EGFR Molecular Variants Amivantamab PMactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.233 test43active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.234 ROS1 Molecular Variants Repotrectinib PMactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.235 ROS1 Repotrectinib Molecular Variantsactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.236 ROS1 Negative (geneinterpretation) SNOMEDCTactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.237 ROS1 Negative (geneinterpretation) NCIactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.238 ROS1 Negative (geneinterpretation) SNOMEDCT,NCIactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.239 ROS1 Positive (geneinterpretation)active2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.24 Stage IIICactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.240 ROS1 results (HGNC)active2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.241 ROS1 Gene Rearrangementactive2024-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.242 RET Test (HGNC)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.243 RET Positive (Genei interpretation )active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.244 RET Gene Rearrangementactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.245 RET Negative (geneinterpretaion) SNOMEDactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.246 RET Negative (geneinterpretaion) NCIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.247 RET Negative (geneinterpretaion) SNOMEDCT,NCIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.248 RET Fusion Molecular Variantsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.249 pralsetinibactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.25 ESR1 Gene Testactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.250 Repotrectinib Value setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.251 Amivantamabactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.252 Alectinib Drugactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.253 Gemcitabine Drug Value setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.254 vinorelbine Drugactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.255 NSCLC_Tumor_resection SNOMEDCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.256 NSCLC_Tumor_resection CPTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.257 NSCLC_Tumor_resection SNOMEDCT CPTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.258 ALK results (HGNC)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.259 ALK Positive (geneinterpretation) SNOMEDactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.26 ESR1 Genetic Mutationactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.260 ALK Positive (geneinterpretation) NCIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.261 ALK Positive (geneinterpretation) SNOMEDCT NCIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.262 ALK Negative (geneinterpretation) SNOMEDCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.263 ALK Negative (geneinterpretation) NCIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.264 ALK Negative (geneinterpretation) SNOMEDCT NCIactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.265 Locoregional Sitesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.266 NSCLC N2 Stageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.267 NSCLC N1 Stageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.268 NSCLC N0 Stageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.269 NSCLC T3_T4 Stageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.27 Genetic Test Findingactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.270 NSCLC T2 Stageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.271 NSCLC T1 Stageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.272 Locally_Advanced_Metastatic_NSCLC Stage Groupactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.273 Localized_Inclusion_NSCLC Stage Groupactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.274 Localized_Exclusion_NSCLC Stage Groupactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.275 tarlatamab dlleactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.276 Extensive SCLC Stage Group SNOMEDCTactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.277 Extensive SCLC Stage Group NCIMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.278 Extensive SCLC Stage Groupactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.279 Localized SCLC Stage Groupactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.28 Her2 Negativeactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.280 SCLC M Stage (metastatic)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.281 SCLC T Stageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.282 SCLC N Stageactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.283 SCLC histology (to include those patients)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.284 Binimetinibactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.285 Encorafenibactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.286 Encorafenib PM Molecular variantactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.288 BRAF Positive (geneinterpretation)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.289 BRAF test (HGNC)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.29 HER2 Positiveactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.292 Prior therapy for Amivantamabactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.293 ENHERTU Drugactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.294 Metastatic_Solid_Cancer_Stage Group SNOMED CTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.295 Locally_Advanced_Solid_Cancer_Stage Group SNOMED CTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.296 Localized_Solid_Cancer_Stage Group SNOMED CTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.297 Solid cancer M Stage (metastatic)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.298 Solid Cancer T Stageactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.299 Solid Cancer N Stageactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.30 HER2 Positiveactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.302 HER2_IHC_Positiveactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.303 HER2 Negative (geneinterpretation/Labtestvalue) SNOMEDactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.304 HER2 Negative (geneinterpretation/Labtestvalue) LOINCactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.305 HER2 Negative (geneinterpretation/Labtestvalue) NCIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.307 HER2 Negative (geneinterpretation/Labtestvalue)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.308 Solid Cancer Diagnosis ICD 9active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.309 Solid Cancer Diagnosis SNOMED CTactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.31 HER2 Positiveactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.310 Solid Cancer Diagnosisactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.311 Localized_Solid_Cancer_Stage Group NCIMactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.313 Localized_Solid_Cancer_Stage Groupactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.314 Locally_Advanced_Solid_Cancer_Stage Group NCIMactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.315 Locally_Advanced_Solid_Cancer_Stage Groupactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.316 Metastatic_Solid_Cancer_Stage Group NCIMactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.317 Metastatic_Solid_Cancer_Stage Groupactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.318 Solid Cancer T Stage LOINCactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.319 Solid Cancer T Stage NCIactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.32 HER2 Positiveactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.320 Solid Cancer T Stage codesactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.321 Prior_Systemic_therapy_Enhertuactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.322 RET test_Solid_cancer (HGNC)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.323 RET Positive_Solid_Cancer (geneinterpretation)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.324 RET Negative_Solid_Cancer (geneinterpretation)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.325 RET fusion Molecular Variants_Solid_Canceractive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.326 Prior_systemic_therapy_Retevmoactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.327 Selpercatinib (Retevmo) Drugactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.328 Breast Cancer Diagnosis ICD9active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.329 Breast Cancer Diagnosis ICD10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.33 Metastatic Breast Canceractive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.330 Breast Cancer Diagnosisactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.331 Metastatic_Breast_Cancer_Stage Groupactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.332 Locally_Advanced_Breast_Cancer_Stage Groupactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.333 Localized_Breast_Cancer_Stage Groupactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.334 Breast cancer M Stage (metastatic)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.335 Breast Cancer T Stageactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.336 Breast Cancer N Stageactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.337 Metastatic Sites All Breast SNOMEDCTactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.338 Metastatic Sites All Breast ICD9active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.339 Metastatic Sites All Breast ICD10active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.340 Metastatic Sites All Breast (grouped, SNOMEDCT/ICD9/ICD10)active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.341 Aromatase_Inhibitor therapyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.342 Capivasertib_therapyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.343 Fulvestrant_therapyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.344 PTEN_geneactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.345 PTEN_geneinterpretationactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.346 PIK3CA_geneactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.347 PI3KCA_geneinterpretationactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.348 AKTI_geneactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.349 AKTI_geneinterpretationactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.35 All Metastatic Sitesactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.350 Progesterone_receptor_geneactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.351 Progesterone_receptor_geneinterpretationactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.352 Estrogen_receptor_geneactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.353 Estrogen_receptor_geneinterpretationactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.354 Progesterone_receptor_labtestactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.355 Progesterone_receptor_labinterpretationactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.356 Estrogen_receptor_labtestactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.357 Estrogen_receptor_labinterpretationactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.358 NSCLC M0 Stageactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.359 HER2_IHC_test_Geneactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.36 All Metastatic Sitesactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.360 HER2_IHC_test_Labactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.361 HER2_Fish_testactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.362 HER2_IHC_Negativeactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.363 Trodelvyactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.364 Chemotherapy_breast_canceractive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.365 Cyclin_dependent_kinaseactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.366 Taxane_Trodelvyactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.367 Endocrine_therapyactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.368 HER2_Fish_test_Negativeactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.369 HER2_IHC_Equivocalactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.37 Locoregional Breast Canceractive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.370 HER2 Positive_PM_resultsactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.371 HER2 test_Labactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.372 HER2 test_geneactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.374 Thyroid Cancer Diagnosisactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.375 Metastatic_Thyroid_Stage Groupactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.376 RET mutation_Molecular Variantsactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.377 RET Gene mutationactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.378 Locally_Advanced_Localized_Thyroid_Cancer_Stage Groupactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.379 Thyroid cancer M1_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.38 Locoregional Breast Canceractive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.380 Thyroid_cancer_M0_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.381 Thyroid_cancer_T_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.382 Thyroid_cancer_T1_T2_T3_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.383 Thyroid_cancer_T4_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.384 Thyroid_cancer_N1b_Stage&Aboveactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.385 Thyroid_cancer_N_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.386 Medullary_thyroid_histologyactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.387 RET test_Thyroid_cancer (HGNC)active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.388 RET Positiveactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.389 NSCLC N3 Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.39 Locoregional Breast Canceractive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.390 CRC Cancer Diagnosis ICD9active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.391 CRC Cancer Diagnosis ICD10active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.392 CRC Cancer Diagnosis ICD9/ICD10active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.393 Metastatic_CRC_Cancer_Stage Groupactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.394 Locally_Advanced_Localized_CRC_Stage Groupactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.395 CRC cancer M Stage (metastatic)active2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.396 CRC Cancer T Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.397 CRC Cancer N Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.398 KRAS_geneactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.399 KRAS_negativeactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.40 Locoregional Breast Canceractive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.400 Fluoropyrimidine_CRCactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.401 Oxaliplatinactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.402 Irinotecan_based_therapyactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.403 anti_VEGF_therapy_CRCactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.404 anti_EGFR_therapy_CRCactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.405 fruquitinibactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.406 Locally_Advanced_CRC_Stage Groupactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.407 Localized_CRC_Stage Groupactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.408 CRC cancer M0_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.409 CRC_Cancer_T1_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.41 All Metastatic Sites ICD910active2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.410 CRC_Cancer_T2_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.411 CRC_Cancer_T3_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.412 CRC_Cancer_T4_Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.413 CRC Cancer N1 Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.414 CRC Cancer N2 Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.415 CRC Cancer N2b Stageactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.416 KRAS_G12C_MVactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.417 KRAS_G12C_PMactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.418 KRAS_positiveactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.419 Adagrasibactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.42 Breast Canceractive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.420 cetuximab_therapyactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.421 Tamoxifen_therapyactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.423 Endometrial Cancer Diagnosis ICD 10active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.425 Endometrial Cancer Diagnosis ICD9CMactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.426 Endometrial Cancer Diagnosisactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.428 Localized_Endometerial_Stage Group SNOMEDactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.429 Localized_Endometerial_Stage Group NCIMactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.43 Breast Canceractive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.431 Endometrial_Sarcoma_Tumor_Histology_excactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.432 Endometrial cancer M Stage (metastatic)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.433 Endometrial_M0_Stageactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.436 Prior_therapy_Endometrialactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.437 Paclitaxel_therapyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.44 Breast Canceractive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.441 Carboplatin_therapyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.442 Durvalumab_therapyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.444 MMR_Gene_Lab_LOINCactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.447 MMR_Gene_HGNCactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.449 Endometrial_ Cancer N Stageactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.45 Endometrial Cancer ICD9active2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.451 Endometrial_N0_Stageactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.453 Endometrial_N1_N2_Stageactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.455 Endometrial_T1_T3_Stageactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.456 Endometrial_T3_Stageactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.458 Endometrial_T4_Stageactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.459 Endometrial Cancer T Stageactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.46 Endometrial Cancer ICD10active2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.460 Localized_Endometerial_Stage Group_SNOMED/NCIMactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.461 Metastatic Sites All CRCactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.462 Metastatic Sites All CRC ICD 10active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.463 Metastatic Sites All CRC ICD 9active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.464 Metastatic Sites All CRC (grouped, SNOMEDCT/ICD9/ICD10)active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.465 NTRK Repotrectinib Molecular Variantsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.466 NTRK_Gene_rearrangmentactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.467 Prior_Systemic_therapy_Repotrectinibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.468 NTRK_Positiveactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.469 NTRK_test_geneactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.47 Systemic treatment for endometrial canceractive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.470 Tamoxifen_Trodelvyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.471 Toremifene_trodelvyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.472 Fulvestrant_Trodelvyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.473 Elacestrantactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.474 Anastrozole_Trodelvyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.475 Leuprolide_Trodelvyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.476 Abemaciclibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.477 Palbociclibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.478 Ribociclibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.479 Carboplatin_Trodelvyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.48 Endometrial Cancersactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.480 Cisplatin_Trodelvyactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.481 Cyclophosphamideactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.482 Methotrexateactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.483 Gemcitabineactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.484 Capecitabineactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.485 Eribulinactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.486 Doxorubicinactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.487 Vinorelbineactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.488 Epirubicinactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.489 Ixabepiloneactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.49 MSI Testingactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.490 Olaparibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.491 Talazoparibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.492 Entrectinibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.493 larotrectinibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.494 Alpelisibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.495 Capivasertibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.496 Pembrolizumabactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.497 Dostarlimabactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.498 Selpercatinibactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.499 Everolimusactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.50 MSI Highactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.500 Trastuzumab_deruxtecanactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.501 Test 23active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.502 All Metastatic sites Endometrial SNOMEDactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.503 All Metastatic sites Endometrial ICD9active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.504 All Metastatic sites Endometrial ICD10active2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.505 All Metastatic sites Endometrialactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.506 Create CRC_Cancer_T4a_Stageactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.507 Create CRC_Cancer_T4b_Stageactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.508 High Emetogenic Risk Chemotherapyactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.510 InactiveFollowupactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.53 MMR Gene Testingactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.54 MSI Highactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.55 MSI Highactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.56 Early and Limited Stageactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.57 Early Stage IIB or loweractive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.58 MMR Deficientactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.59 MMR Deficientactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.6 Orserduactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.60 MMR Deficientactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.61 Stage IIB or lower and limitedactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.62 Stage III or higheractive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.63 Stage III or higheractive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.64 Stage III or higheractive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.65 Staging Unknownactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.66 Staging Unknownactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.67 Staging Unknownactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.68 Jemperliactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.69 Uterine Sarcomaactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.7 Her2 Test For Orserduactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.70 Tumor Histologyactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.71 Platinum based therapyactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.72 Prior Therapies for Tucatinibactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.73 Tucatinibactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.74 Colorectal Cancer ICD10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.75 Colorectal Cancer ICD9active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.76 Colorectal Cancer ICD9 and ICD10active2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.78 Advanced or Unresectable Colorectal Cancer Stagingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.79 0 to IIIB Colorectal Cancer Stagingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.80 Colorectal Cancer M1 Stageactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.81 RAS Genesactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.82 RAS Gene Interpretation Negative LOINCactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.83 RAS Gene Interpretation Negative SNOMEDactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.84 RAS Gene Interpretation Negative NCMactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.85 RAS Gene Negativeactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.86 RAS Gene Interpretation Positive SNOMEDactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.87 RAS Gene Interpretation Positive LOINCactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.88 RAS Gene Positiveactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.89 Her2 Testingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.9 ER Test for Orserduactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.90 Patient Reasonactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.91 MSI High NCIactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.92 MSI Low SNOMEDactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.93 MSI Low LOINCactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.94 MSI Low NCIactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.95 MSI Lowactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.96 MMR Deficient NCIactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.97 MMR Proficient SNOMEDactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.98 MMR Proficient LOINCactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.99 MMR Proficient NCIactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1262.3 ICD9 Codes for HIV Diagnosisactive2023-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.1 Inpatient Pneumonia Diagnosisactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.11 Chest Imaging for Pneumonia, HCPCSactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.12 Chest Imaging for Pneumonia Grouping Definitionactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.18 ICD9 Abnormal Finding on Chest Imagingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.19 ICD10 Abnormal Finding on Chest Imagingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.2 ICD9 Pneumonia Definitionactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.20 SNOMEDCT Abnormal Finding on Chest Imagingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.21 Abnormal Finding on Chest Imagingactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.22 SNOMEDCT Pneumonia Definitionactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.23 CAP Concurrent Infectionsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.24 CAP Pneumonia Diagnosticactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.25 Antibiotic Usage for CAP Diagnosisactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.27 Legionella Presence by Urine Antigen or DNAactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.29 Broad Spectrum Antibiotics for MDROactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.3 ICD10 Pneumonia Definitionactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.32 CPT Transplants, Stem Cell and Solidactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.33 HCPCS Transplant, Stem Cell and Solidactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.34 ICD10CM Transplant, Stem Cell and Solidactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.35 ICD10PCS Transplant, Stem Cell and Solidactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.37 SNOMEDCT Transplant, Stem Cell and Solidactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.38 Transplant, Stem Cell and Solidactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.39 Antibiotic Usage for CAP Durationactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.40 CAP Sepsis Diagnosticactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.41 CAP Respiratory Failure Diagnosticactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.42 MRSA Organism or Substance in Lab Resultsactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.8 Systemic Antimicrobialsactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.9 Chest Imaging for Pneumonia, CPTactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.1 Problem Typeactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.10 Information Source for Medication Adherence HSLOCactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.11 Information Source for Medication Adherenceactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.13 Screening and Assessment Survey Codesactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.14 Unknown and Asked but Unknown (DAR)active2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.15 Yes or No SCTactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.16 Answer Set with Yes No and Unknownsactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.17 Common LOINC Lab Codesactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.18 Radiology Procedures (LOINC)active2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.19 Clinical Testsactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.21 Universal Common LOINC Lab Ordersactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.22 Route of Administration of Therapeutic Agentsactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.23 Encounter Typeactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.24 Specimen Condition SCTactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.25 Detailed race including absence reasons.active2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.26 Healthcare Facility type (SCT)active2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.27 Social History Type (LOINC)active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.28 Social History Typeactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.29 Encounter Type CPTactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.3 Smoking status comprehensiveactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.31 Healthcare Service Location Type Combinedactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.4 Smoking Status Type LOINCactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.5 Smoking Status Pack Years SCTactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.6 Smoking Status Typeactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.7 Information Source for Medication Adherence HL7 Role Codeactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.8 Information Source for Medication Adherence ParticpationFunctionactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.9 Information Source for Medication Adherence SCTactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.1 Malnutritionactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.10 Fractureactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.11 Transplant Diagnosesactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.13 Transplant Diagnoses ICD10CMactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.14 Transplant Diagnoses SNOMED CTactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.15 Respiratory Proceduresactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.2 Moderate Injuries (SNOMEDCT)active2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.3 Diabetesactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.4 Diabetesactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.5 Diabetesactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.6 Immobilityactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.7 Smoking statusactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.8 Obesityactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.9 Hormone Therapyactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.1 Drug Intervention Not Indicated/Contraindicatedactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.10 Endotracheal Intubationactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.2 Procedure Not Indicated/Contraindicatedactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.9 Mechanical Circulatory Assist Deviceactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.1 RXNormSBD0305active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.2 RXNormSCD0305active2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.4 Sequential Organ Failure Assessment SOFAactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.5 Septic Shockactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.6 Septic Shockactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.1 Administrative Gender (HL7 V3)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10267 ParticipationFunctionactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10416 Financially Responsible Party Type Value Setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10612 Unknown Nullactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10637 PostalAddressUseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10901 ParticipationTypeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.11610 x_ActRelationshipDocumentactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12199 LanguageAbilityProficiencyactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12212 Marital Statusactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12249 LanguageAbilityModeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.14914 Race Value Setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.15913 EntityNameUseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.16926 HL7 BasicConfidentialityKindactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.18877 Coverage Role Type Value Setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19185 Religious Affiliationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19563 Personal Relationship Role Typeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19579 Family Member Valueactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19601 x_ServiceEventPerformeractive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19717 No Immunization Reasonactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.12 HealthStatusactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.3 ReferralDocumentTypeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.4 TransferDocumentTypeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.5 Wound Measurementsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.6 Wound Typeactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.7 Nutritional Statusactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.9 Nutrition Recommendationsactive2018-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2 Advance Directive Type Codeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.22 HPDocumentTypeactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20275 HealthcareServiceLocationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20549 Criticality Observationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.78 Observation Interpretation (HL7)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.1 Initial Case Report Trigger Code Result Statusactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.12 Therapeutic Response to Medicationactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.300 Transmission Based Precaution Typesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.304 Organismactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.305 Microbiology and Antimicrobial Susceptibility Testsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.306 Infectious Diseaseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.2 Codes for MDRO and CDI Summary Data LTCFactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.3 NHSNPrimaryResidentServiceTypeactive2020-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.4 Codes for Denominators for Long Term Care Locations LTCFactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.5 Codes for Prevention Process Measures LTCFactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.9.1 NHSNReportNoEventsMDROLTCFactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.10 Codes for Healthcare Personnel Influenza Vaccination (HP FLU) Summary Dataactive2019-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.11 Codes for Hemovigilance (HV) Summary Dataactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.12 Codes for Intensive Care Unit (ICU) Summary Dataactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.13 Codes for Neonatal Intensive Care Unit (NICU) Summary Dataactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.15 Codes for Prevention Process and Outcome Measures (POM) Summary Dataactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.16 Codes for Specialty Care Area (SCA) Summary Dataactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.17 Codes for Vascular Access Type (Dialysis) Summary Dataactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.18 NHSNReportNoEventsICUactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.19 NHSNReportNoEventsNICUactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.20 NHSNReportNoEventsSCAactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.21 NHSNReportNoEventsMDROactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.22 NHSNReportNoEventsDialysisactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.24 NHSNVascularSpecimenCollectionSiteactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.29 NHSNSSIDetectionMethodactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.3 NHSNLastLocationEncounterTypeCodeactive2020-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.30 NHSNLOS/MENDischargeDispositionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.31 NHSNSSIDetectionMethodTypeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.32 Codes for Outpatient Procedure Component Same Day Outcome Measures Summary Dataactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.33 NHSNReportNoEventsOPCSameDayOutcomeMeasuresactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.34 NHSNOPCProcedureCategoryCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.35 NHSNReportNoEventsARactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.4 NHSNDrugSusceptibilityTestMethodactive2020-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.40 NHSN COVID19 Case Classificationactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.5 NHSN Pathogen Reduced Apheresis Platelet Usageactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.50 NHSNGenotypicTestInterpretationactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.6 HealthcarePersonnelTypeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.7 NHSNInfluenzaVaccinationSettingactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.8 Codes for Antimicrobial Resistance Option (ARO) Summary Dataactive2020-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.9 Codes for Antimicrobial Usage, Pharmacy (AUP) Summary Dataactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.1.1 SurgicalOperationNoteDocumentTypeCodeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.12.1 Personal And Legal Relationship Role Typeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.4.1 DischargeSummaryDocumentTypeCodeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.6.1 ProcedureNoteDocumentTypeCodesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.7.1 SupportedFileFormatsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.8.1 ProgressNoteDocumentTypeCodeactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.18 MoodCodeEvnIntactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.19 ProblemAct statusCodeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.20 Telecom Use (US Realm Header)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.21 AgePQ_UCUMactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.22 ProcedureAct statusCodeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.23 Planned moodCode (Act/Encounter/Procedure)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.24 Planned moodCode (SubstanceAdministration/Supply)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.25 Planned moodCode (Observation)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.26 EntityPersonNamePartQualifieractive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.29 DIRQuantityMeasurementTypeCodesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.31 ConsultDocumentTypeactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.32 DIRDocumentTypeCodesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.33 INDRoleclassCodesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.34 Patient Educationactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.35 Pressure Ulcer Stageactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.36 Pressure Pointactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.37 TargetSite Qualifiersactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.38 Smoking Statusactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.39 Result Statusactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.41 Tobacco Useactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.44 Mental and Functional Status Responseactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.46 Abilityactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.47 ADL Result Typeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.49 Residence and Accommodation Typeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.50 Sensory Status Problem Typeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.51 Healthcare Agent Qualifieractive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.52 Encounter SCTactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.54 Planned Intervention moodCodeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.55 Goal Achievementactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.56 Referral Typesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.58 Wound Characteristicactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.59 DIRSectionTypeCodesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.60 Priority Levelactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.61 Care Modelactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.62 Related Document (append/replace)active2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.65 Physical Exam Typeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.66 Patient Referral Act moodCodeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.68 Note Typesactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.1 Advance Care Planning Services CPTactive2018-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.2 Advance Care Planning Services SCTactive2018-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.3 Advance Care Planning Services Groupingactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.17 Obligation or Prohibition Instruction Typeactive2018-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.4 Advance Healthcare Directive Categories LOINCactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.5 Advance Directives Content Typesactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.6 Planned or Completed moodCodeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.7 Obligation or Prohibition Instruction Typeactive2017-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.80 Pregnancy Status Determination Methodactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.81 Estimated Date of Delivery Including Methodactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.82 Estimated Gestational Age Code Including Methodactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.84 Other Pregnancy Outcomeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.86 Pregnancy Outcomeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.87 Postpartum Statusactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.88 Pregnancy Related Findingsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.89 D(Rh) Typeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.90 D(Rh) Sensitizedactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.91 Rho(D) Immune Globulinactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.1 NHSNEncounterTypeCodeactive2019-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.10 NHSNASAClassCodeactive2019-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.11 NHSNSpinalFusionLevelCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.12 NHSNOccasionOfDetectionCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.13 NHSNDrugSusceptibilityFindingCodeactive2020-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.15 NHSNDrugSusceptibilityTestsCodeactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.16 NHSNPathogenCodeactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.17 NHSNProcedureCategoryCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.19 NHSNHealthcareServiceLocationCodeactive2019-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.2 NHSNSpinalFusionApproachCodeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.20 NHSNInfectionTypeCodeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.3 NHSNHipReplacementCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.4 NHSNKneeReplacementCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.6 NHSNInfectionRiskFactorsCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.7 NHSNBloodStreamInfectionEvidenceTypeCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.9 NHSNWoundClassCodeactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.17.4077.2.1017 Closed Head and Facial Traumaactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.17.4077.2.1018 Closed Head and Facial Traumaactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.1 Major Surgical Procedureactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.134 Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatmentactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.136 Perforation of Uterusactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.137 Uterine Windowactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.138 Uterine Ruptureactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.200 Anticoagulant Therapyactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.201 Antithrombotic Therapy Anticoagulantactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.202 Atrial Fibrillation or Flutteractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.203 Atrial Ablationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.204 Carotid Interventionactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.205 Direct Thrombin Inhibitoractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.207 Discharged to Health Care Facility for Hospice Careactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.209 Discharged to Home for Hospice Careactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.211 Injectable Factor Xa Inhibitor for VTE Prophylaxisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.212 Hemorrhagic Strokeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.213 INRactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.214 Intermittent pneumatic compression devicesactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.215 LDLcactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.218 Unfractionated Heparinactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.219 Low Molecular Weight Heparin for VTE Prophylaxisactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.222 Intravenous routeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.223 Subcutaneous routeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.226 Thrombolytic tPA Therapyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.230 Venous foot pumpsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.232 Warfarinactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.234 Hemorrhagic Strokeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.235 Hemorrhagic Strokeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.238 Carotid Interventionactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.239 Carotid Interventionactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.242 Atrial Ablationactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.243 Atrial Ablationactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.244 Atrial Fibrillation or Flutteractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.245 Atrial Fibrillation or Flutteractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.246 Atrial Fibrillation or Flutteractive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.247 Ischemic Strokeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.25 Single Live Birthactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.251 Ischemic Stroke Embolismactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.252 Ischemic Stroke Embolismactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.255 General Surgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.256 Graduated compression stockingsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.257 Gynecological Surgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.258 Hip Fracture Surgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.259 Hip Replacement Surgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.26 Single Live Born Newborn Born in Hospitalactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.260 Intracranial Neurosurgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.261 Knee Replacement Surgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.263 Obstetrical or Pregnancy Related Conditionsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.264 Obstetrics VTEactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.27 Dietary Intake Other than Human Milkactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.270 Acute or Persistent Asthmaactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.271 Acute or Persistent Asthmaactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.272 Urological Surgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.279 Venous Thromboembolismactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.281 Laboractive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.282 Cesarean Birthactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.286 Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestationactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.288 Medical Induction of Laboractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292 Emergency Department Visitactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.294 Decision to Admit to Hospital Inpatientactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.295 Decision to Admit to Hospital Inpatientactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.296 Psychiatric/Mental Health Diagnosisactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.298 Psychiatric/Mental Health Diagnosisactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.299 Psychiatric/Mental Health Diagnosisactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.30 Human Milkactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.308 Left Against Medical Adviceactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.309 Patient Expiredactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.310 Gynecological Surgeryactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.313 Gynecological Surgeryactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.315 Knee Replacement Surgeryactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.317 Knee Replacement Surgeryactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.319 Hip Replacement Surgeryactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.321 Hip Replacement Surgeryactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.323 Hip Fracture Surgeryactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.325 Hip Fracture Surgeryactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.328 Venous Thromboembolismactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.33 Galactosemiaactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.330 Venous Thromboembolismactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.331 Urological Surgeryactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.333 Urological Surgeryactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.335 Obstetrical or Pregnancy Related Conditionsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.337 Obstetrical or Pregnancy Related Conditionsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.338 Obstetrics VTEactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.340 Obstetrics VTEactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.344 Intracranial Neurosurgeryactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.346 Intracranial Neurosurgeryactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.348 General or Neuraxial Anesthesiaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.35 Galactosemiaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.361 General Surgeryactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.365 General Surgeryactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.367 Cesarean Birthactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.369 Cesarean Birthactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.37 Parenteral Nutritionactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.38 Parenteral Nutritionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.384 Medical Induction of Laboractive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.393 Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestationactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.395 Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestationactive2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.400 Low Riskactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.401 Delivery Proceduresactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.418 Classical Cesarean Birthactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.419 Classical Cesarean Birthactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.421 Classical Cesarean Birthactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.422 Myomectomyactive2024-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.423 Statin Allergenactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.424 Nonelective Inpatient Encounteractive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.473 Medical Reason For Not Providing Treatmentactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.75 Neonatal Intensive Care Unitactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.76 Single Live born Newbornactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.78 Galactosemiaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.79 Parenteral Nutritionactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.87 Discharge To Acute Care Facilityactive2021-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.93 Patient Refusalactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1434.1047 Skin Melanoma pT1active2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.100 Injectable Fluorouracilactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.101 Trastuzumab and Biosimilarsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.102 Breast Canceractive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.103 HER2 Presence in Tissueactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.104 Depression Screening for Adultactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.105 Long Acting Opioidsactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.106 High Fiber Supplement or Diet Educationactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.107 Standardized Assessment Tools for Dyspneaactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.108 Nausea or Vomiting Assessmentactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.109 Pancreatic Canceractive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.110 Pancreatic Canceractive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.111 Audio Visual Telehealth Encounteractive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.112 Telephone Encounteractive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.113 Telehealth Emergency Department or Initial Inpatientactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.114 Karnofsky Performance Statusactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.115 Referral to Hospice Careactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.116 Referral to Palliative Careactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.117 Assessment Scale for Dyspneaactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.118 Nausea or Vomiting Assessmentactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.119 Enrollment in Hospice Careactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.120 Palliative Careactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.121 Advance Directive Including Durable Power of Attorney or Instructionalactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.122 Carmustine Injectableactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.123 Dacarbazine Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.124 Streptozocin Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.126 Alemtuzumab Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.127 Azacitidine Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.128 Bendamustine Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.129 Busulfan Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.130 Temozolomide Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.131 Thiotepa Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.132 Oxaliplatin Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.133 Romidepsin Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.134 Trabectedin Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.135 Dolasetron Oralactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.136 Dolasetron Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.137 Granisetron Oralactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.138 Granisetron Transdermalactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.139 Granisetron Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.140 Ondansetron Oralactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.141 Ondansetron Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.142 Ifosfamide Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.143 Arsenic Trioxide Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.144 Netupitant Palonosetron Oralactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.145 Fosnetupitant Palonosetron Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.146 Aprepitant Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.147 Rolapitant Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.148 Dexamethasone Oralactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.149 Dexamethasone Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.150 Dexamethasone Drug Implantactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.151 Olanzapine Oralactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.152 Olanzapine Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.153 Idarubicin Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.154 Neurokinin 1 Receptor Antagonist Ingredientactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.155 Serotonin Receptor Antagonist Ingredientactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.156 Clofarabine Injectableactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.157 Belinostat Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.158 Bortezomib Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.159 Cabazitaxel Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.160 Carfilzomib Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.161 Decitabine Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.162 Elotuzumab Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.163 Enfortumab Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.164 Eribulin Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.165 Etoposide Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.166 Inotuzumab Ozogamicin Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.167 Mitoxantrone Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.168 Moxetumomab Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.169 Necitumumab Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.170 Nelarabine Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.171 Temsirolimus Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.172 Tisagenlecleucel Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.173 Topotecan Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.178 Atezolizumab Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.179 Avelumab Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.180 Bleomycin Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.181 Cemiplimab Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.182 Cladribine Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.183 Daratumumab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.184 Durvalumab Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.185 Emapalumab Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.186 Fludarabine Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.187 Ipilimumab Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.188 Nivolumab Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.189 Pembrolizumab Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.190 Polatuzumab Vedotin Injectableactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.191 Pralatrexate Injectableactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.192 Vincristine Injectableactive2021-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.193 Methotrexate Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.194 Trastuzumab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.195 Mitomycin Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.196 Brentuximab Vedotin Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.197 Doxorubicin Pegylated Liposomal Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.198 Blinatumomab Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.199 Trastuzumab Emtansine Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.200 Gemtuzumab Ozogamicin Injectableactive2021-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.201 Tagraxofusp Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.202 Axicabtagene Ciloleucel Injectableactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.203 BRCA1active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.204 BRCA2active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.205 BRCA1 Testingactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.207 Epithelial Ovarian Canceractive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.208 Primary Peritoneal Canceractive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.209 Fallopian Tube Canceractive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.210 Multigene Panelactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.211 BRCA1 and BRCA2active2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.212 BRCA1 and BRCA2 Testingactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.213 BRAF V600active2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.214 BRAF V600 Testingactive2023-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.215 Colorectal Canceractive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.216 BRAF V600 Mutation Statusactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.217 Cancer Stage Iactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.218 Head and Neck Canceractive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.219 Malignant Melanoma of Skinactive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.220 Brain Canceractive2022-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.221 Waldenstrom Macroglobulinemiaactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.222 High Emetic Risk Intravenous Antineoplastic Agentactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.223 Moderate Emetic Risk Intravenous Antineoplastic Agentactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.224 Docetaxel Injectableactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.225 Cyclophosphamide Injectableactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.226 LAG 3 Inhibitoractive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.227 Neoplasm of Brainactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.233 Chemotherapy Administrationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.240 Pathological N Stage N3cactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.241 Audio Visual Telehealth Encounteractive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.242 Moderate or High Emetic Risk Oral Antineoplastic Agentactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.243 Minimal to Low Emetic Risk Oral Antineoplastic Agentactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.244 Copanlisib Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.245 Isatuximab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.246 Loncastuximab tesirine Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.247 Margetuximab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.248 Mirvetuximab soravtansine Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.249 Tafasitamab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.250 Teclistamab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.251 Tisotumab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.252 Asparaginase Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.254 Belantamab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.255 Dostarlimab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.256 Mosunetuzumab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.257 Tremelimumab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.258 Indication for Dexamethasoneactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.260 Indication for Olanzapineactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.261 Indication for Dexamethasoneactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.263 Indication for Olanzapineactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.264 Prednisoneactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.265 As Needed PRNactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.266 Amivantamab Injectableactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.200 Doxorubicinactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.201 Epirubicinactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.202 Capecitabineactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.203 Cyclophosphamideactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.204 Injectable Fluorouracilactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.205 Methotrexateactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.206 Trastuzumab and Biosimilarsactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.207 HER2 Presence in Tissueactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.208 Carboplatinactive2020-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.209 Depression Screening for Adultactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.210 Long Acting Opioidsactive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.211 High Fiber Supplement or Diet Educationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.212 Dexamethasoneactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.213 Olanzapineactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.214 Pancreatic Canceractive2020-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.215 Audio Visual Telehealth Encounteractive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.216 Telephone Encounteractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.217 Telehealth Emergency Department or Initial Inpatientactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.218 Dyspnea Assessmentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.219 Nausea or Vomiting Assessmentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.220 Karnofsky Performance Statusactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.221 Referral to Hospice Careactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.222 Referral to Palliative Careactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.223 Palliative Careactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.224 Enrollment in Hospice Careactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.225 Advance Directive Including Durable Power of Attorney or Instructionalactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.228 Low Emetic Risk Intravenous Antineoplastic Agentactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.229 Minimal Emetic Risk Intravenous Antineoplastic Agentactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.232 Epithelial Ovarian Canceractive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.233 Primary Peritoneal Canceractive2022-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.235 BRCA2 Testingactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.236 Multigene Panelactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.237 BRCA1 Testingactive2023-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.238 First Line Drug Therapy for Metastatic Colorectal Canceractive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.239 BRAF V600 Testingactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.240 Cancer Stage 4active2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.241 Cancer Stage M1active2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.242 High Emetic Risk Intravenous Antineoplastic Agentactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.243 Moderate Emetic Risk Intravenous Antineoplastic Agentactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.244 Anthracycline Injectableactive2024-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.245 Antiemetic Agentactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.247 Indication for Dexamethasoneactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.249 Indication for Olanzapineactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.2074.1.1.3 Race Category Excluding Nullsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1 Abdomen CT without contrastactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.11 Oxycodoneactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.12 Oxymorphoneactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.70 Morphineactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.71 Methadone Medicationsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.72 Meperidineactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.73 Levorphanolactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.74 Hydromorphoneactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.75 Hydrocodoneactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.76 Fentanylactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.77 Codeineactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.12 Butorphanolactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.13 Dihydrocodeineactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.14 Nalbuphineactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.15 Opium Combinationsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.16 Pentazocineactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.17 Tapentadolactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.18 Tramadolactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1017 Adrenal Massactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1019 Diseases of Urinary Systemactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1020 Hematuriaactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1021 Infections of Kidneyactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1022 Jaundiceactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1023 Liver Lesion (Mass or Neoplasm)active2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1024 Malignant Neoplasm of Bladderactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1025 Malignant Neoplasm of Pancreasactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1026 Non Traumatic Aortic Diseaseactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1028 Unspecified Disorder of Kidney and Ureteractive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1301 Surgery Integumentary System Breastactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1302 Surgery Respiratory System Accessory Sinusesactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1303 Surgery Respiratory System Larynxactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1304 Surgery Respiratory System Trachea and Bronchiactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1305 Surgery Respiratory System Lungs and Pleuraactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13064 Surgery Digestive System Esophagusactive2020-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1307 Surgery Digestive System Intestines (Except Rectum)active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1308 Surgery Digestive System Rectumactive2019-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1309 Surgery Digestive System Anusactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1310 Surgery Digestive System Biliary Tractactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1311 Surgery Digestive System Abdomen Peritoneum Omentumactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1312 Surgery Digestive System Kidneyactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13133 Surgery Digestive System Ureteractive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1314 Surgery Digestive System Bladderactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1315 Surgery Female Genital System Cervix Uteriactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1316 Surgery Female Genital System Corpus Uteriactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1317 Surgery Female Genital System Oviduct Ovaryactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1318 Surgery Eye and Ocular Adnexa Anterior Segmentactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13193 Other Surgeriesactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13202 SPECT MPIactive2020-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13213 Stress Echocardiographyactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13222 Stress MRIactive2020-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1323 CCTAactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1329 Diabetes Mellitusactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1330 Renal insufficiencyactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1331 Stroke transient ischemic attackactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1332 Prior heart failureactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1333 Ischemic heart diseaseactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1802 Physical Therapyactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1803 Chiropractic Evaluationactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1804 Claim(s) for evaluation and management > 28 days and <60 days preceding the lumbar spine MRIactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1805 MRI Lumbar Spine Proceduresactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1809 Other Deforming Dorsopathiesactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1810 Spondylopathiesactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1811 Other Dorsopathiesactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1812 Biomechanical Lesions (not Elsewhere Classified)active2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1813 Dislocation or Sprain of those Joints and Ligaments Located in the Lumbar Spine or Pelvisactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.18143 Patients with lumbar spine surgery in the 90 days prior to MRIactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1832 Canceractive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1833 Congenital spine and spinal cord malformationsactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1834 Inflammatory and autoimmune disordersactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1835 Infectious conditionsactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1836 Spinal vascular malformations and/or the cause of occult subarachnoid hemorrhageactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1837 Spinal cord infarctionactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1838 Neoplastic abnormalitiesactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1839 Treatment fields for radiation therapyactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1840 Spinal abnormalities associated with scoliosisactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1841 Syringohydromyeliaactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1842 Postoperative fluid collections and soft tissue changesactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1843 Traumaactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1844 IV Drug Abuseactive2022-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1845 Neurological Impairmentactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1846 Human Immunodeficiency Virusactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1847 Unspecified Immune Deficienciesactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.190123 Diagnostic Mammography Studyactive2018-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1902 Ultrasound of the Breastactive2019-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.190412 Screening Mammography and DBT Studiesactive2018-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2 Abdomen CT with contrastactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.1 Percutaneous Coronary Intervention ICD10active2018-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.2 Percutaneous Coronary Intervention SNOMEDCTactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.3 Percutaneous Coronary Intervention CPTactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.4 Percutaneous Coronary Intervention HCPCSactive2018-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.5 Percutaneous Coronary Interventionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.21 Abdomen CT Without then With Contrastactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4009 Malignant Intracranial Neoplasmactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4010 Malignant Intracranial Neoplasmactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4015 STEMIactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4016 STEMIactive2019-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4017 STEMIactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4019 Fibrinolytic Therapyactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4023 Cerebral Vascular Lesionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4024 Cerebral Vascular Lesionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4025 Cerebral Vascular Lesionactive2019-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4026 Closed Head and Facial Traumaactive2019-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4028 Aortic Dissection or Ruptured Aortic Aneurysmactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4029 Acute Peptic Ulceractive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4030 Acute Peptic Ulceractive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4031 Acute Peptic Ulceractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4032 Dementia and Related Intracranial Pathologiesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4033 Dementia and Related Intracranial Pathologiesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4034 Active Bleeding or Bleeding Diathesis, Excluding Mensesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4035 Active Bleeding or Bleeding Diathesis, Excluding Mensesactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4036 Active Bleeding or Bleeding Diathesis, Excluding Mensesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4043 Dementia and Related Intracranial Pathologiesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4044 Aortic Dissection or Ruptured Aortic Aneurysmactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4045 Oral Anticoagulant Medicationsactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4046 Cardiopulmonary Emergencyactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4047 Cardiopulmonary Emergencyactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4048 Cardiopulmonary Emergencyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4049 Mechanical Circulatory Assist Deviceactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4050 Mechanical Circulatory Assist Deviceactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4052 Mechanical Circulatory Assist Deviceactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4053 Pregnant Stateactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4054 Pregnant Stateactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4055 Pregnant Stateactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4056 Major Surgical Procedureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4057 Emergency Department Encounteractive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4066 Diagnostic DBT Studyactive2022-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.2.1005 Chronic Stable Anginaactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.2.1006 Chronic Stable Anginaactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.3.1002 Chronic Stable Anginaactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1001 Hospice Encounteractive2021-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1002 Hospice Encounteractive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1003 Hospice Encounteractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1004 Nutrition Servicesactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1005 Nutrition Servicesactive2021-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1006 Nutrition Servicesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1007 Hospice Care Ambulatoryactive2021-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1008 Hospice Care Ambulatoryactive2021-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1005 Office Visitactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1020 Initial Hospital Inpatient Visitactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1030 Discharge Services Hospital Inpatient Same Day Dischargeactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1035 Discharge Services Hospital Inpatientactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1040 Outpatient Consultationactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1050 Emergency Department Evaluation and Management Visitactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1060 Nursing Facility Visitactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1065 Discharge Services Nursing Facilityactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1080 Home Healthcare Servicesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1110 Preventive Care, Initial Office Visit, 0 to 17active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1115 Preventive Care Services Initial Office Visit, 18 and Upactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1120 Preventive Care, Established Office Visit, 0 to 17active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1125 Preventive Care Services Established Office Visit, 18 and Upactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1130 Preventive Care Services Individual Counselingactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1135 Preventive Care Services Group Counselingactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1215 Referralactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1216 Face-to-Face Interactionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1221 Behavioral Health Follow up Visitactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1222 Psychotherapy and Pharmacologic Managementactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1228 Detoxification Visitactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1232 Audiology Visitactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1233 Medical Disability Examactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1260 Telephone Visitsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1261 Nursing Facility Visitactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1262 Care Services in Long Term Residential Facilityactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1264 Office Visitactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1265 Home Healthcare Servicesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1266 Outpatient Consultationactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1276 Frailty Encounteractive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1277 Outpatient Encounteractive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1278 Outpatient Encounteractive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1279 Frailty Encounteractive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1281 Virtual Encounteractive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1282 Virtual Encounteractive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1284 Outpatient Encounteractive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1285 Palliative Encounteractive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1286 Palliative Encounteractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1287 Telephone Visitsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 Office Visitactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1004 Initial Hospital Inpatient Visitactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1006 Discharge Services Hospital Inpatient Same Day Dischargeactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1007 Discharge Services Hospital Inpatientactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1008 Outpatient Consultationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1010 Emergency Department Evaluation and Management Visitactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1012 Nursing Facility Visitactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1013 Discharge Services Nursing Facilityactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1014 Care Services in Long Term Residential Facilityactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1016 Home Healthcare Servicesactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1022 Preventive Care Services, Initial Office Visit, 0 to 17active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1023 Preventive Care Services Initial Office Visit, 18 and Upactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1024 Preventive Care, Established Office Visit, 0 to 17active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1025 Preventive Care Services Established Office Visit, 18 and Upactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1026 Preventive Care Services Individual Counselingactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1027 Preventive Care Services Group Counselingactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1046 Referralactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1048 Face-to-Face Interactionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1054 Behavioral Health Follow up Visitactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1055 Psychotherapy and Pharmacologic Managementactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1059 Detoxification Visitactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1066 Audiology Visitactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1073 Medical Disability Examactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1080 Telephone Visitsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1087 Outpatient Encounteractive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1088 Frailty Encounteractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1089 Virtual Encounteractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1090 Palliative Care Encounteractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1010 Multiple Myelomaactive2021-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1011 Multiple Myelomaactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1012 Premature Menopauseactive2021-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1013 Premature Menopauseactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1014 Multiple Myelomaactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1015 Premature Menopauseactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1019 Amenorrheaactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1031 Acute Pharyngitisactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1033 Acute Pharyngitisactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1034 Acute Tonsillitisactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1036 Acute Tonsillitisactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1058 Upper Respiratory Infectionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1059 Upper Respiratory Infectionactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1066 Comorbid Conditions for Respiratory Conditionsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1067 Comorbid Conditions for Respiratory Conditionsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1011 Acute Pharyngitisactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1012 Acute Tonsillitisactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1017 Competing Conditions for Respiratory Conditionsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1022 Upper Respiratory Infectionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1025 Comorbid Conditions for Respiratory Conditionsactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1021 Amenorrheaactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1022 Amenorrheaactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1025 Bilateral Oophorectomyactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1026 Unilateral Oophorectomy Leftactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1028 Unilateral Oophorectomy Leftactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1029 Unilateral Oophorectomy Leftactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1001 Diabetesactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1020 Type 1 Diabetesactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1030 Unilateral Oophorectomy Rightactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1031 Unilateral Oophorectomy Rightactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1032 Unilateral Oophorectomy Rightactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1034 Unilateral Oophorectomy, Unspecified Lateralityactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1035 Unilateral Oophorectomy, Unspecified Lateralityactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1036 Eating Disordersactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1038 Eating Disordersactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1039 Eating Disordersactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.104.11.1029 Essential Hypertensionactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.104.11.1031 Essential Hypertensionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.104.12.1011 Essential Hypertensionactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1040 Major Transplantactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1042 Major Transplantactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1043 Potentially Harmful Antihistamines for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1046 Evidence of Bilateral Oophorectomyactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1048 Evidence of Bilateral Oophorectomyactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1049 Potentially Harmful Antiparkinsonian Agents for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1010 Mental Health Diagnosesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1012 Mental Health Diagnosesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1017 Major Depressionactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1019 Major Depressionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1060 Major Depression In Remissionactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1062 Major Depression In Remissionactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1161 Schizophrenia or Psychotic Disorderactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1162 Schizophrenia or Psychotic Disorderactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1163 Schizophrenia or Psychotic Disorderactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1178 Pervasive Developmental Disorderactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1180 Pervasive Developmental Disorderactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1206 Mental Behavioral and Neurodevelopmental Disordersactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1207 Mental Behavioral and Neurodevelopmental Disordersactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1210 Schizophreniaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1211 Schizophreniaactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1212 Seizure Disorderactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1213 Seizure Disorderactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1214 REMactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1215 REMactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1216 Benzodiazepine Withdrawalactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1217 Benzodiazepine Withdrawalactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1218 Alcohol Withdrawalactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1219 Alcohol Withdrawalactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1220 General Anxietyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1221 General Anxietyactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1004 Mental Health Diagnosesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1007 Major Depressionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1104 Schizophrenia or Psychotic Disorderactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1152 Pervasive Developmental Disorderactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1203 Mental Behavioral and Neurodevelopmental Disordersactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1205 Schizophreniaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1206 Seizure Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1207 REM Sleep Behavior Disorderactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1208 Benzodiazepine Withdrawalactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1209 Alcohol Withdrawalactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1210 Generalized Anxiety Disorderactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1050 Potentially Harmful Gastrointestinal Antispasmodics for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1051 Dipyridamole Medicationsactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1053 Nifedipine Medicationsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1054 Potentially Harmful Antidepressants for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1055 Potentially Harmful Barbiturates for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1057 Meprobamate Medicationsactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1058 Potentially Harmful Estrogens for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1059 Potentially Harmful Sulfonylureas for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1001 Substance Use Disorderactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1003 Substance Use Disorderactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1012 Substance Use Disorder Treatmentactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1036 Substance Use Disorder Treatmentactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.12.1001 Substance Use Disorderactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.12.1005 Substance Use Disorder Treatmentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1060 Desiccated Thyroid Medicationsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1062 Potentially Harmful Skeletal Muscle Relaxants for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1063 Potentially Harmful Pain Medications for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1065 Digoxin Medicationsactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1066 Digoxin Medicationsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1067 Doxepin Medicationsactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1068 Doxepin Medicationsactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1001 Malignant Neoplasm of Colonactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1003 Malignant Neoplasm of Colonactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1025 Malignant Neoplasm of Lymphatic and Hematopoietic Tissueactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1027 Malignant Neoplasm of Lymphatic and Hematopoietic Tissueactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1044 Pap Testactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1047 Mammographyactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1051 Colonoscopyactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1052 Colonoscopyactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1053 Colonoscopyactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1145 sDNA FIT Testactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1001 Malignant Neoplasm of Colonactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1009 Malignant Neoplasm of Lymphatic and Hematopoietic Tissueactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1017 Pap Testactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1018 Mammographyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1020 Colonoscopyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1038 CT Colonographyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1039 sDNA FIT Testactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1024 Kidney Transplantactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1025 Kidney Transplantactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1026 Dialysis Servicesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1027 Dialysis Servicesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1028 Dialysis Servicesactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1029 ESRD Monthly Outpatient Servicesactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1052 Kidney Transplantactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1060 Kidney Transplant Recipientactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1067 Kidney Transplantactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1012 Kidney Transplantactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1013 Dialysis Servicesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1014 ESRD Monthly Outpatient Servicesactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1029 Kidney Transplant Recipientactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1065 DTaP Vaccine Administeredactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1066 DTaP Vaccine Administeredactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1068 Hepatitis Aactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1070 Hepatitis Aactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1078 Measlesactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1080 Measlesactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1085 Measles, Mumps and Rubella (MMR) Vaccine Administeredactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1086 Measles, Mumps and Rubella (MMR) Vaccine Administeredactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1087 Mumpsactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1089 Mumpsactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1098 Rubellaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.110 Rubellaactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1104 Varicella Zosteractive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1105 Varicella Zosteractive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1106 Varicella Zoster Vaccine (VZV) Administeredactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1107 Varicella Zoster Vaccine (VZV) Administeredactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1109 Hepatitis A Vaccine Administeredactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1110 Hepatitis A Vaccine Administeredactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1111 Hepatitis B Vaccine Administeredactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1112 Hepatitis B Vaccine Administeredactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1115 Child Influenza Vaccine Administeredactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1116 Child Influenza Vaccine Administeredactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1117 Inactivated Polio Vaccine (IPV) Administeredactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1118 Inactivated Polio Vaccine (IPV) Administeredactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1119 Pneumococcal Conjugate Vaccine Administeredactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1120 Rotavirus Vaccine (3 dose schedule) Administeredactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1121 Rotavirus Vaccine (2 dose schedule) Administeredactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1123 Genital Herpesactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1124 Genital Herpesactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1128 Lab Tests for Sexually Transmitted Infectionsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1129 Chlamydia Screeningactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1133 Pneumococcal Conjugate Vaccine Administeredactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1135 HPV Testactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1148 Rotavirus Vaccine (2 Dose Schedule) Administeredactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1149 Rotavirus Vaccine (3 Dose Schedule) Administeredactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1150 Advanced Illnessactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1151 Advanced Illnessactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1152 HiB Vaccine (3 dose schedule)active2021-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1153 HiB Vaccine (3 dose schedule) Administeredactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1154 HiB Vaccine (4 dose schedule)active2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1155 HiB Vaccine (4 dose schedule) Administeredactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1156 HiB Vaccine (3 dose schedule) Administeredactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1157 HiB Vaccine (4 dose schedule) Administeredactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1158 Competing Conditions for Respiratory Conditionsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1159 Competing Conditions for Respiratory Conditionsactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1022 DTaP Vaccine Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1024 Hepatitis Aactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1031 Measles, Mumps and Rubella (MMR) Vaccine Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1032 Mumpsactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1037 Rubellaactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1039 Varicella Zosteractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1040 Varicella Zoster Vaccine (VZV) Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1041 Hepatitis A Vaccine Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1042 Hepatitis B Vaccine Administeredactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1044 Child Influenza Vaccine Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1045 Inactivated Polio Vaccine (IPV) Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1046 Pneumococcal Conjugate Vaccine Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1047 Rotavirus Vaccine (3 dose schedule) Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1048 Rotavirus Vaccine (2 dose schedule) Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1049 Genital Herpesactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1051 Lab Tests for Sexually Transmitted Infectionsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1052 Chlamydia Screeningactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1053 Measlesactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1059 HPV Testactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1082 Advanced Illnessactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1083 Hib Vaccine (3 dose schedule)active2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1084 Hib Vaccine (3 dose schedule) Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1085 Hib Vaccine (4 dose schedule)active2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1086 Hib Vaccine (4 dose schedule) Administeredactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1087 Influenza Virus LAIV Vaccineactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1088 Influenza Virus LAIV Vaccine Administeredactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1012 Lab Tests During Pregnancyactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1013 Diagnostic Studies During Pregnancyactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1019 Pregnancy Testactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1022 Complications of Pregnancy, Childbirth and the Puerperiumactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1023 Complications of Pregnancy, Childbirth and the Puerperiumactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1028 Procedures for Sexual Activityactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1030 Procedures for Sexual Activityactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1031 Diagnosis for Sexual Activityactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1032 Diagnosis for Sexual Activityactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1033 Procedures for Sexual Activityactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1007 Lab Tests During Pregnancyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1008 Diagnostic Studies During Pregnancyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1011 Pregnancy Testactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1012 Complications of Pregnancy, Childbirth and the Puerperiumactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1016 Congenital or Acquired Absence of Cervixactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1017 Procedures Used to Indicate Sexual Activityactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1018 Diagnoses Used to Indicate Sexual Activityactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.112.11.1024 Absence of Cervixactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.112.11.1025 Absence of Cervixactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.112.11.1026 Absence of Cervixactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1073 Osteoporosis Without Current Fractureactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1074 Osteoporosis Without Current Fractureactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1078 History of hip fracture in parentactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1080 Rheumatoid Arthritisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1081 Rheumatoid Arthritisactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1083 Central DXA of Hip or Spineactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1085 Osteogenesis Imperfectaactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1087 Osteogenesis Imperfectaactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1088 Ankylosing Spondylitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1090 Ankylosing Spondylitisactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1091 Psoriatic Arthritisactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1093 Psoriatic Arthritisactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1094 Ehlers Danlos Syndromeactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1096 Ehlers Danlos Syndromeactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1097 Marfan's Syndromeactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1099 Marfan's Syndromeactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1100 Osteopeniaactive2018-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1102 Osteopeniaactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1200 Osteoporosis With Current Fractureactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1201 Osteoporosis With Current Fractureactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1202 DXA (Dual energy Xray Absorptiometry) Scan Non Hip or Spineactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1308 Frailty Diagnosisactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1309 Frailty Diagnosisactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1310 Frailty Symptomactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1311 Frailty Symptomactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1005 Rheumatoid Arthritisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1038 Osteoporosis Without Current Fractureactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1040 History of hip fracture in parentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1044 Osteogenesis Imperfectaactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1045 Ankylosing Spondylitisactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1046 Psoriatic Arthritisactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1047 Ehlers Danlos Syndromeactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1048 Marfan's Syndromeactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1049 Osteopeniaactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1050 Osteoporosis With Current Fractureactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1051 DXA (Dual energy Xray Absorptiometry) Scanactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1074 Frailty Diagnosisactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1075 Frailty Symptomactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1021 Narcolepsyactive2018-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1023 Narcolepsyactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1024 Neurologic impairmentactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1025 Neurologic impairmentactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1026 Neurologic impairmentactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.12.1011 Narcolepsyactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.12.1012 Neurologic impairmentactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1149 Substance Use Disorder Long Acting Medicationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.115.11.1248 Retinal or Dilated Eye Examactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.115.12.1088 Retinal or Dilated Eye Examactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1150 Substance Use Disorder Short Acting Medicationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1151 Substance Use Disorder Long Acting Medication Administrationactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1152 Substance Use Disorder Short Acting Medication Administrationactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1155 Substance Use Disorder Short Acting Medication Administrationactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1156 Substance Use Disorder Long Acting Medication Administrationactive2021-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1157 Substance Use Disorder Short Acting Medication Administrationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1163 Encephalitis Due to Diphtheria, Tetanus or Pertussis Vaccineactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1164 Encephalitis Due to Diphtheria, Tetanus or Pertussis Vaccineactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1165 Hospice Diagnosisactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1166 Hospice Diagnosisactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1167 Palliative Care Diagnosisactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1168 Palliative Care Diagnosisactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1169 Palliative Care Diagnosisactive2022-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1023 Cushings Syndromeactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1025 Cushings Syndromeactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1026 Lupusactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1028 Lupusactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1031 Hyperthyroidismactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1033 Hyperthyroidismactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1034 Hyperparathyroidismactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1036 Hyperparathyroidismactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1009 Cushings Syndromeactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1010 Lupusactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1015 Hyperthyroidismactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1016 Hyperparathyroidismactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1170 Atomoxetineactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1171 Clonidineactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1172 Dexmethylphenidateactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1173 Dextroamphetamineactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1174 Lisdexamfetamineactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1176 Methylphenidateactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1177 Lower Body Fractures Excluding Ankle and Footactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1178 Lower Body Fractures Excluding Ankle and Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1179 Malignant Neoplasms of Lower and Unspecified Limbsactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1042 Counseling for Physical Activityactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1077 Falls Screeningactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1097 CT Colonographyactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1220 Frailty Device SNOMEDactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.12.1028 Falls Screeningactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.12.1035 Counseling for Physical Activityactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.12.1300 Frailty Deviceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1180 Malignant Neoplasms of Lower and Unspecified Limbsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1181 Mechanical Complications Excluding Upper Bodyactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1182 Mechanical Complications Excluding Upper Bodyactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1183 Partial Arthroplasty of Hipactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1184 Partial Arthroplasty of Hipactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1188 Removal, Revision and Supplement Procedures of the Lower Body and Spineactive2022-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1189 Removal, Revision and Supplement Procedures of the Lower Body and Spineactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1190 Antibiotic Medications for Upper Respiratory Infectionactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1193 Malignant Neoplasmsactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1194 Malignant Neoplasmsactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1196 Atherosclerosis of the Extremitiesactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1197 Atherosclerosis of the Extremitiesactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1198 Atherosclerosis of the Extremitiesactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1199 Lower Extremity Neurological Assessment Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1001 Disorders of the Immune Systemactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1003 Disorders of the Immune Systemactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1004 HIV Viral Loadactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1005 HIV 1active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1007 HIV 1active2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1008 HIV 2active2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1010 HIV 2active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1011 Severe Combined Immunodeficiencyactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1012 Severe Combined Immunodeficiencyactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1001 Disorders of the Immune Systemactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1002 HIV Viral Loadactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1003 HIVactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1007 Severe Combined Immunodeficiencyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1200 Lower Extremity Neurological Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1201 Lower Extremity Visual Inspection Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1202 Lower Extremity Visual Inspection Testactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1203 Monofilament Test Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1204 Monofilament Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1205 Pedal Pulse Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1206 Peripheral Neuropathyactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1207 Peripheral Neuropathyactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1208 Peripheral Neuropathyactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1209 Amputation of Bilateral Feetactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1011 Consultant Reportactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1028 BMI percentileactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1030 Heightactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1031 Weightactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1006 Consultant Reportactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1012 BMI percentileactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1014 Heightactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1015 Weightactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1210 Amputation of Bilateral Feetactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1211 Amputation of Bilateral Feetactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1212 Amputation of Left Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1213 Amputation of Left Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1214 Amputation of Left Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1215 Amputation of Right Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1216 Amputation of Right Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1217 Amputation of Right Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1218 Amputation of Unspecified Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1219 Amputation of Unspecified Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.122.11.1003 Ambulatoryactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.122.12.1003 Ambulatoryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1220 Foot Assessment With Abnormal Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1221 Foot Assessment With Abnormal Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1222 Acquired Absence of Bilateral feetactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1223 Acquired Absence of Bilateral feetactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1224 Acquired Absence of Left Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1225 Acquired Absence of Left Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1226 Acquired Absence of Left Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1227 Acquired Absence of Right Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1228 Acquired Absence of Right Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1229 Acquired Absence of Right Footactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1230 Lower Body Fractures Excluding Ankle and Footactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1231 Malignant Neoplasms of Lower and Unspecified Limbsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1232 Mechanical Complications Excluding Upper Bodyactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1233 Partial Arthroplasty of Hipactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1234 Partial Arthroplasty of Hipactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1235 Removal, Revision and Supplement Procedures of the Lower Body and Spineactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1236 Removal, Revision and Supplement Procedures of the Lower Body and Spineactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1237 Removal, Revision and Supplement Procedures of the Lower Body and Spineactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1238 Primary THA Procedureactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1239 Foot Ulceractive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1240 Foot Ulceractive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1241 Foot Ulceractive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1242 Referral for Foot Careactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1243 Therapeutic Footwearactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1244 Foot Deformityactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1245 Foot Deformityactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1246 Foot Deformityactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1247 Megestrol Medicationsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1248 Meperidine Medicationsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1249 Potentially Harmful Antidepressants for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1004 Fluoride Varnish Application for Childrenactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1007 Dental Cariesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1009 Dental Cariesactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1010 Clinical Oral Evaluationactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1011 Fluoride Varnish Application for Childrenactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1002 Fluoride Varnish Application for Childrenactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1003 Clinical Oral Evaluationactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1004 Dental Cariesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1250 Potentially Harmful Antihistamines for Older Adultsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1251 Potentially Harmful Antiparkinsonian Agents for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1252 Potentially Harmful Barbiturates for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1253 Potentially Harmful Estrogens for Older Adultsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1254 Potentially Harmful Gastrointestinal Antispasmodics for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1255 Potentially Harmful Pain Medications for Older Adultsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1256 Potentially Harmful Skeletal Muscle Relaxants for Older Adultsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1257 Potentially Harmful Sulfonylureas for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1258 Substance Use Disorder Long Acting Medicationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1259 Substance Use Disorder Short Acting Medicationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1260 Viloxazineactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1266 Diabetic Retinopathy Severity Levelactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1272 Diabetesactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1273 Diabetesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.11.1003 Counseling for Nutritionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.11.1004 Counseling for Nutritionactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.12.1003 Counseling for Nutritionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1001 Antibiotic Medications for Pharyngitisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1078 Nifedipine Medicationsactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1080 Contraceptive Medicationsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1109 Meperidine Medicationsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1129 Desiccated Thyroid Medicationsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1143 Isotretinoinactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1167 Dipyridamole Medicationsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1205 Leucovorinactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1211 Aspirin and Other Antiplateletsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1212 DTaP Vaccineactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1214 Hepatitis A Vaccineactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1216 Hepatitis B Vaccineactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1220 Child Influenza Vaccineactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1222 Inactivated Polio Vaccine (IPV)active2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1228 Pneumococcal Conjugate Vaccineactive2023-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1232 Rotavirus Vaccine (3 dose schedule)active2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1234 Varicella Zoster Vaccine (VZV)active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1235 Measles, Mumps and Rubella (MMR) Vaccineactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1252 Guanfacine Medicationsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1255 Megestrol Medicationsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1256 Meprobamate Medicationsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1266 Aromatase Inhibitorsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1267 Glucocorticoids (oral only)active2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1481 Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adultsactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1482 Potentially Harmful Antiinfectives for Older Adultsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1517 Dementia Medicationsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1530 Antidepressant Medicationactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1531 Potentially Harmful Benzodiazepines for Older Adultsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1532 Potentially Harmful Antipsychotics for Older Adultsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1001 Antibiotic Medications for Pharyngitisactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1080 Contraceptive Medicationsactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1143 Isotretinoinactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1170 Varicella Zoster Vaccine (VZV)active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1205 Leucovorinactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1211 Aspirin and Other Antiplateletsactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1213 Antidepressant Medicationactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1214 DTaP Vaccineactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1215 Hepatitis A Vaccineactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1216 Hepatitis B Vaccineactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1218 Child Influenza Vaccineactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1219 Inactivated Polio Vaccine (IPV)active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1221 Pneumococcal Conjugate Vaccineactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1223 Rotavirus Vaccine (3 dose schedule)active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1224 Measles, Mumps and Rubella (MMR) Vaccineactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1265 Aromatase Inhibitorsactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1266 Glucocorticoids (oral only)active2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1480 Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adultsactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1481 Potentially Harmful Antiinfectives for Older Adultsactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1510 Dementia Medicationsactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1522 Potentially Harmful Benzodiazepines for Older Adultsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1523 Potentially Harmful Antipsychotics for Older Adultsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1005 Bilateral Mastectomyactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1009 Primary THA Procedureactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1015 Flexible Sigmoidoscopyactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1016 Flexible Sigmoidoscopyactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1017 Flexible Sigmoidoscopyactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1020 Fecal Occult Blood Test (FOBT)active2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1023 Group A Streptococcus Testactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1024 HbA1c Laboratory Testactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1026 Hysterectomy with No Residual Cervixactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1027 Hysterectomy with No Residual Cervixactive2024-11
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1035 Total Colectomyactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1036 Total Colectomyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1055 XRay Studyactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1061 Gastric Bypass Surgeryactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1062 Gastric Bypass Surgeryactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1080 Primary THA Procedureactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1084 History of bilateral mastectomyactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1085 History of bilateral mastectomyactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1086 Status Post Left Mastectomyactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1087 Status Post Right Mastectomyactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1089 Unilateral Mastectomy, Unspecified Lateralityactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1090 Unilateral Mastectomy, Unspecified Lateralityactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1091 Status Post Left Mastectomyactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1092 Status Post Right Mastectomyactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1096 Major Transplantactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1097 Major Transplantactive2021-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1132 Unilateral Mastectomy Leftactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1133 Unilateral Mastectomy Rightactive2021-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1134 Hysterectomy with No Residual Cervixactive2023-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1135 Hysterectomy with No Residual Cervixactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1140 Bilateral Mastectomyactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1143 Total Colectomyactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1144 Unilateral Mastectomy Leftactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1145 Unilateral Mastectomy Rightactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1148 Palliative Interventionactive2023-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1005 Bilateral Mastectomyactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1006 Primary THA Procedureactive2023-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1010 Flexible Sigmoidoscopyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1011 Fecal Occult Blood Test (FOBT)active2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1012 Group A Streptococcus Testactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1013 HbA1c Laboratory Testactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1014 Hysterectomy with No Residual Cervixactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1019 Total Colectomyactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1034 XRay Studyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1050 Gastric Bypass Surgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1068 History of bilateral mastectomyactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1069 Status Post Left Mastectomyactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1070 Status Post Right Mastectomyactive2017-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1071 Unilateral Mastectomy, Unspecified Lateralityactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1075 Major Transplantactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1133 Unilateral Mastectomy Leftactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1134 Unilateral Mastectomy Rightactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135 Palliative Care Interventionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1064 Anaphylactic Reaction to DTaP Vaccineactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1065 Chronic Liver Diseaseactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1067 Chronic Liver Diseaseactive2022-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1068 Chronic Malnutritionactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1070 Chronic Malnutritionactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1100 Malabsorption Syndromesactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1102 Malabsorption Syndromesactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1105 Intussusceptionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1106 Intussusceptionactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1107 Influenza Virus LAIV Vaccineactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1108 Influenza Virus LAIV Vaccine Administeredactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1031 Anaphylactic Reaction to DTaP Vaccineactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1035 Chronic Liver Diseaseactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1036 Chronic Malnutritionactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1050 Malabsorption Syndromesactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1056 Intussusceptionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2446 Lower Extremity Visual Inspection Testactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2447 Pedal Pulse Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2448 Monofilament Test Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2449 Monofilament Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2450 Lower Extremity Neurological Assessment Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2451 Lower Extremity Neurological Testsactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2452 Lower Extremity Visual Inspection Result or Findingactive2023-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2616 Autonomous Eye Exam Result or Findingactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.1577 Pharmacologic Therapy for Hypertensionactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1036 Chronic Kidney Disease, Stage 5active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1037 Chronic Kidney Disease, Stage 5active2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1049 Patient Provider Interactionactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1058 Psych Visit for Family Psychotherapyactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1062 Physical Therapy Evaluationactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1063 Occupational Therapy Evaluationactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1064 Neurobehavioral Status Exam (CPT)active2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1067 Dementia and Mental Degenerationsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1068 Dementia and Mental Degenerationsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1069 Standardized Tools for Assessment of Cognitionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1071 Radiation Treatment Managementactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1072 Radiation Treatment Managementactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1073 Standardized Pain Assessment Toolactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1078 Canceractive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1079 Canceractive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1080 Chemotherapy Administrationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1081 Chemotherapy Administrationactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.111 Ophthalmological Servicesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.113 Prostate Cancer Treatmentactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.118 Initial Myocardial Infarctionactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.119 Initial Myocardial Infarctionactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.120 Coronary Artery Disease No MIactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1238 Ejection Fractionactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1243 Psychoanalysisactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1244 Renal Failure Due to ACE Inhibitoractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1251 Group Psychotherapyactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1256 Allergy to ACE Inhibitor or ARBactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1257 Intolerance to ACE Inhibitor or ARBactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.133 Beta Blocker Therapyactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1333 Allergy to Beta Blocker Therapyactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1334 Intolerance to Beta Blocker Therapyactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1341 Heart Rateactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1342 Beta Blocker Therapy for LVSDactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1344 Acute and Subacute Iridocyclitisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1353 Limited Life Expectancyactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1363 Annual Wellness Visitactive2023-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1364 Macular Examactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1372 Tobacco Use Screeningactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1374 Bone Scanactive2018-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1377 Level of Severity of Retinopathy Findingsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1381 Macular Edema Findings Presentactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1401 Cognitive Assessmentactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1402 Cup to Disc Ratioactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1403 Optic Disc Exam for Structural Abnormalitiesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1509 Acute and Subacute Iridocyclitisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1521 Burn Confined to Eye and Adnexaactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1523 Burn Confined to Eye and Adnexaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1524 Cataract Secondary to Ocular Disordersactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1526 Cataract Secondary to Ocular Disordersactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1527 Cataract Surgeryactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1528 Cataract Surgeryactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1529 Cataract Congenitalactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1530 Cataract Congenitalactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1532 Cataract Mature or Hypermatureactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1534 Cataract Mature or Hypermatureactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1535 Cataract Posterior Polaractive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1537 Cataract Posterior Polaractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1538 Certain Types of Iridocyclitisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1540 Certain Types of Iridocyclitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1542 Chronic Iridocyclitisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1543 Chronic Iridocyclitisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1544 Cloudy Corneaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1546 Cloudy Corneaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1548 Corneal Edemaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1549 Corneal Edemaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1550 Disorders of Cornea Including Corneal Opacityactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1552 Disorders of Cornea Including Corneal Opacityactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1561 Glaucomaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1562 Glaucomaactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1564 Hereditary Corneal Dystrophiesactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1566 Hereditary Corneal Dystrophiesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1571 Hypotony of Eyeactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1572 Hypotony of Eyeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1574 Injury to Optic Nerve and Pathwaysactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1575 Injury to Optic Nerve and Pathwaysactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1577 Central Corneal Ulceractive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1578 Central Corneal Ulceractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1582 Open Wound of Eyeballactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1583 Open Wound of Eyeballactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1587 Pathologic Myopiaactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1588 Pathologic Myopiaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1590 Posterior Lenticonusactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1591 Posterior Lenticonusactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1601 Retrolental Fibroplasiasactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1603 Retrolental Fibroplasiasactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1612 Traumatic Cataractactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1613 Traumatic Cataractactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1615 Uveitisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1617 Uveitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1618 Vascular Disorders of Iris and Ciliary Bodyactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1620 Vascular Disorders of Iris and Ciliary Bodyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1621 Visual Field Defectsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1623 Visual Field Defectsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1626 Amblyopiaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1628 Amblyopiaactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1632 Choroidal Degenerationsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1634 Choroidal Degenerationsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1635 Choroidal Detachmentactive2024-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1637 Choroidal Detachmentactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1638 Choroidal Hemorrhage and Ruptureactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1640 Choroidal Hemorrhage and Ruptureactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1641 Degeneration of Macula and Posterior Poleactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1643 Degeneration of Macula and Posterior Poleactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1644 Degenerative Disorders of Globeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1646 Degenerative Disorders of Globeactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1647 Diabetic Macular Edemaactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1649 Diabetic Macular Edemaactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1653 Disorders of Optic Chiasmactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1655 Disorders of Optic Chiasmactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1656 Disorders of Visual Cortexactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1658 Disorders of Visual Cortexactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1659 Disseminated Chorioretinitis and Disseminated Retinochoroiditisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1661 Disseminated Chorioretinitis and Disseminated Retinochoroiditisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1662 Focal Chorioretinitis and Focal Retinochoroiditisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1664 Focal Chorioretinitis and Focal Retinochoroiditisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1665 Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1667 Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromesactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1668 Hereditary Choroidal Dystrophiesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1670 Hereditary Choroidal Dystrophiesactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1671 Hereditary Retinal Dystrophiesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1673 Hereditary Retinal Dystrophiesactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1677 Nystagmus and Other Irregular Eye Movementsactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1679 Nystagmus and Other Irregular Eye Movementsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.168 Cardiac Surgeryactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1680 Optic Atrophyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1682 Optic Atrophyactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1683 Optic Neuritisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1685 Optic Neuritisactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1686 Other and Unspecified Forms of Chorioretinitis and Retinochoroiditisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1688 Other and Unspecified Forms of Chorioretinitis and Retinochoroiditisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1689 Other Background Retinopathy and Retinal Vascular Changesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.169 Cardiac Surgeryactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1691 Other Background Retinopathy and Retinal Vascular Changesactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1695 Other Disorders of Optic Nerveactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1697 Other Disorders of Optic Nerveactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1701 Other Endophthalmitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1703 Other Endophthalmitisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1707 Prior Penetrating Keratoplastyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1709 Prior Penetrating Keratoplastyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1713 Purulent Endophthalmitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1715 Purulent Endophthalmitisactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1716 Retinal Detachment with Retinal Defectactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1718 Retinal Detachment with Retinal Defectactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1719 Retinal Vascular Occlusionactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1721 Retinal Vascular Occlusionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1722 Other Proliferative Retinopathyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1724 Other Proliferative Retinopathyactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1728 Separation of Retinal Layersactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1730 Separation of Retinal Layersactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1731 Visual Acuity 20/40 or Betteractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.175 Hypotensionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1752 Speech and Hearing Evaluationactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.176 Arrhythmiaactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1766 Morgagnian Cataractactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1767 Morgagnian Cataractactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1769 Macular Scar of Posterior Polaractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.177 Atrioventricular Blockactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1770 Macular Scar of Posterior Polaractive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1771 Ophthalmological Servicesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1772 Annual Wellness Visitactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1773 Speech and Hearing Evaluationactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1774 Occupational Therapy Evaluationactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1775 Behavioral Neuropsych Assessmentactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1776 Psych Visit Diagnostic Evaluationactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1777 Psych Visit Psychotherapyactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1778 Psychoanalysisactive2019-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1779 Group Psychotherapyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.178 Cardiac Pacer in Situactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1780 Psych Visit for Family Psychotherapyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1781 Best Corrected Visual Acuity Exam Using Snellen Chartactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1782 Physical Therapy Evaluationactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.180 Hypotensionactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.181 Arrhythmiaactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.183 Cardiac Pacer in Situactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.185 Hypotensionactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.186 Arrhythmiaactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.187 Atrioventricular Blockactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1912 Major Depressive Disorder Activeactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1918 Major Depressive Disorder Activeactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1921 Beta Blocker Therapy Ingredientactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1923 Psych Visit Diagnostic Evaluationactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1924 Cardiac Pacer in Situactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.408 Bradycardiaactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.410 Bradycardiaactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.411 Bradycardiaactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.422 Tobacco Useractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.423 Tobacco Use Cessation Pharmacotherapyactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.424 Tobacco Use Cessation Counselingactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.425 Tobacco Use Cessation Counselingactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.450 Pain Warranting Further Investigation for Prostate Canceractive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.469 Bilateral Oophorectomyactive2017-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.470 Bilateral Oophorectomyactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.483 Chemotherapyactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.484 Chemotherapyactive2021-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.511 Tobacco Non Useractive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.532 Pregnancyactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.56 Coronary Artery Disease No MIactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.57 Coronary Artery Disease No MIactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.58 Initial Myocardial Infarctionactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.589 End Stage Renal Diseaseactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.59 Asthmaactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.590 End Stage Renal Diseaseactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.60 Asthmaactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.61 Asthmaactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.73 Primary Open Angle Glaucomaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.74 Primary Open Angle Glaucomaactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.76 Diabetic Retinopathyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.80 Diabetic Retinopathyactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.859 Left Ventricular Systolic Dysfunctionactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.860 Moderate or Severeactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.861 Moderate or Severe LVSDactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.91 Prostate Canceractive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.92 Prostate Canceractive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1002 Chronic Kidney Disease, Stage 5active2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1005 Dementia and Mental Degenerationsactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1006 Standardized Tools Score for Assessment of Cognitionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1007 Medical Reasonactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1008 Patient Reasonactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1010 Canceractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1011 Occupational Therapy Evaluationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1012 Patient Provider Interactionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1018 Psych Visit for Family Psychotherapyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1022 Physical Therapy Evaluationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1023 Behavioral or Neuropsych Assessmentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1026 Radiation Treatment Managementactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1027 Chemotherapy Administrationactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1028 Standardized Pain Assessment Toolactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1090 Moderate or Severe LVSDactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1091 Left Ventricular Systolic Dysfunctionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1092 Moderate or Severeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1134 Ejection Fractionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1139 ACE Inhibitor or ARB or ARNIactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1140 Patient Reason for ACE Inhibitor or ARB Declineactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1141 Psychoanalysisactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1151 Renal Failure Due to ACE Inhibitoractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1170 Tobacco Useractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1174 Beta Blocker Therapyactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1176 Heart Rateactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1177 Allergy to Beta Blocker Therapyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1178 Intolerance to Beta Blocker Therapyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1184 Beta Blocker Therapy for LVSDactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1187 Group Psychotherapyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1189 Tobacco Non Useractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1190 Tobacco Use Cessation Pharmacotherapyactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1193 Cardiac Paceractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1211 Allergy to ACE Inhibitor or ARBactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1212 Intolerance to ACE Inhibitor or ARBactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1240 Annual Wellness Visitactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1241 Acute and Subacute Iridocyclitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1251 Macular Examactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1259 Limited Life Expectancyactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1278 Tobacco Use Screeningactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1283 Level of Severity of Retinopathy Findingsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1285 Ophthalmological Servicesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1320 Macular Edema Findings Presentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1332 Cognitive Assessmentactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1333 Cup to Disc Ratioactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1334 Optic Disc Exam for Structural Abnormalitiesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1409 Burn Confined to Eye and Adnexaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1410 Cataract Secondary to Ocular Disordersactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1411 Cataract Surgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1412 Cataract Congenitalactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1413 Cataract Mature or Hypermatureactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1414 Cataract Posterior Polaractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1415 Certain Types of Iridocyclitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1416 Chronic Iridocyclitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1417 Cloudy Corneaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1418 Corneal Edemaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1419 Disorders of Cornea Including Corneal Opacityactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1423 Glaucomaactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1424 Hereditary Corneal Dystrophiesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1426 Hypotony of Eyeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1427 Injury to Optic Nerve and Pathwaysactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1428 Central Corneal Ulceractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1430 Open Wound of Eyeballactive2021-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1432 Pathologic Myopiaactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1433 Posterior Lenticonusactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1438 Retrolental Fibroplasiasactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1443 Traumatic Cataractactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1444 Uveitisactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1445 Vascular Disorders of Iris and Ciliary Bodyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1446 Visual Field Defectsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1448 Amblyopiaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1450 Choroidal Degenerationsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1451 Choroidal Detachmentactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1452 Choroidal Hemorrhage and Ruptureactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1453 Degeneration of Macula and Posterior Poleactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1454 Degenerative Disorders of Globeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1455 Diabetic Macular Edemaactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1457 Disorders of Optic Chiasmactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1458 Disorders of Visual Cortexactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1459 Disseminated Chorioretinitis and Disseminated Retinochoroiditisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1460 Focal Chorioretinitis and Focal Retinochoroiditisactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1461 Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromesactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1462 Hereditary Choroidal Dystrophiesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1463 Hereditary Retinal Dystrophiesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1465 Nystagmus and Other Irregular Eye Movementsactive2021-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1466 Optic Atrophyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1467 Optic Neuritisactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1468 Other and Unspecified Forms of Chorioretinitis and Retinochoroiditisactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1469 Other Background Retinopathy and Retinal Vascular Changesactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1471 Other Disorders of Optic Nerveactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1473 Other Endophthalmitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1475 Prior Penetrating Keratoplastyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1477 Purulent Endophthalmitisactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1478 Retinal Detachment with Retinal Defectactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1479 Retinal Vascular Occlusionactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1480 Other Proliferative Retinopathyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1482 Separation of Retinal Layersactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1483 Visual Acuity 20/40 or Betteractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1489 ACE Inhibitor or ARB or ARNI Ingredientactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1491 Major Depressive Disorder Activeactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1492 Psych Visit Diagnostic Evaluationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1493 Beta Blocker Therapy Ingredientactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1496 Psych Visit Psychotherapyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1530 Speech and Hearing Evaluationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1558 Morgagnian Cataractactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1559 Macular Scar of Posterior Polaractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1560 Best Corrected Visual Acuity Exam Using Snellen Chartactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1561 Medications for Above Normal BMIactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1562 Medications for Below Normal BMIactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1563 Underweightactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1566 Adult Depression Medicationsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1567 Adolescent Depression Medicationsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1568 Follow Up for Adult Depressionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1569 Follow Up for Adolescent Depressionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1570 Referral for Adolescent Depressionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1571 Referral for Adult Depressionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1572 High Intensity Statin Therapyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1573 LDL Cholesterolactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1574 Low Intensity Statin Therapyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1575 Moderate Intensity Statin Therapyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1576 Outpatient Encounters for Preventive Careactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1578 Follow Up Within 4 Weeksactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1580 Referral to Primary Care or Alternate Provideractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1581 Lifestyle Recommendationactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1582 Patient Declinedactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1583 Referral or Counseling for Alcohol Consumptionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1584 Hospice Care Ambulatoryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.3000 Metforminactive2019-12
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.319 Prostate Canceractive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.320 Bone Scanactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.326 Primary Open Angle Glaucomaactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.327 Diabetic Retinopathyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.353 End Stage Renal Diseaseactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.362 Asthmaactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.366 Arrhythmiaactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.367 Atrioventricular Blockactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.368 Cardiac Pacer in Situactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.369 Coronary Artery Disease No MIactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.370 Hypotensionactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.371 Cardiac Surgeryactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.376 Heart Failureactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.378 Pregnancyactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.398 Prostate Cancer Treatmentactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.399 Salvage Therapyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.401 Prostate Specific Antigen Testactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.403 Initial Myocardial Infarctionactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.412 Bradycardiaactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.451 Pain Warranting Further Investigation for Prostate Canceractive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.471 Bilateral Oophorectomyactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.485 Chemotherapyactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.509 Tobacco Use Cessation Counselingactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1498 Medications for Above Normal BMIactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1499 Medications for Below Normal BMIactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1519 Follow Up for Above Normal BMIactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1523 Follow Up for Above Normal BMIactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1524 Follow Up for BMI Outside Normal Parametersactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1525 Follow Up for Above Normal BMIactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1526 Follow Up for Above Normal BMIactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1527 Referrals Where Weight Assessment May Occuractive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1528 Follow Up for Below Normal BMIactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1549 Follow Up for Below Normal BMIactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1550 Follow Up for Below Normal BMIactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1551 Follow Up for Below Normal BMIactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1578 Palliative Careactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1579 Palliative or Hospice Careactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1608 Encounter to Document Medicationsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1609 Encounter to Document Medicationsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1610 Referrals Where Weight Assessment May Occuractive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1751 Encounter to Evaluate BMIactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1834 Encounter to Document Medicationsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1917 Encounter to Document Medicationsactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.695 Encounter to Evaluate BMIactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.885 Encounter to Evaluate BMIactive2018-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.886 Encounter to Evaluate BMIactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1475 Referral to Primary Care or Alternate Provideractive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1476 Pharmacologic Therapy for Hypertensionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1482 Laboratory Tests for Hypertensionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1497 Encounter to Screen for Blood Pressureactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1508 Lifestyle Recommendationactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1509 Weight Reduction Recommendedactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1510 Weight Reduction Recommendedactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1511 Dietary Recommendationsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1512 Dietary Recommendationsactive2025-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1514 Dietary Recommendationsactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1515 Dietary Recommendationsactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1516 Exercise Classactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1518 Recommendation to Increase Physical Activityactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1537 Follow Up Within 4 Weeksactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1538 Encounter to Screen for Depressionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1914 Encounter to Screen for Depressionactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1915 Encounter to Screen for Depressionactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1916 Encounter to Screen for Depressionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1918 Encounter to Screen for Blood Pressureactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.192 Encounter to Screen for Blood Pressureactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1920 Encounter to Screen for Blood Pressureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2387 Overweight or Obeseactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2388 Underweightactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2395 Finding of Hypertensionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2462 Laboratory Tests for Hypertensionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2466 Dental Tooth Extractionactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.259 Diagnosis of Hypertensionactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.261 Diagnosis of Hypertensionactive2021-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.263 Diagnosis of Hypertensionactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.467 Follow Up for Adolescent Depressionactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.468 Follow Up for Adult Depressionactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.469 Adolescent Depression Medicationsactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.470 Adult Depression Medicationsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.537 Referral for Adolescent Depressionactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.538 Referral for Adult Depressionactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.791 Patient Declinedactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.805 Weight Reduction Recommendedactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.810 Recommendation to Increase Physical Activityactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.823 Referral or Counseling for Alcohol Consumptionactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6366.117 Absence of Cervixactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1250 Major Surgical Procedureactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1668 CABG Surgeriesactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1743 General or Neuraxial Anesthesiaactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1940 Immunocompromised Conditionsactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2262 CABG Surgeriesactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2328 Immunocompromised Conditions I10active2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2343 Immunocompromised Conditionsactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2363 Creatinine Lab Testactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.3011 Acute Myocardial Infarctionactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.3024 Acute Myocardial Infarctionactive2016-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 Encounter Inpatientactive2020-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.335 Bone Marrow Transplantactive2021-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.336 Bone Marrow Transplantactive2024-01
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.404 Bone Marrow Transplantactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.623 Acute Myocardial Infarctionactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.694 CABG Surgeriesactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.737 PCIactive2018-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.747 Endotracheal Intubationactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.128 Bipolar Disorderactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.2433 Deliveryactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.2435 HBsAgactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.246 Personality Disorder Emotionally Labileactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.247 Personality Disorder Emotionally Labileactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.248 Personality Disorder Emotionally Labileactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.249 Personality Disorder Emotionally Labileactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.254 Dysthymiaactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.256 Dysthymiaactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.257 Dysthymiaactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.262 Deceasedactive2014-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.263 PHQ 9 and PHQ 9M Toolsactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.269 Hepatitis Bactive2017-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.271 Hepatitis Bactive2017-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.272 Hepatitis Bactive2023-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.273 Live Birth or Deliveryactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.274 Live Birth or Delivery I10active2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.275 Live Birth or Deliveryactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.277 Deliveryactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.278 Delivery - Diagnosisactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.279 HBsAgactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.281 HBsAgactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.43 Bipolar Disorderactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.44 Bipolar Disorderactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.45 Bipolar Disorderactive2022-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.82 Deliveryactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.11.721 Deceasedactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.11.723 PHQ-9 Toolactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.2.1000 Estimated Glomerular Filtration Rateactive2024-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.2.1002 Urine Albumin Creatinine Ratioactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.3.1000 Estimated Glomerular Filtration Rateactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.3.1007 Urine Albumin Creatinine Ratioactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1000 Strabismic Amblyopiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1001 Strabismic Amblyopiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1002 Refractive Amblyopiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1003 Refractive Amblyopiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1004 Routine Ophthalmological Examinationactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1005 Pediatric Best Corrected Visual Acuity Examactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1006 LogMAR Visual Acuity Examactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1007 Aphakiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1008 Aphakiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1009 Infantile and Juvenile Cataractactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1010 Infantile and Juvenile Cataractactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1011 Congenital Corneal or Anterior Segment Conditionsactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1012 Congenital Corneal or Anterior Segment Conditionsactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1013 Eyelid or Orbital Conditionsactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1014 Eyelid or Orbital Conditionsactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1015 Coloboma of Optic Discactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1016 Coloboma of Optic Discactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1017 Hemorrhage of Optic Nerve Sheathactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1018 Hemorrhage of Optic Nerve Sheathactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1019 Optic Nerve Hypoplasiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1020 Optic Nerve Hypoplasiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1021 Disorder of Visual Cortex Due to Underlying Conditionactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1022 Disorder of Visual Cortex Due to Underlying Conditionactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1023 Cortical Blindnessactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1024 Cortical Blindnessactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1025 Congenital Condition of Retinaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1026 Congenital Condition of Retinaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1000 Strabismic Amblyopiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1001 Refractive Amblyopiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1002 Routine Ophthalmological Examinationactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1003 Pediatric Best Corrected Visual Acuity Examactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1004 LogMAR Visual Acuity Examactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1005 Aphakiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1006 Infantile and Juvenile Cataractactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1007 Congenital Corneal or Anterior Segment Conditionsactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1008 Eyelid or Orbital Conditionsactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1009 Coloboma of Optic Discactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1010 Hemorrhage of Optic Nerve Sheathactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1011 Optic Nerve Hypoplasiaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1012 Disorder of Visual Cortex Due to Underlying Conditionactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1013 Cortical Blindnessactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.3.1014 Congenital Condition of Retinaactive2019-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.6.2 Allergy and Intolerance Typeactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.6.8 Severityactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.7.2 Problem Type (SNOMEDCT)active2025-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.7.4 Problemactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.11 Medication Product Formactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.7 SPL Drug Route of Administration Terminologyactive2024-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.3221.8.9 Body Site Value Setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.16 Medication Brand Nameactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.17 Medication Clinical General Drugactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.18 Medication Drug Classactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.22 CVX Vaccines Administered Complete Setactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.28 Procedureactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.60 Social History Type (SCT)active2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.62 Vital Sign Result Typeactive2024-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.64 Medication Fill Statusactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.88.12.80.68 Problem Statusactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.2.575 Race Categoriesactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.3.155 Care Team Categoryactive2024-06
us.nlm.vsacR4http://hl7.org/fhir/ValueSet/event-timing EventTimingactive2023-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.40.2.48.1 Detailed Ethnicity Including Absence Reasonsactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.4.642.40.2.48.3 Ethnicity Categoriesactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.24.7.14 Clinically Important Bacteria and Fungiactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.24.7.280 NHSNGenotypicTestsactive2024-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.24.7.281 Bacterial Skin Commensalsactive2024-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.1066 Healthcare Provider Taxonomyactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3180 NHSNInsertionSiteCodeactive2020-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3181 NHSNRoleOfPerformerCodeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3182 NHSNReasonForInsertionCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3183 NHSNSkinPreparationCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3184 NHSNSterileBarrierCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3185 NHSNCatheterTypeCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3194 NHSNSignificantPathogenCodeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3195 NHSNCriterionOfDiagnosisCodeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3196 NHSNInfectionConditionCodeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3234 NHSNPopulationCategoryCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3247 NHSNTimingCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3248 NHSNEligibilityCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3249 NHSNSpecimenTypeCodeactive2025-02
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3283 NHSNOrganismASTCodeactive2020-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3360 NHSNAntimicrobialAgentAURPCodeactive2025-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3361 NHSNRouteOfAdministrationAURPCodeactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3591 Payer Typeactive2025-04
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.3595 NHSNPopulationSummaryReportTypeCodeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6007 NHSNVascularAccessTypeCodeactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6008 NHSNSuspectedSourceTypeCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6042 NHSNVascularAccessSiteCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6051 NHSNClosureTechniqueCodeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6074 NHSNStaphAureusTestResultsactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7160 NHSNStaphAureusSpecificTestactive2020-07
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7214 NHSNSameDayOutcomeMeasureactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7215 NHSNInfectionFirstReportedSourceactive2022-03
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7232 NHSNRaceCategoryactive2020-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7233 NHSNPreviousPatientLocationactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7237 NHSNBloodCollectionLocationactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7238 NHSNPreviousFacilityactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7239 NHSNContraindicationTypeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7240 NHSNCarbaTestMethodactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7241 NHSNCarbaDetectTypeactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7242 NHSNCdiffTestMethodactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7338 NHSNStartOrContinuationactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7353 NHSNSummaryBloodProductUsageactive2020-08
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.836 Raceactive2012-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.837 Ethnicityactive2012-10
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.114222.4.11.877 Detailed Ethnicityactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.13883.3.3157.4067 MRI of the Breastactive2024-06
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.13883.3.3157.4068 MRI of the Breastactive2022-05
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.13883.3.3157.4069 Intraspinal Abscessactive2022-09
us.nlm.vsacR4http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.113883.3.67.1.101.3.2444 Major Depression Including Remissionactive2021-02
fhir.argonaut.questionnaireR3CapabilityStatement/adaptive-questionnaire-service Argonaut Adaptive Questionnaire Service CapabilityStatementactive2019-02
fhir.argonaut.questionnaireR3CapabilityStatement/answerbank Argonaut Answerbank CapabilityStatementactive2019-02
fhir.argonaut.questionnaireR3CapabilityStatement/argo-questionnaire-provider-ehr Argonaut Argo Questionnaire Provider Ehr CapabilityStatementactive2019-02
fhir.argonaut.questionnaireR3CapabilityStatement/assessmentbank Argonaut Assessmentbank CapabilityStatementactive2019-02
fhir.argonaut.questionnaireR3ImplementationGuide/argonaut.us.questionnaire-1.0.0 Argonaut Questionnairedraft
fhir.argonaut.questionnaireR3OperationDefinition/next-question Argonaut Next Question Operationdraft2018-08
fhir.argonaut.questionnaireR3Questionnaire/questionnaire-example-audit-c Alcohol Use Disorder Identification Test - Consumption [AUDIT-C]draft2019-02
fhir.argonaut.questionnaireR3Questionnaire/questionnaire-example-dast Drug Abuse Screening Test-10 [DAST-10]draft2018-07
fhir.argonaut.questionnaireR3Questionnaire/questionnaire-example-housing Housing Questionsdraft2018-07
fhir.argonaut.questionnaireR3Questionnaire/questionnaire-example-phq9 Patient Health Questionnaire (PHQ-9)draft2018-07
fhir.argonaut.questionnaireR3Questionnaire/questionnaire-example-sampler Argonaut Questionnaire Samplerdraft2018-07
fhir.argonaut.questionnaireR3SearchParameter/Questionnaire-context-type-value context-type-valuedraft2018-12
fhir.argonaut.questionnaireR3SearchParameter/Questionnaire-context-type context-typeactive2018-12
fhir.argonaut.questionnaireR3SearchParameter/Questionnaire-context contextdraft2018-12
fhir.argonaut.questionnaireR3SearchParameter/Questionnaire-publisher questionnaire_publisheractive2019-02
fhir.argonaut.questionnaireR3SearchParameter/Questionnaire-status questionnaire_statusactive2019-02
fhir.argonaut.questionnaireR3SearchParameter/Questionnaire-title questionnaire_titleactive2019-02
fhir.argonaut.questionnaireR3SearchParameter/Questionnaire-version questionnaire_versionactive2019-02
fhir.argonaut.questionnaireR3SearchParameter/QuestionnaireResponse-author questionnaireresponse_authoractive2019-02
fhir.argonaut.questionnaireR3SearchParameter/QuestionnaireResponse-context questionnaireresponse_contextactive2019-02
fhir.argonaut.questionnaireR3SearchParameter/QuestionnaireResponse-patient questionnaireresponse_patientactive2019-02
fhir.argonaut.questionnaireR3SearchParameter/QuestionnaireResponse-questionnaire questionnaireresponse_questionnaireactive2019-02
fhir.argonaut.questionnaireR3SearchParameter/QuestionnaireResponse-source questionnaireresponse_sourceactive2019-02
fhir.argonaut.questionnaireR3SearchParameter/QuestionnaireResponse-status questionnaireresponse_statusactive2019-02
fhir.argonaut.questionnaireR3SearchParameter/patient-birthdate patient_birthdateactive2019-02
fhir.argonaut.questionnaireR3StructureDefinition/argo-adap-questionnaireresponse Argonaut Adaptive QuestionnaireResponse Profileactive2019-02
fhir.argonaut.questionnaireR3StructureDefinition/argo-questionnaire-valueset Argonaut Questionnaire Contained ValueSet Profileactive2018-05
fhir.argonaut.questionnaireR3StructureDefinition/argo-questionnaire Argonaut Questionnaire Profileactive2018-04
fhir.argonaut.questionnaireR3StructureDefinition/argo-questionnaireresponse Argonaut QuestionnaireResponse Profileactive2018-04
fhir.argonaut.questionnaireR3StructureDefinition/extension-itemOrder Argonaut Questionnaire Item Order Extensionactive2019-02
fhir.argonaut.questionnaireR3StructureDefinition/extension-multipleAnd Argonaut SearchParameter Multiple AND Extensionactive2018-04
fhir.argonaut.questionnaireR3StructureDefinition/extension-multipleOr Argonaut SearchParameter Multiple OR Extensionactive2018-04
fhir.argonaut.questionnaireR3StructureDefinition/extension-responsePeriod Argonaut QuestionnaireResponse Response Period Extensionactive2018-04
fhir.argonaut.questionnaireR3StructureDefinition/extension-timeLimit Argonaut Questionnaire Time Limit Extensionactive2018-02

XIG built as of 21 Jun 2025. Found 77163 resources in 1237 packages.